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Abstract 
 
The chemical modification of proteins to produce protein bioconjugates has 
revolutionised the field of chemical biology, with wide-ranging applications in cell 
biology and chemical medicine. Of particular note are bioconjugates linked by 
carbon-carbon (C-C) bonds, which are highly prized due to their hydrolytic stability. 
Current strategies for their synthesis, however, suffer from a number of practical 
limitations, such as utilising acidic/basic conditions, showing reduced reactivity in 
the presence of oxygen, and requiring large concentrations of chemical probe in high 
molar excess.  
This thesis describes the design and development of a novel protein bioconjugation 
strategy, the Organocatalyst-mediated Protein Aldol Ligation, or “OPAL”. During 
this project, the OPAL was conceived, designed, and rigorously optimised, and 
subsequently found to site-selectively modify proteins bearing previously installed α-
oxo-aldehyde handles via hydrolytically stable C-C bonds at neutral pH within an 
hour using minimal molar equivalents of chemical probe through an organocatalyst-
mediated process. The OPAL, along with the palladium mediated decaging of 
thiazolidine-containing unnatural amino acids, was found to be compatible with site-
selective affinity tagging and protein pulldown in cell lysate. Additionally, the 
OPAL products could be site-selectively functionalised further using alternative 
protein aldehyde ligation strategies through modification of a newly generated β-
hydroxy aldehyde handle that results from the initial OPAL modification. The OPAL 
strategy was applied to the chemical mimicry of lipidated Leishmania surface 
proteins previously inaccessible through conventional methods in molecular biology. 
Finally, within the context of protein bioconjugation, further aldol based C-C bond 
cleaving and forming protocols were designed and investigated. 
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Figure 4.19. 130 
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1.1. Protein bioconjugation 
Protein bioconjugation is a term used to collectively describe chemical strategies for 
linking synthetic groups to proteins via covalent bonds.3 Over the last 25 years (and 
particularly within the last decade), protein bioconjugation has generated major 
interest within the field of chemical biology, where the chemical ligation of 
functional molecules to proteins can vastly enhance their properties and allow for 
wide-ranging applications (Figure 1.1). For example, conjugation of compounds 
such as polyethyleneglycol (PEG) to proteins has been well established for 
improving the half-life of protein probes and therapeutics,4 with several PEGylated 
protein therapeutics approved by the U.S Food and Drug Administration (FDA). 
These drugs include PEGylated interferon alfa-2a (Pegasys) used to treat hepatitis B 
and C, PEGylated anti-tumour necrosis factor (Certolizumab pegol, or Cimzia) used 
to treat Crohn’s disease and rheumatoid arthritis, and PEGylated asparginase 
(Oncaspar, or pegaspargase) used to treat leukemia.5 PEGylation of proteins has also 
been demonstrated in the preparation of protein-based nanoparticles, which can 
encapsulate and carry cytotoxic compounds for use in drug delivery. 6 Alternatively, 
preformed nanoparticles can be functionalised with proteins using bioconjugation 
strategies for potential use as biomedical diagnostic tools. 7,8 Bioconjugation is also 
routinely used for covalent immobilisation of proteins to surfaces for applications 
such as surface plasmon resonance (SPR). 9 Ligation of fluorescent/spectroscopic 
probes has been utilised for in vivo imaging of proteins and other biomolecules, such 
as tracking glycosylated proteins in developing zebrafish, giving insights into glycan 
distribution during embryogenesis,10,11 whereas ligation of affinity tags allows for 
selective protein pulldown in complex biological mixtures.12 Additionally, 
pioneering advances in modern medicine have been achieved through protein 
bioconjugation, primarily in the construction of antibody-drug conjugates (ADCs) by 
linking therapeutic antibodies with small molecules drugs via chemical ligation 
strategies.13 Four ADCs are currently approved by the FDA for therapeutic use; these 
include trastuzumab emtansine (Kadcyla) used to treat breast cancer and approved 
for use on the National Health Service (NHS), brentuximab vedotin (Adcetris) used 
to treat Hodgkin lymphoma, inotuzumab ozogamicin (Besponsa) used to treat acute 
lymphoblastic leukemia, and gemtuzumab ozogamicin (Mylotarg) used to treat acute 
myeloid leukemia, with many more in the clinical pipeline. 14 From a cell biology 
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perspective, the ability to functionalise proteins at specific sites also shows particular 
promise in the design of new tools for probing post-translational modifications 
(PTMs), giving access to proteins bearing PTM “mimics”.15 For example, N-glycans 
can be chemically re-installed into non-glycosylated antibodies,16 whereas histone 
proteins can be functionalised with a range of different PTM mimics in a process 
known as “chemical mutagenesis”. 17,18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Outline of protein bioconjugation and its wide ranging applications in chemistry and biology. 
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1.1.1 Requirements and challenges of protein bioconjugation 
The ultimate goal of protein bioconjugation is akin to that of small molecule organic 
synthesis; to assemble new compounds by making chemical bonds from one 
molecule to another. For protein bioconjugation, however, additional considerations 
must be taken into account in comparison to more traditional approaches to synthesis 
(Figure 1.2). Proteins are large polypeptides consisting of a sequence of amino acids 
(primary structure), which adopt local conformations (secondary structure) that fold 
into a more complex three dimensional structure (tertiary structure). Some proteins 
also comprise several polypeptide chains that form protein subunits (quaternary 
structure). Many proteins are capable of carrying out particular functions based on 
their aforementioned three dimensional structure; enzymes, for example, catalyse 
reactions and turn over substrates. It is vital, therefore, that any activity of the protein 
target in question is maintained post modification i.e. bioconjugation does not 
compromise the target proteins original function. Broadly speaking, this requires 
protein bioconjugation methodology to be compatible with conditions tolerated by 
proteins, such as having an aqueous solvent system, buffered conditions with a pH 
that is neutral (or near neutral), and mild temperatures typically ranging between 4 - 
37 oC.19 Additionally, protein bioconjugation strategies that selectively modify a 
particular site of the target protein in a controlled manner via stable linkages are 
highly prized, as they avoid generating mixtures of bioconjugation products. As 
proteins comprise amino acids, all protein bioconjugation must also be carried out in 
an environment containing a vast array of functional groups (a so-called “sea of 
functionality”),20 with limited access to protecting group chemistry.  
 
 
 
 
 
 
 
Figure 1.2 Consideration of reaction conditions for the design of successful, synthetically useful protein 
bioconjugation strategies. 
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1.1.2. Brief overview of current strategies for protein bioconjugation 
From a synthetic perspective, the restrictive nature of the system in which protein 
bioconjugation must be performed presents significant chemical challenges. Despite 
these challenges, there are now multiple methods that have been reported in the 
literature. 19,21,22 Many chemical protein modification strategies involve reaction of a 
reactive amino acid side chain, the most common of which focus on the ε-amino 
group of a lysine residue, or the thiol group of a cysteine. Lysine residues, for 
example, can be covalently modified at the ε-amino group with activated ester 
compounds to form amide bonds (Figure 1.3A) ,23 with isothiocyanates to form ureas 
(Figure 1.3B),24 or with aldehyde compounds to form imines that can be 
subsequently reduced via reductive amination (Figure 1.3C). 25 In particular, lysine 
modification via amide bond formation with succinimidyl trans-4-
(maleimidylmethyl)cyclohexane-1-carboxylate (SMCC) 1 is instrumental in the two-
step preparation of Kadcyla (2, Figure 1.3D).26 Examples of cysteine conjugation 
include alkylation with iodoacetamides (Figure 1.4A),27 coupling with maleimides 
(Figure 1.4B) ,28 coupling to allenamides (Figure 1.4C),29 palladium mediated 
arylation (Figure 1.4D),30 and modification with carbonylacrylic reagents (Figure 
1.4E) 31 Maleimide coupling, in particular, is used in the synthesis of Adcetris 
(Figure 1.4F).26 Cysteine residues can also be converted to dehydroalanine following 
treatment with α,α′-di-bromo-adipyl(bis)amide,32 further increasing the range of 
cysteine-related bioconjugation strategies. The alkene side chain of dehydroalanine 
is primed to react with thiol based reagents to form thioether bonds,32 or alkylated to 
form carbon-carbon bonds via addition of alkyl radicals (generated from alkyl 
halides) in a metal mediated process (Figure 1.5).17,18 Much of dehydroalanine 
chemistry has underpinned the synthesis of proteins bearing PTM mimics.17,18,32 
Disulfide bridged cysteines on the other hand can undergo reduction followed by 
addition33 (Figure 1.6A) or dibromopyridazinedione addition34 (Figure 1.6B), or 
alternatively a one-step reduction-rebridging modification using tris(2-
carboxyethyl)phosphine (TCEP)-derived pyridazinediones 5 (Figure 1.6C). 35 
Alongside lysine and cysteine modifications, tyrosine side chains can be modified 
via coupling hemin activated luminol reagents (Figure 1.7A), 36 with diazonium 
chemistry (Figure 1.7B), 37 and with Mannich-type reactions using aniline derived 
probes and formaldehyde 6 (Figure 1.7C). 38 Additionally, tryptophan side chains act 
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as reactive groups in rhodium carbenoid mediated reactions (Figure 1.7D), 39 and in 
organo-radical mediated reactions (Figure 1.7E).40 Methionine residues can be 
modified via redox–activated chemical tagging using oxaziridine reagents (also 
known as the “ReACT” strategy (Figure 1.7F).41 These methods, along with other 
strategies for the chemical modification of endogenous amino acids, have been 
extensively reviewed.21,22  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Modification of the ε-amino group of lysine. A) Amide bond formation. B) Urea formation. C) 
Reductive amination. D) Structure of Kadcyla, highlighting the amide bond generated through lysine 
modification that conjugates the cytotoxic payload to the antibody. 
1 
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Figure 1.4 Modification of thiol side chain of cysteine. A) Alkylation. B) Maleimide coupling. C) 
Allenamide coupling. D) Arylation. E) Michael addition of carbonylacrylic reagents. F) Structure of Adcetris, 
highlighting the thioether bond generated through cysteine  modification that conjugates the therapeutic 
payload to the antibody. 
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Figure 1.5 Conversion of cysteine to dehydroalanine, and modification via thioether formation or alkylation. 
 
Figure 1.6 Disulfide bridging. A) Reduction, followed by dibromomaleimide addition. B) Reduction, followed 
by dibromopyridazinedione addition. C) Two in one reduction-bridging using TCEP-derived pyridazinediones. 
4 
5 
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Figure 1.7 Other protein modifications of naturally occurring amino acid side chains . A) Modification of 
tyrosine with activated luminols B) Modification of tyrosine with diazonium salts. C) Modification of 
tyrosine via a three-component-Mannich reaction. D) Modification of tryptophan with rhodium carbenoids. 
E) Modification of tryptophan with organo-radicals. F) Modification of methionine with oxaziridine reagents. 
6 
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All of these methodologies share one common drawback however, in that site-
selectivity cannot be achieved when more than one of these naturally occurring 
groups is present within a protein. There are exceptions to this; for example, 
perfluoraromatic reagents can be used to site-selectively modify a single cysteine 
residue located within a “π-Clamp”, a four amino acid sequence comprising of Phe-
Cys-Pro-Phe (Figure 1.8 A). 42 Selectivity of the π-clamp strategy is thought to result 
from energetically favourable interactions between the hydrophobic amino acids 
surrounding the cysteine residue within the π-clamp, and the hydrophobic 
perfluroaromatic reagents used in the reaction.42,43 Equally, site selective lysine 
modification has been demonstrated through initial modification of a single lysine 
residue with sulfonyl acrylate 7, followed by aza-Michael addition (Figure 1.8B); the 
selectivity of this procedure for a given lysine residue is thought to result from the 
given residue bearing a lower-than-usual ε-amino group pKa value due to local 
microenvironment, making that given lysine residue more reactive than other lysines 
present in the protein. 44 Selective, although incomplete, labelling of lysine can also 
be achieved through kinetically controlled amide formation with activated esters.23  
 
 
 
 
 
 
 
 
 
 
The N-terminal residue of proteins often provides a native site suitable for site-
selective modification. For single chain proteins, there is only one of these residues, 
Figure 1.8 Site-selective protein modification of naturally occuring amino acid side chains. A) π-clamp 
mediated modification of cysteine. B) Modification of lysine using sulfonyl acrylates, followed by aza-
Michael addition. 
7 
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and the α-amino group displays a different pKa (~6-8) compared to that of the ε-
amino groups of lysine (~10.5), and therefore different reactivity at low-neutral pH.45 
In addition to modification via strategies previously described for non-selective 
lysine modification, the N-terminal group of proteins can be site-selectively acylated 
with ketenes (Figure 1.9A),46 and undergo site-selective imidazolidinone formation 
using 2-pyridinecarboxaldehyde (2PCA) reagents (Figure 1.9B) .47 N-terminal 
cysteines can also be selectively targeted using 2-cyanobenzothiazoles (Figure 
1.9C),48 and are also used in native chemical ligation (Figure 1.9D) ,49 whilst N-
terminal proline residues can react with o-aminophenols in an oxidative coupling 
process, using potassium ferricyanide as the oxidant (Figure 1.9E) 50. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 Selective N-terminal protein modifications A) N-terminal modification with ketene. B) N-
terminal modification with 2PCA reagents. C) N-terminal modification with 2-cyanobenzothiazoles. D) 
Native chemical ligation of N-terminal cysteine. E) Oxidation coupling of o-aminophenols to N-terminal 
proline. 
37 
 
 
 
In a drive to avoid the selectivity issues encountered from targeting naturally 
occurring amino acid side chains, recent years have seen a growing number of 
protein labelling techniques emerging that modify non-naturally occurring 
functionalities in proteins. These strategies primarily focus around incorporating a 
unique functional ‘handle’ into a protein that is not naturally present within the 
proteinogenic amino acid side chains, and then subjecting the tagged protein to a 
substrate that bears a reactive moiety that specifically reacts with the incorporated 
handle. Such reactions do not interact with other functional groups present in the 
protein, therefore generating homogenous bioconjugates. This area of protein 
bioconjugation has primarily been enabled by advance in methods that allow for the 
incorporation of unnatural amino acids into proteins, otherwise known as unnatural 
amino acid mutagenesis, or genetic code expansion. The field of unnatural amino 
acid mutagenesis has been the subject of several reviews in the literature.51-53 
Arguably the most popular non-naturally occurring handles used in protein 
bioconjugation are the azide and alkyne functionalities. Azides act as reactive 
partners with phosphines in the Staudinger ligation (Figure 1.10A) 54 and its traceless 
variant,55 and also with alkyne substrates in copper-mediated azide-alkyne 
cycloadditions (CuAAC, Figure 1.10B).56 Similarly, azides can also take part in 
copper-free [3+2] cycloadditions with cyclooctynes, known as strain-promoted 
azide-alkyne cycloaddition (SPAAC, Figure 1.10C).57 The latter is more applicable 
to biological systems, since it does not require the use of copper which exhibits 
cytotoxicity in cells at high concentrations. Strain-promoted cycloadditions with 
quinones have also been reported. 58 By extension, alkyne and cyclooctyne handles 
incorporated into proteins can also participate in CuAAC and SPAAC respectively 
using azide substrates. Alkynes can also act as handles for metal-mediated cross 
coupling reactions (Figure 1.10D). 59,60 More recently, terminal alkynes have been 
demonstrated as handles in copper-mediated Glaser-Hay bioconjugations.61,62 Rapid 
protein labelling can also be achieved with strained alkene handles by performing 
inverse-demand Diels-Alder reactions with tetrazine substrates (Figure 1.10E); 
similar reactions can also be performed on alkyne handles.11,63,64 Alongside 
recombinant protein labelling, these strategies have also been utilised in live cell 
labelling, and labelling of glycoproteins in complex biological environments, 
including live Zebrafish embryos,10,11 without perturbing the native environment. 
This branch of bioconjugation is known as “bioorthogonal chemistry”. These 
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strategies, alongside other methods for modification of unnatural amino acids, have 
been extensively reviewed. 15,19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10 Modification of unnatural amino acid containing proteins. A) Staudinger ligation. B) 
CuAAC. C) SPAAC. D) Cross coupling E) Tetrazine coupling of strained alkene handles. 
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1.2 Site-selective incorporation of protein aldehydes 
One functional group not traditionally found within proteins is the aldehyde 
functionality. This reactive carbonyl moiety has wide ranging applications in 
traditional organic synthesis and can participate in a variety of synthetically useful 
reactions, including synthesis of native peptide bonds.65-67 Aldehydes also feature 
notably in protein semisynthesis protocols, including serine/threonine ligations at C-
terminal salicylaldehyde esters,68,69 and a variant of the α-ketoacid-hydroxylamine 
(KAHA) ligation where incorporated aldehyde side chains can act as purification 
handles.70 It is therefore of no surprise that the aldehyde functionality has seen 
frequent use within the field of site-selective protein modification. Upon installation 
of an aldehyde handle, it is possible to perform chemistry that reacts with the 
aldehyde group to site-selectively label a target protein. Many strategies exist for the 
incorporation an aldehyde handle into a desired protein, along with an increasing 
selection of ligation protocols for subsequent site-selective labelling. Of particular 
note is the significant number of chemical probes targeting these handles that are 
now available commercially. Numerous examples of aldehyde-based ligations have 
been reported in the literature, including synthesis of antibody-drug conjugates 
(ADCs), design of proteins bearing PTM ‘mimics’, and labelling of specific proteins 
within crude cell lysates (Figure 1.11). This section will provide an overview of the 
strategies currently reported for incorporating aldehydes into proteins, alongside 
reported ligation methods exploited in their subsequent chemical modification. 
 
 
 
 
 
 
 
 
Figure 1.11 Overview of site-selective ligation of an aldehyde incorporated into a protein. 
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A wide variety of strategies can be employed for the incorporation of aldehyde 
handles into proteins. It is worth noting at this point that, although all strategies 
described incorporate an aldehyde functionality, the electronic properties of the 
aldehyde installed can vastly differ depending on which strategy is used. These range 
from α,β-unsaturated aldehydes to aryl aldehydes, as well as electron rich to electron 
deficient aldehydes. The tag can also differ in location and distance from the protein 
it is attached to. Some of the methods described for installing aldehyde handles into 
proteins can also be used to install ketone handles into proteins; these will be briefly 
considered where appropriate. 
1.2.1 Oxidation of β amino-alcohols and vicinal diols via periodate cleavage 
Aldehydes can be installed into proteins via oxidative cleavage of serine and 
threonine residues located on the N-terminus of a protein (Figure 1.12A).71 This can 
be achieved through reaction with sodium periodate (NaIO4) and is analogous to 
vicinal diol cleavage (also known as the Malaprade reaction) 72. The resulting 
electron-poor N-terminal aldehyde is referred to as an α-oxo aldehyde or 
glyoxylamide (or glyoxylylamide). An extensive review on glyoxylamides, along 
with their carboxylic acid counterpart (glyoxylic acids), has recently been published. 
73 A particular advantage of generating an aldehyde via this method is that the 
reaction is rapid; oxidation of β amino alcohols is 100-1000 times faster than the 
oxidation of vicinal diols encountered in carbohydrates, 74 and, from a practical 
perspective, typically gives  complete conversion to the desired aldehyde product 
within 5-60 minutes. In a similar fashion, aldehydes can also be installed into 
proteins containing carbohydrate groups (i.e. proteins bearing sialic acid capped N-
glycans) via periodate mediated diol cleavage. 
 
 
 
 
 
 
Figure 1.12 (A) Oxidation of serine/threonine N-terminated proteins to generate a glyoxylamide (glyoxyl) 
species. (B) The aldehyde and hydrate form of the glyoxyl species. 
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Care must be taken when using this method however as other amino acids can be 
oxidised under certain conditions, particularly cysteine and methionine residues. 73 
For example, periodate oxidation of the peptide SYSMEHFRWG at pH 4.0 results in 
undesired oxidation of the methionine residue to methionine sulfoxide, whereas 
oxidation at pH 7.0 gives the desired glyoxyl-YSYMEHFRWG peptide.75 Therefore, 
the reaction is usually performed at neutral pH, with another component added, such 
as excess methionine or ethylene glycol, during or after oxidation to quench 
unreacted periodate. This is then followed by purification of the oxidised protein,76,77 
which exists in an equilibrium as a mixture of aldehyde and hydrate form (Figure 
1.12B). 
1.2.2 N-terminal transamination strategies 
Transamination refers to the transfer of the amino group of an amino acid to a keto 
acid, and was first established in the 1930s.78 In nature, this process is catalysed by 
transaminases, with different transaminases existing for different amino acids.78 A 
biomimetic transamination reaction for the installation of both aldehydes and ketones 
into proteins has also been described in the literature (Figure 1.13A). An initial 
screen of aldehyde reagents on the peptide antiogensin I identified pyridoxal 5-
phosphate (PLP) 8 as a successful reagent for the oxidation of the N-terminal 
aspartate residue (generating a ketone) under mild conditions (pH 6.5, 25 mM 
phosphate buffer, 18 hours, 37 oC). The N-terminal ketone generated from this 
biomimetic transformation can then be site-selectively modified further. PLP-
mediated transamination was successfully demonstrated on a number of proteins 
bearing different amino acids at their N-terminus, including conversion of N-terminal 
glycine to a glyoxylamide in horse heart myoglobin, and oxidation of N-terminal 
lysine to a ketone in RNAase A.79 The transamination is specific for the amino group 
of the N-terminal amino acid, and does not modify other amine bearing residues such 
as lysine side chains. Optimisation of PLP-mediated transamination has since 
undergone extensive investigation utilising solid phase peptide synthesis (SPPS) 80 
and combinatorial peptide libraries.81 PLP 8 mediated transamination of resin bound 
peptides identified that sequences containing alanine, glycine, aspartate, glutamate, 
or glutamine residues at the N-terminus were transformed into the desired 
transamination product in the highest yields. Histidine, lysine, tryptophan and 
proline N-termini containing peptides gave rise to PLP-adduct-type byproducts, 
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whereas isoleucine and valine N-terminated peptides displayed very poor reactivity 
in PLP-mediated transamination.80  
 
 
 
 
 
 
 
 
 
 
The observation that  the valine N-termini are unsuitable for transamination is 
contradictory to the previously reported successful transamination of valine N-
terminal green fluorescent protein (GFP1V).79 This was rationalised on the basis that 
the internal sequence of a peptide/protein may also affect the success of PLP-
mediated transamination. Additional screening of resin bound lysine and valine N-
terminal tetrapeptides demonstrated that the identity of the amino acid at position 2 
and 3 can dramatically affect the outcome of the transamination reaction.80 
Combinatorial peptide libraries screens have subsequently revealed that alanine N-
terminated peptides/proteins, directly followed by a lysine residue, are highly 
reactive towards PLP-mediated transamination.81 Transamination of short isoleucine, 
leucine, and valine N-terminal peptides using another pyridoxal derivative, along 
with the effects of using an imidazole-based buffer system on the transamination 
reaction, have also been recently reported. 82 An alternative reagent for 
transamination-mediated reactions on proteins has been reported more recently.83 
Using previously described combinatorial peptide libraries, 81 N-methylpyridinium-
4-carboxaldehyde 9 (Rapoport’s Salt, ‘RS’, see Figure 1.13B)  has since been 
Figure 1.13 (A) Oxidation of the N-terminus using pyridoxal-5-phosphate (PLP) to generate a reactive 
aldehyde (or ketone). (B) The structure PLP and Rapoport’s Salt (RS). 
8 9 
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identified as an effective reagent for transamination-type modification of proteins; in 
particular, RS 9 is highly suitable for glutamate N-terminated peptides/proteins. 83 
Optimisation of the transamination using SPPS has demonstrated that RS is a poor 
transamination reagent for glycine, serine, threonine, or proline N-terminated 
peptides, but is very suitable for alanine, and glutamate N-terminated peptides. 
Additionally, it is worth noting that for all N-terminated amino acids discussed (with 
the exception of proline), improved yields of the desired transamination product 
were obtained when using RS under more basic conditions (pH 7.5-8.5 as opposed to 
pH 6.5). 84 
1.2.3 Genetic incorporation of a formylglycine tag 
Formylglycine (fGly) is an electron-rich aldehyde side chain derived from the 
chemoenzymatic oxidation and subsequent hydrolysis of a cysteine residue that is 
located within a consensus sequence of CxPxR (where x = any amino acid, Figure 
1.14A). Conversion of the thiol to the aldehyde is carried out enzymatically by the 
Formylglycine Generating Enzyme (FGE, Figure 1.14B). In nature, this 
transformation is essential for the enzymatic turnover in the active site of sulfatase 
enzymes; fGly is the active site residue that is responsible for the catalytic hydrolysis 
of sulfate esters.85 Use of the fGly residue as a handle for protein bioconjugation was 
first described in 2007.86 Short tags containing motifs that are targeted by sulfatases 
and subjected to fGly conversion in nature were installed at the N or C-terminus of 
human growth hormone, mycobacterial sulfotransferase, and maltose-binding 
protein. Co-expression of the recombinant target proteins in E. coli alongside M. 
tuberculosis FGE resulted in >85% conversion of the CxPxR-containing proteins to 
the desired fGly-tagged proteins (confirmed by MS and subsequent tryptic 
digest/modification experiments). The fGly tag has since been utilised to install 
monosaccharides87 (which can be used as glycosyl acceptors to build N-glycans via 
endoglycosynthase enzymatic derivatisation),16 biotinylated probes,88 and 
therapeutically relevant small molecules.88-91 The fGly handle has also been used in 
the specific labelling of tagged proteins in cell extracts.92 In addition to prokaryotic 
cell lines, this methodology has also been utilised successfully in mammalian 
expression systems.93 Investigation into preactivation of FGE to improve turnover 
rates using copper has also been reported.94 For a more detailed discussion on FGEs 
and the fGly, readers are directed to a recent review in the field.95 
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1.2.4 Enzymatic incorporation of farnesyl pyrophosphate analogues 
Protein farnesyl-transferase (PFTase) is an enzyme that catalyses the farnesylation of 
thiol side chains of cysteine residues in proteins. PFTase utilises farnesyl 
pyrophosphate (FPP) for this transformation and is specific for cysteine residues 
within a tetrapeptide domain at the C-terminus of a peptide/protein. This tetrapeptide 
domain is commonly referred to as a CAAX-box, where A = aliphatic amino acid, 
and X = alanine, serine, methionine, or valine (usually the CAAX-box comprises of 
the sequence cysteine-valine-isoleucine-alanine).96,97 Along with its natural substrate 
FPP, PFTase can also incorporate FPP analogues such as farnesyl aldehyde 
pyrophosphate (FAPP), allowing for installation of an α,β-unsaturated aldehyde tag 
into proteins bearing a CAAX-box motif (Figure 1.15A) 98 FAPP installation has 
been demonstrated on N-dansyl peptides and CAAX-box tagged GFP. Following 
aldehyde installation, tagged proteins can then be specifically isolated via 
modification of the installed aldehyde.99 PFTase strategies for aldehyde tag 
incorporation have since been extended to incorporation of an aryl aldehyde 
analogue (Figure 1.15B),99 and modification of other proteins such as ciliary 
neurotrophic factor protein (CNTF).100 Other aryl aldehyde handles that bear alkyne 
functionality can also be incorporated using PFTase, allowing for selective, dual 
Figure 1.14 (A) Outline of generating the formylglycine (fGly) residue on peptide/proteins bearing a cysteine 
within a CxPxR sequence. (B) Expression of a plasmid encoding for the desired protein containing the CxPxR 
sequence, followed by treatment with the formylglycine generating enzyme (FGE) leads to fGly-proteins. 
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functionalisation of GFP.100 Mutant variants of PFTase have also been explored in 
improving the catalytic efficiency of FPP aldehyde analogues; a 43 fold increase, for 
example, is observed for the incorporation of aryl aldehyde FPP into CAAX-box-
bearing CNTF when using a W102A β subunit PFTase variant (as opposed to using 
wild type PFTase).101 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.5 Enzymatic incorporation using lipoic acid ligase 
In Escherichia coli, lipoic acid ligase (LplA) is responsible for linking lipoic acid to 
various proteins involved in oxidative metabolism.102 LplA specifically targets lysine 
side chains located within a GFEIDKVWYDLDA sequence known as the LplA 
acceptor peptide (LAP). The incorporation of aldehyde tags utilising this enzymatic 
strategy has recently been described (see Figure 1.16A-C). W37I mutants of LplA 
could be used to incorporate aryl aldehydes into a LAP peptide in a 500:150:1 ratio 
of lipoic acid-analogue:LAP-peptide:LplA, with a maximum of 62% conversion to 
Figure 1.15 (A) Protein farnesyl-transferase (PFTase) mediated installation of farnesyl-derived aldehydes 
into a protein bearing a C-terminal CAAX box. (B) Aldehyde analogues that can be incorporated. 
46 
 
 
 
the aldehyde-tagged LAP peptide observed after 5 minutes of incubation. 
Additionally, proteins bearing LAP tags at the N-terminus, including LAP-tagged 
streptavidin and LAP-tagged alkaline phosphatase, were also successfully 
modified.103 More recently, this methodology has been extended to the labelling of 
LAP-tagged nanobodies. 104 
 
 
 
 
 
 
 
 
1.2.6 Enzymatic incorporation of 3-formyl-L-tyrosine 
A recently described chemoenzymatic method for installation of aldehyde tags into 
proteins is through enzymatic transformation using tubulin tyrosine ligase (TTL, see 
Figure 1.17A-C).105 Although the natural function of TTL is to post-translationally 
modify the C-terminus of α-tubulin with tyrosine, TTL can also accept tyrosine 
analogues, such as 3-formyl-L-tyrosine (denoted as ‘3ForTyr’), in ligation of C-
terminal peptides/proteins bearing a VDSVEGEGEEEGEE tag (known as a Tub 
tag). Mixing of Tub-tagged peptides with TTL in a 200:1 ratio afforded a 63% 
incorporation of 3ForTyr after 2 h (monitored by HPLC, with >90% incorporation 
observed after 6 hours). This methodology has also been utilised in the tagging of 
Tub-tagged GFP, ubiquitin, and GFP-specific nanobodies. Incubation of TTL:Tub-
tagged-protein in an optimal ratio of 1:5 for 3 h at 37 °C gave rise to successful 
labelling with 3ForTyr (confirmed by tryptic digestion experiments). Conversions of 
99% were achieved under these conditions (based on SDS-PAGE analysis and 
observations of other incorporated tyrosine analogues).105 
Figure 1.16(A) Outline of using Lipoic acid ligase (LplA) mutants for installing aldehydes into LplA accepter 
peptide (LAP) bearing proteins. (B) Amino acid sequence of the LAP. (C) Structure of the incorporated aldehyde. 
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1.2.7 Genetic incorporation of non-native aldehyde containing amino acids 
Similarly to installation of other protein handles, another well-publicised strategy51,52 
for installing an aldehyde (or ketone) tag into a protein is to utilise the ever-
increasing number of evolved tRNA/tRNA synthetase pairs to perform unnatural 
amino acid mutagenesis. (Figure 1.18).106-109  Currently, there a three variants of 
aldehyde handle that can be incorporated into proteins via unnatural amino acid 
mutagenesis. The most commonly used unnatural amino acid carbonyl handles are 
derived from phenylalanine-type side chains, such as phenylalanine derivative 10. 
Upon installation, the aldehyde (or ketone) side chain can then be modified with a 
range of functional handles, including fluorescent probes,106,109,110 biotinylated 
probes,106,107,110 and carbohydrates.111 ADCs have also recently been developed 
utilising this methodology.112,113 More recently described unnatural amino acid –
derived aldehyde handles are installed into proteins using precursor unnatural amino 
acids, followed by deprotection to reveal the desired aldehyde side chain. Installation 
of azidobenzoxycarbonyl lysine derivative 11 can be deprotected with TCEP to 
reveal allysine (bearing an alkyl aldehyde),114 whereas thiazolidine lysine derivative 
12 can be deprotected in metal mediated reactions to reveal α-oxo aldehyde side 
chains.115,116 Subjecting allysine handles to reductive amination allows access to 
histone bearing PTM methylated lysine mimics,114 whereas α-oxo aldehyde side 
chains can be used for site-selective fluorescent labelling or biotinylation.116 
 
Figure 1. 17 (A) Outline of using Tubulin Tyrosine Ligase (TTL) to for the incorporation of 3-formyl-L-
tyrosine (3ForTyr) into proteins bearing a ‘Tub Tag’. (B) The amino acid sequence of the Tub Tag. (C) 
Structure of the incorporated 3ForTyr. 
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Figure 1.18 (A) Installation of aldehyde into proteins via unnatural amino acid mutagenesis. Expression of a 
plasmid encoding for the desired protein containing an amber STOP codon in conjunction with an orthogonal 
tRNA synthetase/tRNA pair and unnatural amino acid allows for incorporation of an aldehyde-containing 
amino acid at the aforementioned STOP position. (B) Unnatural amino acids and subsequent reactions used to 
incorporate aldehyde handles into proteins. 
10 
11 12 
49 
 
 
 
1.3 Chemical strategies for the modification of proteins bearing aldehyde 
handles 
There is now a plethora of strategies for the site-selective modification of proteins 
following installation of one of the aforementioned aldehyde tags. These range from 
C=N bond formation to C-C bond formation, and from metal mediated ligations to 
intramolecular cyclisation ligations. The choice of aldehyde handle, along with the 
conditions for aldehyde modification (such as pH or use of additional co-solvent) 
ranges from strategy to strategy. The rate of ligation has also been profiled for the 
majority of strategies described; often using small molecule aldehydes mimics and, 
on some occasions, proteins bearing an aldehyde handle. Selected rate constants (and 
the conditions used) for each ligation strategy discussed herein can be found in Table 
1.1. 
1.3.1 Hydrazone/Oxime ligations 
The reaction of hydrazine and hydroxylamine/aminooxy reagents with proteins 
bearing aldehydes (or ketones) to form hydrazone and oxime bonds, respectively, are 
among the best established  methods for generating homogenous ligation products 
(Figure 1.19A-B). These ligation strategies proceed via an iminium-type 
intermediate, and are by far the most popular method of modifying aldehydes 
installed into proteins. Indeed, a standard method for validating installation of an 
aldehyde handle into a protein is to perform hydrazone or oxime ligation with small 
molecule substrates, and then analyse the anticipated ligation product by protein 
mass spectrometry (protein MS).71,79,83,86,99,106 Uniquely, to date, they are the only 
ligation strategies reported in literature that have been demonstrated on all aldehyde 
handles that can be incorporated into proteins, with the exception of allysine (Figure 
1.19C, Table 1.1 entries 1-7). More complex, functionalised 
hydrazine/hydroxylamine reagents are frequently employed for the purpose of 
protein bioconjugations. For example, labelling with hydrazine/hydroxylamine 
functionalised biotin facilitates isolation of the modified protein via binding with 
streptavidin.86,110,117 Use of aminooxy functionalised resins can also be applied to 
isolate aldehyde-tagged proteins via oxime ligation from crude cell lysates.98,99 
Successful incorporation of an aldehyde handle into a protein is also frequently 
showcased through the reaction with hydrazine or hydroxylamine functionalised 
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fluorescent probes.79,83,103,105,109 Analysis of these ligation products via SDS PAGE 
analysis with fluorescence emission scanning can be used to determine the level of 
success of the initial aldehyde incorporation method.16 In a similar manner, 
hydroxylamine functionalised PEG reagents can also be used to label incorporated  
Table 1.1 Comparison of selected rate constants for strategies used in the modification of aldehydes under 
various conditions. * No rate/yield/conversion given. ** No rate studies performed, reaction time and obtained 
yield quoted as an alternative. *** No rate studies performed, reaction time and conversion as judged by Liquid 
Chromatography-Mass Spectrometry (LC-MS) quoted as an alternative. 
Entry Reaction Conditions Rate (M-1s-1) Ref 
1 
Hydrazone 
1 mM aldehyde 
1 mM hydrazine 
 
pH 5.7, NH4OAc 
0.0031 
(uncatalysed) 
0.21 
(10 mM aniline) 
118
 
2 
Hydrazone 
 
 1 mM aldehyde 
18 µM hydrazine 
 
pH 7.4, PBS (10% 
DMF) 
0.0013 
(uncatalysed) 
0.11 
(1 mM 5-methoxyanthralic 
acid) 
119
 
3 
Hydrazone  
10 µM aldehyde 
 10 µM hydrazine 
 
pH 7.0, PB 
170 
(100 mM aniline) 
120
 
4 
Oxime  
1 mM aldehyde 
1 mM aminooxy 
 
pH 4.5, NH4OAc 
or 
pH 7.0, PB 
0.057 
(pH 4.5, uncatalysed) 
0.68 
(pH 4.5, 10 mM aniline) 
 
0.015 
(pH 7.0, uncatalysed) 
0.061 
(pH 7.0, 100 mM p-
methoxyaniline) 
121
 
5 
Oxime  
50 µM aldehyde 
100 µM aminooxy 
 
pH 7.0, PB 
24 
(25 mM aniline) 
41 
(25 mM m-
phenylenediamine) 
122
 
6 
Oxime  
 
91 µM aldehyde 
455 µM aminooxy 
 
pH 4.0, Na citrate 
or 
pH 7.0, PB 
0.22 
(pH 4.0, uncatalysed) 
4.3 
(pH 4.0, 10 mM p-
phenylenediamine) 
 
0.006 
(pH 7.0, uncatalysed) 
0.29 
(pH 7.0, 10 mM p-
phenylenediamine) 
123
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7 
Oxime  
10 mM aldehyde 
10 mM aminooxy 
 
pH 7.0, PB:MeOH 
(1:1) 
0.0013 124
 
8 
Pictet Spengler  
60 µM aldehyde 
50 mM indole 
 
pH 6.5, PB 
N/A* 125
 
9 
iso-Pictet Spengler  
500 µM aldehyde 
500 µM indole 
 
pH 4.5, NaOAc 
or 
pH 7.0, PB 
10.6 
(pH 4.5) 
 
0.26 
(pH 7.0) 
88
 
10 
iso-Pictet Spengler  
2.5 mM aldehyde 
2.5 mM aldehyde 
 
pH 4, 
NaOAc:MeOH 
(1:1) 
0.015 124
 
11 
Hydrazino-iso-Pictet Spengler  
50 µM aldehyde 
50 µM indole 
 
pH 6, PB 
4.2 89
 
12 
Strain-promoted alkyne-nitrone cycloaddition  
300 µM nitrone 
330 µM alkyne 
 
H2O:MeCN (9:1) 
12.8 126
 
13 
Strain-promoted alkyne-nitrone cycloaddition  
1:100 molar ratios 
(nitrone:alkyne) 
 
MeCN 
58.8 127
 
14 
Mukaiyama aldol  
200 µM aldehyde 
400 µM silyl 
ketene acetal 
 
pH 7.0, PB 
24 hours, 55% yield 
(obtained)** 
128
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15 
Mukaiyama aldol  
37.5 µM 
7.13 mM silyl 
ketene acetal 
 
H2O:t-BuOH (5:1) 
5 hours, 90% 
(conversion)*** 
128
 
16 
Indium mediated allylation 
21 mM aldehyde 
150 mg indium 
63 mM allyl 
bromide 
 
PB pH 7.0 
16 hours, 56% yield 
(obtained)** 
129
 
17 
Indium mediated allylation  37.5 µM aldehyde 
1 mg indium 
836 µM allyl 
bromide 
 
H2O:t-BuOH (6:4) 
20 hours, 54% 
(conversion)*** 
129
 
18 
Wittig  
10 mM aldehyde 
20 mM ylide 
 
H2O:t-BuOH (1:1) 
90 min, 67% yield 
(obtained)** 
130
 
19 
Wittig  
4 mM aldehyde 
800 µM ylide 
 
100 mM PBS 
0.11 
(pH 6.75) 
0.90 
(pH 7.70) 
5.9 
(pH 8.4)0 
131
 
20 
2-Amino benzamidooxime  
15 mM aldehyde 
3 mM 2-
aminobenzamido
xime 
 
pH 4.5, NaOAc 
0.0086 132
 
21 
2-Amino benzamidooxime  
2 mM aldehyde 
1 mM 2-amino 
benzamidooxime 
 
pH 4.5, NaOAC 
1 132
 
22 
2-Amino benzamidooxime  
2 mM aldehyde 
1 mM 2-amino 
benzamidooxime 
 
pH 4.5, NaOAC 
40 132
 
23 
Thiazolidinedione aldol  
10 mM aldehyde 
10 mM 
thiazolidinedione 
 
pH 7.0, PB (25% 
DMSO) 
0.0078 133
 
24 
Thiazolidinedione aldol  
37.5 µM aldehyde 
37.5 mM 
thiazolidinedione 
 
pH 7.0, PB 
3 hours, 83% 
(conversion)*** 
133
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25 
Trapped Knoevenagel 
 
 
 
 
 
 
25 µM aldehyde 
1 mM 
thiopyrazolone 
 
pH 7.0, Na citrate 
0.387 91
 
 
aldehyde handles; these ligation products can then be visualised via SDS PAGE 
analysis.80,84,100,134 As discussed earlier, carbohydrates have also been installed into 
proteins via oxime ligation.16,87,106 In an alternate approach, glycosylated proteins 
have also been modified by initial oxidative cleavage of carbohydrate diols with 
NaIO4, followed by hydrazone ligation of the resultant aldehyde.
135,136 Oxime linked 
ADCs have also been reported;104,137 these constructs display both in vitro112 and in 
vivo134 cytotoxicity. More unconventional uses of oxime ligations strategies involve 
linking protein species together for the design of new therapeutics.77,138 A review on 
oxime chemistry within the field of aldehyde handle labelling has recently been 
published.139 Hydrazone and oxime ligations are undoubtedly the most frequently 
used method for modifying protein aldehyde/ketone handles; indeed, the 
aforementioned commercially available probes for modifying aldehyde handles are 
all hydrazine and hydroxylamine-based. However, these strategies are not without 
their drawbacks.  Both ligation strategies result in formation of a C=N bond between 
protein and substrate, and thus both are susceptible to hydrolysis over time. Of the 
two, oxime bonds display greater hydrolytic stability.140 Reductive amination of 
hydrazone bonds using sodium cyanoborohydride to form a more stable amine bond 
can be employed; however, this strategy is not commonly used within the context of 
modifying protein aldehydes (sodium cyanoborohydride is a water sensitive reagent 
and its use can lead to undesirable reduction of disulfide bonds22).  Additionally, the 
optimal pH for hydrazone and oxime ligations is pH 4.5, with poor reactivity 
observed at neutral pH, typically displaying rate constants of 10-3 M-1 s-1.123,141 To 
address this, several catalysts for performing hydrazone and oxime ligation at neutral 
pH have been investigated; aniline in particular has received a great deal of attention 
in the area of hydrazone/oxime ligation catalysis. For hydrazone ligations of peptide 
substrates in 10 mM anilinium buffer, a 20 fold increase in ligation rate is observed 
at pH 4.5, and a 70 fold increase in ligation rate is observed at pH 5.7 (Table 1.1, 
entry 1). Similarly, for oxime ligations of peptide substrates in 100 mM anilinium 
buffer solutions, a 400 fold increase in ligation rate is observed at pH 4.5, and a 40 
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fold increase in ligation rate is observed at pH 7.0.121 Ligations between aryl 
aldehydes and 6-hydrazinopyridyl reagents are of particular note, displaying rate 
constants within the range of 102-103 M-1 s-1 (Table 1.1, entry 3).120  The use of 
aniline in protein bioconjugation at a neutral pH has subsequently been reported.77,109 
Other aniline-based catalysts have also been reported, with meta-substituted anilines 
(Table 1.1, entry 5)122 and para-substituted anilines (Table 1.1, entry 6).  displaying 
improved kinetics to that of aniline for oxime ligations at pH 7.0. 70 In all cases, the 
catalysis is hypothesised to proceed via a ‘transimination’ type mechanism.121 In 
very particular cases, aniline does not appear to improve conjugation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.19 (A) Outline of hydrazone ligation on a generic protein bearing an aldehyde handle. (B) Outline of 
oxime ligation. (C). Structure of hydrazone/oxime bond on protein aldehyde handles. 
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yields of oxime ligations.138 Additionally, it has been reported that typical 
concentrations of aniline used in oxime ligation strategies (i.e. 100 mM aniline)77,121 
exhibit toxicity in live cell labelling experiments.109 Other catalysts include boronic 
acids142 and 2-aminophenols/2-(aminomethyl)benzimidazoles.143 
1.3.2 Pictet-Spengler, iso-Pictet Spengler, and Hydrazino-iso-Pictet Spengler 
The cyclisation reaction between tryptamines and aldehydes is known as the Pictet-
Spengler reaction. Formation of the Pictet-Spengler product occurs through initial 
iminium formation between the tryptamine amine and aldehyde, followed by 
intramolecular cyclisation. In the context of protein modification, an N-terminal 
Pictet-Spengler ligation on myoglobin has been reported (Figure 1.20).125 Following 
transamination with PLP,79 the Pictet-Spengler ligation between glyoxylamide-
containing myoglobin (glyoxyl-myoglobin) 13, and tryptamine 14, tryptophan 
methyl ester 15, and tryptamine-functionalised-biotin 16 was successfully carried out 
at pH 6.5 (confirmed by MS and subsequent proteolytic digest experiments), leading 
to protein constructs ligated to substrates via a C-C bond.125 
 
 
 
 
 
 
 
 
A variation of the Pictet-Spengler ligation, known as the iso-Pictet-Spengler ligation, 
has recently been reported for chemical modification of aldehyde handles 
incorporated into proteins (Figure 1.21A).88 Analysis of the reaction kinetics of the 
traditional Pictet-Spengler ligation was used as the basis for the design of the iso-
Pictet-Spengler ligation. Aminooxy-functionalised indoles (as opposed to 
Figure 1.20 (A) The Pictet-Spengler ligation on glyoxyl-myoglobin. (B) The Pictet Spengler ligation at a 
glyoxyl handle 
13 
14 15 
16 
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tryptamines) were utilised to accelerate the initial iminium formation between the 
indole and the aldehyde tag. Additionally, the aminooxy side chain was located on 
the 2-position of the indole ring (as opposed to the 3 position which is the case for 
tryptamine reagents) to accelerate the final cyclisation step. Based on an 
isobutyraldehyde system (Table 1.1, entry 9), the optimal pH for the reaction was 
found to be pH 4.5 (rate constant of 10.6 M-1 s-1), although product formation is still 
observed at pH 6.0-7.0 (observed rate constants of 0.76 M-1 s-1 at pH  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.21 (A)The iso-Pictet Spengler ligation on fGly-tagged maltose binding protein. (B). The 
Hydrainzo-iso-Pictet Spengler ligation on an fGly-tagged antibody. (C). The iso-Pictet/Hydrazino-iso-Pictet 
Spengler ligation at glyoxyl handle (left) and at an fGly handle (right). 
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6.0 and 0.26 M-1 s-1 at pH 7.0). 37 For glyoxyl systems, reduced rate constants for 
the iso-Pictet Spengler ligation have since been reported (Table 1.1, entry 10).124 The 
use of an aniline catalyst had no effect on the rate of reaction (and was noted to be 
inhibitory at  pH 5.0-6.5). Iso-Pictet-Spengler ligations with PEGylated, biotinylated, 
and fluorescent probes were successfully demonstrated on glyoxyl-myoglobin, fGly-
tagged maltose binding protein (MBP), and fGly-tagged Herceptin antibodies.88 
Compared to the original Pictet-Spengler ligation,125 both reagent concentrations and 
reaction time are vastly reduced in the iso-Pictet-Spengler ligation.88 A minor 
alteration to the iso-Pictet-Spengler ligation, known as the Hydrazino-iso-Pictet-
Spengler (HIPS) ligation, has also been described in the literature (Figure 1.21B).89 
The concept of the ligation strategy is nearly identical to that of the iso-Pictet-
Spengler ligation – except an N-methyl hydrazine-functionalised indole is used 
instead of an aminooxy functionalised indole. This facilitates the ligation at a higher 
pH of 6.0 (as hydrazines are more reactive than aminooxy compounds at a higher 
pH).144 The HIPS ligation shows improved ligation kinetics to that of the iso-Pictet-
Spengler ligation at pH 6.0 (observed rate constants of 4.2 M-1 s-1 using a 
benzyloxyacetaldehyde system, Table 1.1, entry 11), and has subsequently been 
utilised in the synthesis of ADCs.90 The combination of the fGly handle and the 
Hydrazino-iso-Pictet Spengler ligation forms the basis of SMARTag technology by 
Catalent Pharma Solutions (formerly Redwood Biosciences) for synthesis of next-
generation ADCs.14,90 
1.3.3 Strain-promoted alkyne-nitrone cycloaddition 
As discussed previously, alkyne reagents are frequently employed in strategies to 
selectively modify proteins,145 and alkyne mediated ligation strategies are commonly 
utilised in metabolic labelling experiments due to their bioorthogonality.11 Alkynes 
can also be used to site-selectively modify glyoxyl-proteins via the Strain-Promoted 
Alkyne-Nitrone Cycloaddition (SPANC) ligation (Figure 1.22). The SPANC ligation 
is a one-pot modification strategy that involves formation of a nitrone species 
between the aldehyde and N-methylhydroxylamine 17, followed by a cycloaddition 
reaction between the nitrone and strained cyclooctyne (see Table 1.1, entries 12 and 
13 for examples with small molecules).126 The addition of p-anisidine 18 greatly 
enhances the rate of the SPANC ligation – presumably by a mechanism that is akin 
to catalysis of hydrazone and oxime ligations. The SPANC ligation is usually 
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performed at pH 6.8 (NH4OAc buffer) and has been used to site-selectively modify 
the oxidised chemokine interleukin 8 (glyoxyl-IL-8) with a 2kDa PEG unit 19. 126 
Dual functionalisation of glyoxyl-peptides/proteins incorporating both azide-alkyne 
click chemistry and the SPANC ligation has also been reported.146 Additionally, 
SPANC ligation has been utilised in the design of antibody-nanoparticle constructs 
to design multivalent nanoparticles (MNPs) using an N-terminal serine variant of an 
anti-HER2 scFv antibody; these MNPs can then be used to selectively, fluorescently 
label HER2 membrane receptors in breast cancer cells.8 A variation of the SPANC 
ligation using preformed nitrones has also been utilised in metabolic labelling of live 
cells (although these nitrones are susceptible to hydrolysis in aqueous systems).147 
Preformed nitrones have also been the subject of various kinetic studies, identifying 
biaryl-aza-cycloctyne126 and acyclic nitrones systems127 as yielding the highest rate 
constants for the SPANC (58.8 M-1 s-1). A review of the SPANC ligation has 
recently been published.148  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.22 (A) Glyoxyl-interleukin 8 20, and formation of a nitrone species 21. (B). Reaction of an alkyne 
with the pre-formed nitrone via a cycloaddition to generate PEGylated  protein 22. 
18 
17 
19 
20 
21 
21 
22 
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1.3.4 Mukaiyama aldol 
The Mukaiyama aldol reaction involves the reaction of an aldehyde group and silyl 
enol ether to give β-hydroxy ketone products. The reaction forms a C-C bond 
between the aldehyde and silyl enol ether, is catalysed by Lewis acids (such as 
TiCl4) and can be performed in aqueous solvent systems.
149 A Mukaiyama aldol 
ligation for peptide and protein modification was first reported in 2010 (Figure 
1.23).128 Glyoxyl-peptides were functionalised with various silyl enol ethers in 
aqueous conditions to afford the anticipated Mukaiyama aldol ligation products after 
24 hours (see Table 1.1, entry 14 for an example). Products bearing alkene 
functionality could then be modified further by cross metathesis using a Hoveyda-
Grubbs second generation catalyst. The Mukaiyama aldol ligation has been utilised 
to modify glyoxyl-myoglobin 13, with a maximum of 90% conversion observed as 
(judged by LC-MS) in a H2O:t-BuOH (5:1) solvent system (Table 1.1, entry 15). 
Choice of solvent system for the Mukaiyama aldol ligation is of particular 
importance; 1:1 systems such as H2O:t-BuOH, pH 7 PB:EtOH, and H2O:MeCN all 
lead to homogenous product formation (76-90% conversion as judged by LC-MS), 
whereas other solvent systems such as H2O:glycerol and H2O:etheylene glycol lead 
to no observed conversion to the Mukaiyama aldol ligation product, or solvent 
systems such as pH 7 PB:EtOH (4:1), pH 7 PB:t-BuOH (1:1), and H2O:t-BuOH (6:1) 
lead to heterogeneous product mixtures.  UV-vis analysis and circular dichroism 
(CD) analysis of unmodified and modified myoglobin samples confirmed that the 
tertiary structure of the protein was unaffected by the Mukaiyama aldol ligation.128 
 
 
 
 
 
 
 
Figure 1.23 Outline of a Mukaiyama ligation on glyoxyl-myoglobin. 
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1.3.5 Indium mediated allylation 
An indium mediated allylation within the context of modifying glyoxyl peptides and 
proteins with simple allyl bromides has also recently been reported (Figure 1.24).129 
Glyoxyl-peptides were modified by indium mediated allylation with a number of 
allyl bromides to give racemic mixtures of the desired products after 18 hours (Table 
1.1, entry 16).  The ligation results in formation of a C-C bond and has also been 
demonstrated on glyoxyl-myoglobin 13, affording a maximum of 54% conversion 
after 20 hours to the desired product (judged by LC-MS analysis, Table 1.1, entry 
17). A 6:4 H2O:t-BuOH solvent system and sonication of the reaction mixture was 
utilised to achieve conversion to the desired product (these conditions cause partial 
dissociation of the haem group of myoglobin, although it is possible to reconstitute 
the protein following modification).129 
 
 
 
 
 
 
1.3.6 Wittig and tandem Wittig/Diel Alder 
The Wittig reaction, first reported in 1954, is the reaction between aldehydes and 
ylide-type reagents to give alkene products.150 Modification of glyoxyl peptides and 
proteins via a Wittig ligation have been recently demonstrated (Figure 1.25).130 
Glyoxyl-peptides were successfully modified with a number of small molecule 
ylides in a 1:1 H2O:t-BuOH solvent system, generating geometric isomers of the 
desired Wittig products (see Table 1.1, entry 18 for an example). Glyoxyl-myoglobin 
13 and glyoxyl-IL-8 20 were also modified using this chemistry in a 3:1 H2O:t-
BuOH solvent system. The ligation can also be performed in pH 7-10 buffer:t-BuOH 
systems, but does not occur in buffer systems below pH 6. The Wittig ligation results 
in formation of a C-C bond, and gives a 65% conversion complete within 30 minutes 
Figure 1.24 Outline an indium mediated allylation of glyoxyl-myoglobin. 
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on glyoxyl-myoglobin (judged by LC-MS analysis). UV-vis analysis, CD analysis, 
and analysis of the proteins ability to store and release oxygen were performed on 
unmodified and modified myoglobin samples,  
 
 
 
 
 
 
 
confirming that the tertiary structure of the protein was unaffected.130 More recently 
a thorough investigation into the kinetics of Wittig olefination within the context of 
bioconjugation, along with modification of phage libraries has been carried out 
(Figure 1.26A).131 In this study, the effects of aldehyde handle choice on both the 
E/Z product ratio (se Figure 1.26B for structures of both isomers) and the rate of 
Wittig olefination were examined using benzaldehyde, 2-nitrobenzaldehyde, and 
glyoxyl-VEKY peptide. At neutral pH, lower rate constants and higher selectively 
for the E isomer were observed when using benzaldehyde, whereas higher rate 
constants and lower selectively for the E isomer were observed when the aldehyde 
handle of choice was either 2-nitrobenzaldehyde or glyoxyl-VEKY peptide These 
rate constants could be increased further at higher pH values (see Table 1.1, entry 
19); however, hydrolysis of the ester backbone of the Wittig products was found to 
be also accelerated. Total hydrolysis of the Z-isomer was observed after 7 h at pH 8, 
and a half-life of t1/2 = 18 h was observed for the E-isomer, whereas at pH 5, 
hydrolysis half-life was observed to be t1/2 > 75 h. Additionally, choice and 
concentration of buffer salts were also established to affect the rate of Wittig 
olefination. Subsequently Wittig olefination was then applied towards selective 
modification of glyoxyl-bearing phage libraries using a ylide ester biotin 
phosphonium salt precursor (YEB) 23 in MOPS buffer at pH 6.5. These Wittig 
products could then be site-selectively modified further, either via Michael addition 
Figure 1.25 Outline of Wittig ligation of glyoxyl-interleukin 8. 
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using functionalised thiols (for example, using a Cys containing FLAG tag), or via a 
Diels-Alder reaction with cyclopentadiene 24. The Diels-Alder reaction is selective 
for the E-isomer of the Wittig product (Figure 1.26C), whereas the Z-isomer of the 
Wittig product is unreactive towards Diels-Alder modification.131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.26 (A) Labelling of glyoxyl-phage via a Wittig ligation with ylide ester biotin phosphonium salt 
precursor. (B) Structure of the Z and E isomers formed during the Wittig ligation. (C) Diels Alder reaction of 
the Z isomer of the Wittig bioconjugate. 
23 
24 
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1.3.7 2-Amino benzamidoxime (ABAO)  
The use of 2-amino benzamidoxime (ABAO) compounds in the modification of 
peptides and proteins bearing aldehyde handles has been very recently described 
(Figure 1.27).132 Initial screening of a variety of substituted aniline compounds 
against model glyoxyl substrates identified ABAO compounds as suitable reagents 
for site-selective modification, giving rise to single, hydrolytically stable 
dihydroquinazoline products which exhibit fluorescence at 490 nm. The ligation is 
performed under acidic conditions (pH 4.5), and is thought to proceed through via 
imine formation between the aldehyde substrate and aniline component. 
 
 
 
 
 
 
 
 
 
 
This is followed by intramolecular cyclisation via attack of the ABAO ortho 
amidoxime group at the newly formed imine, completing the ligation. The rate of 
ABAO ligation can vary depending on the both the choice of aldehyde and ABAO 
derivative; in particular, higher rate constants are observed in isobutyraldehyde 
systems compared to glyoxyl systems (40 M-1 s-1 compared to 1 M-1 s-1, Table 1.1, 
entries 21 and 22), and also in para-methoxy ABAO systems (Table 1.1, entry 20). 
Acetate (from the NaOAc buffer) can also act as a weak catalyst in the ABAO 
ligation (as observed from altering buffer concentrations). Notably, ABAO ligation 
is slow when the aldehyde substrate in question is glucose (in a ring opened form), 
Figure 1.27 Outline of 2-amino benzamidoxime ligation on M13 phage bearing glyoxyl-peptides. 
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suggesting that ABAO ligation could be expanded to other selective labelling 
applications in more complex biological mixtures. The ABAO ligation has been used 
in the biotinylation of horseradish peroxidase (HRP) bearing aldehydes derived from 
oxidised glycans, and additionally in the biotinylation of glyoxyl-peptide bearing 
M13 phage libraries with ABAO-derived biotin 25.132 
 
1.3.8 Thiazolidinedione aldol 
Thiazolidinedione compounds have been described as acting as donor compounds in 
uncatalysed aldol reactions.151 This methodology has very recently been extended to 
peptide and protein modification (Figure 1.28).133 The ligation was demonstrated on 
C-protected glyoxyl-dipeptides with a number of simple thiazolidinediones bearing 
various functionality such as alkyne, azide and short chain PEG moieties. 
Additionally, modification of glyoxyl-myoglobin 13 can be achieved in a 5:1 pH 6.5 
PB:t-BuOH solvent system with conversions of 66-83% observed within 3 hours at 
37 oC (judged by LC-MS analysis, Table 1.1, entry 24). 
 
 
 
 
 
In all cases, high concentrations of thiazolidinedione reagent were utilised (1000 
molar equivalents with respect to glyoxyl-myoglobin concentration). UV-vis 
analysis, CD analysis, and analysis of the proteins ability to store and release oxygen 
were performed on unmodified and modified myoglobin samples, confirming that 
the tertiary structure of the protein was unaffected.133 Observed reaction kinetics for 
the Thiazolidinedione aldol ligation were 0.0078 M-1 s-1 (Table 1.1, entry 23),133 
which are comparable to that of uncatalysed hydrazone and oxime ligations at pH 
7.0-7.4.123,152 
Figure 1.28 Outline of modification of glyoxyl-myoglobin with thiazolidinediones. 
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1.3.9 Knoevenagel condensations 
A Knoevenagel condensation reaction, dubbed the trapped-Knoevenagel ligation 
(tK), between fGly peptides/antibodies and compounds containing enolisable protons 
has recently been described (Figure 1.29). In this ligation, thiopyrazolone reagents 
are subjected to the fGly species to afford C-C linked 
tetrahydrothiopyranopyrazolone products.91 The reaction occurs via initial enone 
formation between the aldehyde and thiopyrazolone, followed by intramolecular 
cyclisation through Michael-type addition of the thiol side chain. This ligation 
strategy proceeds at pH 7.0-7.2 and has been validated on benzyloxyacetaldehyde, 
benzaldehyde and fGly functionalised peptides. The tK ligation has also been 
explored in the synthesis of ADCs through the tagging of fGly functionalised 
Herceptin with thiopyrazole-functionalised maytansine; ligation of these species 
exhibits a rate constant of 0.387 M-1 s-1 (Table 1.1, entry 25), and the resulting 
constructs display both in vitro and in vivo cytotoxicity.91 
 
 
 
 
 
In addition to the tK ligation, an alternate Knoevenagel condensation, known as the 
Tandem Knoevenagel Condensation-Michael Addition (TKM) has very recently 
been reported in the literature (Figure 1.30).153 The TKM strategy is almost identical 
to that of the tK, with the key difference lying in the identity of the pyrazolone 
partner. In constrast to the tK, which uses thiopyrazolone reagents to facilitate both 
initial Knoevenagel condensation and subsequent Michael-type intramolecular 
cyclisation, the TKM uses pyrazolone partners that do not contain a thiol side chain, 
preventing intramolecular cyclisation as seen in the tK. Instead, following initial 
enone formation as seen in the tK ligation, intermolecular bioconjugation of a second 
pyrazolone molecule occurs via a Michael-type addition, resulting in a second 
bioconjugation in a one pot process (both steps at pH 7.2). The TKM has been 
Figure 1.29 Outline of the Trapped-Knoevenagel ligation on fGly-tagged Herceptin. 
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applied in the synthesis of ADCs bearing drug to antibody ratios (DARs) of four; 
these constructs have subsequently been used to investigate how the location of 
conjugated payloads of ADCs can affect ADC half-life, and in vivo efficacy.153 
 
 
 
 
 
 
 
  
Figure 1.30 Outline of the Tandem Knoevenagel Condensation-Michael addition on fGly-tagged antibodies. 
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1.4 Developing new methodology for protein bioconjugation 
As evident from Chapter 1, there are now numerous elegant methods available for 
generating protein bioconjugates, revolutionising the way chemists and biologists 
approach the fields of medicine, chemical biology, and cell biology. However, many 
of the methods for protein bioconjugation described in the literature suffer from 
various drawbacks. The majority of conjugation methods using naturally occurring 
amino acids are non-selective, and lead to a heterogeneous mixture of bioconjugates; 
this issue can however be avoided by using site-selective strategies. These site-
selective strategies must then operate in aqueous conditions, at neutral pH, at mild 
temperatures, and yield hydrolytically stable bonds, all whilst offering selective 
modification at a particular site on the protein, and maintaining any integrity and 
function the unmodified protein may have. 15,19 In particular, strategies that 
synthesise carbon-carbon (C-C) bonds are highly prized in protein bioconjugation, 
due to the C-C bond being stable across a range of conditions. Although current 
methods to construct C-C linked protein bioconjugates have greatly furthered the 
field of chemical biology, such as in designing new therapeutics or synthesising 
PTM mimics, 17,18,90,91,153 the majority of C-C bond forming bioconjugation 
strategies utilise conditions that fall outside of the requirements of a protein 
bioconjugation strategy, such as conducting ligations outside of neutral pH (usually 
at acidic pH), displaying poor kinetics of ligation, or using reagents that potentially 
can denature the target protein. C-C bond forming strategies are also sometimes 
hampered by the requirement of expensive chemical probes, or by the reduced 
reactivity displayed in the presence of oxygen. There is therefore a need to develop 
C-C bioconjugations strategies that are efficient and, most importantly, operate at 
neutral pH whilst maintain protein integrity. As a bonus, such strategies would also 
utilise simple chemical probes in small ratios, and be oxygen tolerant. 
Site-selective modification of aldehyde handles incorporated into proteins has been 
at the forefront of the field of chemical biology, with protein aldehyde 
bioconjugation proving to be a highly versatile method of generating homogenous 
protein conjugates with wide ranging applications. Particularly notable is that, with 
the exception of hydrazone/oxime strategies which form hydrolytically unstable 
C=N bonds, all protein aldehyde bioconjugation strategies lead to C-C bond 
formation between the target protein and reagent/chemical probe, making the 
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aldehyde handle an ideal choice for bioconjugation studies regarding C-C linked 
protein bioconjguates. Each C-C bond forming protein aldehyde bioconjugation 
strategy has represented a significant landmark in the development of protein 
bioconjugation strategies for designing hydrolytically stable protein bioconjugates, 
and their importance in furthering the field of chemical biology cannot be 
understated. That being said, the protein aldehyde ligation strategies described in the 
literature suffer from at least one of the aforementioned drawbacks, hampering their 
overall utility. The iso-Pictet Spengler ligations88,89 and the ABAO ligation132 show 
greatly reduced reactivity at neutral pH, requiring acidic conditions, whilst the Pictet 
Spengler ligation,125 Mukaiyama aldol ligation,128 and Thiazolidinedione aldol 
ligation133 require very high concentrations of reagent to achieve notable conversions 
to the desired protein bioconjugate. Indeed, as seen in Table 1.1, the majority of the 
protein aldehyde ligations strategies display poor kinetics of ligation at neutral pH.141 
The Mukaiyama aldol ligation 128 is heavily dependent on co-solvent to achieve site-
selectivity, whilst cyclooctyne reagents, which are used in the SPANC,126 are known 
to show off-site reactivity with thiols.154 Additionally, the TKM153 leads to two 
modifications as opposed to one, which may not always be desired depending on the 
application. Wittig bioconjugates have been reported to show hydrolytic instability 
(albeit due to the ester backbone from the probe rather than the actual Wittig bond of 
the bioconjugate itself),132 whilst the Indium mediated allylation129 leads to protein 
denaturation. Undoubtedly, taking all of these factors into account, there is clearly 
scope for the development of C-C bond forming protein bioconjugation strategies 
utilising aldehyde handles that operate at neutral pH, use small ratios of chemical 
probe, show efficient ligation kinetics, and maintain protein integrity. Such 
developments would represent the next important step in developing useful protein 
aldehyde bioconjugation chemistry, and contribute towards furthering the fields of 
protein bioconjugation and chemical biology as a whole. 
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1.5 Aims of the project 
The primary aim of this project was to design new methodology for the site-selective 
modification of protein aldehydes via C-C bonds at neutral pH. Protein scope, 
diversity of chemical probes, and kinetics of the ligation strategy were also deemed 
to be of high importance, and were therefore also taken into major consideration 
during the design process. Additionally, in order to ensure the designed C-C 
bioconjugation strategy was oxygen tolerant, it was decided that, throughout the 
course of the project, all experiments were to be performed in the presence of air. As 
a bonus, the ligation strategy developed would have some downstream application in 
the more underdeveloped areas within the field of protein bioconjugation, such as in 
multi-functionalisation of proteins or in the design of useful protein bioconjugates 
(proteins bearing PTM mimics for example). To achieve these aims, the project was 
mainly focused on developing an enamine-type aldol reaction that would be suitable 
for protein bioconjugation. Enamine catalysed aldol reactions are one of the most 
well documented C-C bond forming reactions in organic synthesis involving 
aldehydes (and ketones), and have previously been documented for their 
compatibility with aqueous/buffered conditions without the need for inert conditions 
(see Section 3.1.7 and references within). The reaction also generates an additional 
carbonyl group which could be theoretically primed for further reactions, allowing 
for further protein modification in the context of bioconjugation. Such a strategy has 
yet to be reported in the literature, and, following its serendipitous discovery during 
the course of the project (see Section 3.1), an enamine-type aldol reaction for protein 
bioconjugation was considered to be a worthwhile strategy to investigate in order to 
achieve the aims outlined above. 
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Chapter 2: Preparation of α-oxo protein aldehydes 
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2.1 Obtaining α-oxo aldehyde containing peptides/proteins 
As discussed previously in Chapter 1, aldehydes are a functional group not naturally 
present within the canonical amino acids, making them suitable handles for site-
selective protein bioconjugation following their incorporation into a target protein. 
There are now seven different methods of installing aldehyde handles into proteins 
reported in the literature, of which there are seven different types of aldehyde handle 
that all display different electronic/steric properties. Of these handles, the α-oxo 
aldehyde handle is the most popular choice of aldehyde handle for site-selective 
protein aldehyde-based bioconjugation, with 11 of the 13 protein aldehyde strategies 
reported in the literature documented to be compatible with the handle. This 
aldehyde handle was therefore chosen to be the primary handle for the development 
of strategies for site-selective protein aldehyde bioconjugation. With this in mind, 
several protein scaffolds known to be (or postulated to be) compatible with α-oxo 
aldehyde installation were chosen for further investigation into the development of 
protein aldehyde bioconjugations. 
2.1.1 Glyoxyl-LYRAG 
For protein bioconjugation, peptides represent ideal model protein systems, as they 
are significantly lower in molecular weight (and therefore easier to characterise), and 
are easy to synthesise and customise via SPPS. Therefore, for this project, the six-
mer peptide SLYRAG 26 (Figure 2.1A) was synthesised using SPPS. SLYRAG 26 
was then oxidised with NaIO4 according to previously reported literature
121 to give 
glyoxyl-LYRAG 27, which, akin the glyoxyl-proteins, exists in equilibrium between 
both an ‘aldehyde’ and ‘hydrate’ species (27 and 27-Hyd, Figure 2.1B), the latter of 
which is the dominant form in solution. Purification of this peptide can be easily 
achieved through reverse phase chromatography, and the purified peptide can be 
stored long term at -20 oC as a lyophilised powder. Glyoxyl-LYRAG 27 has 
previously been described as a test substrate for investigating aniline catalysed 
oxime ligations, 121 and was therefore considered to be a suitable, model substrate to 
act as mimic of a protein α-oxo aldehyde species. 
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2.1.2 Myoglobin 
Horse heart myoglobin 28 is a small, 17 kDa protein155, and is commonly used a 
model protein substrate in the design of new ligation strategies.79,88,125,130,133 The 
protein is commercially available, and glyoxyl functionality can be introduced via a 
transamination reaction with PLP 8 in 25 mM PB pH 6.5 buffer to give glyoxyl-
myoglobin 13 (Figure 2.2A) which primarily exists as the hydrate species (13-Hyd, 
Figure 2.2B).79 Additionally, the protein features a haem group (responsible for 
carrying oxygen to muscle tissue) which has characteristic absorbance within the 
region of λ = 410 nm. This absorbance can be used as an indicator of protein 
integrity after modifications are made to the protein, as any myoglobin samples that 
are denatured and lose protein integrity after modification will no longer give an 
absorption signal within the region of λ = 410 nm.79,128,130 There are two methods for 
installation of the α-oxo aldehyde into myoglobin 28 via biomimetic transamination: 
Gilmore, Francis, and co-workers 2006 method which uses 10 mM loading of PLP 8 
and requires 18 h reaction times,79 and a modified method described in 2013 by 
Agarwal, Bertozzi, and co-workers that uses a 100 mM loading of PLP 8 and 
requires 1 h reaction times.88 Both methods use 50 µM of myoglobin 28 and are 
performed in 25 mM PB buffer that is adjusted to pH 6.5 using NaOH (pH 
Figure 2.1 (A) Structure of SLYRAG peptide. (B) Oxidation of SLYRAG to Glyoxyl-LYRAG, which is in 
equilibrium as both the “aldehyde” and “hydrate” form. 
26 
26 27 27-Hyd 
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adjustment of PLP stock solutions prior to addition to myoglobin is necessary as 
dissolution of PLP into a 25 mM PB pH 6.5 solution causes a reduction in pH). 
Initially, the former transamination method was used to obtain glyoxyl-myoglobin in 
this project; however, as stated in the original 2006 publication and in subsequent 
publications in the field of biomimetic transamination chemistry, this procedure does 
not always lead to complete conversion of myoglobin to glyoxyl myoglobin, which 
affects downstream ligation yields. Through minor optimisation, it was discovered 
during the project that altering PLP loading from 10 mM to 15 mM resulted in a 
more reliable conversion of myoglobin to glyoxyl-myoglobin 13 (as judged by LC-
MS in subsequent ligation experiment yields). Typical LC-MS data observed for 
myoglobin 28 and glyoxyl-myoglobin 13 are shown in Figure 2.2C and Figure 2.2D 
respectively. 
 
 
 
 
 
 
 
 
NB: Myoglobin 28 was obtained from commercial sources as a lyophilised powder 
with ≥ 90% purity as judged by SDS-PAGE. Subsequent SDS-PAGE analyses of 
samples of myoglobin 28, examples of which can be seen in Chapter 5, additionally 
confirmed the identity and purity of myoglobin 28 used throughout this project. 
2.1.3 Cholera toxin subunit B 
In nature, cholera toxin subunit B (CTB) 29 is a pentameric protein that associates 
with a toxic, monomeric protein cholera toxin subunit A (CTA) to form an AB5 toxin 
complex.156 CTB contains carbohydrate binding sites, which allow the AB5 complex 
Figure 2.2 (A) Biomimetic transamination of myoglobin 28 to glyoxyl-myoglobin 13 with PLP 8. (B) Structure 
of glyoxyl-myoglobin 13, which is in equilibrium as both the “aldehyde” and “hydrate” form. (C) ESI-MS of 
myoglobin. (D) ESI-MS of glyoxyl-myoglobin, which is primarily observed as the “hydrate” form 13-Hyd. 
28 
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to bind to GM1 gangliosides on the surface of epithelial cells.157 This facilitates 
endocytosis of the AB5 complex, and eventual release of the toxic CTA, leading to 
symptoms of the disease cholera.156 In the context of protein aldehyde chemistry, 
CTB 29 contains an N-terminal threonine residue which, akin to N-terminal serine, 
can be oxidised using NaIO4 to give the corresponding glyoxyl-CTB protein 30 
(Figure 2.3A) which initially exists as the hydrated species (Figure 2.3B).77,158 LC-
MS data observed for CTB 29 and glyoxyl-CTB 30 are shown in Figure 2.3C and 
Figure 2.3D respectively. 
 
 
 
 
 
 
 
 
 
Conversion of CTB 29 to glyoxyl-CTB 30 is a straightforward procedure; 
modification of glyoxyl-CTB 30 however is challenging, as the protein contains a 
proline residue at position 2, which over time can lead to an intramolecular 
cyclisation reaction to an unreactive hemiaminal as shown in Figure 2.4.158 
 
 
 
 
 
Figure 2.3 (A) Periodate-mediated oxidation of CTB 29 to glyoxyl-CTB 30. (B) Structure of glyoxyl-CTB 30, 
which is in equilibrium as both the “aldehyde” and “hydrate” form. (C) ESI-MS of CTB. (D) ESI-MS of glyoxyl-
CTB, which is primarily seen as the “hydrate” form 30-Hyd. 
Figure 2.4 Intramolecular cyclisation of glyoxyl-CTB 30. Nucleophilic attack of the amide bond at the α oxo-
aldehyde position occurs over time, resulting in the formation of an unreactive hemiaminal 30-Cyc. 
29 
30 
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Experimental details for producing CTB 29, along with its oxidation, have been 
previously described; these were used to generate glyoxyl-CTB 30 for use in the 
project.77 During this project, CTB 29 was produced under IPTG induction of gene 
expression, followed by ammonium sulfate precipitation and nickel purification (as 
outlined in Reference 77, see Experimental for further details). For the production of 
glyoxyl-CTB 30, oxidation of CTB 29 was carried out in the presence of L-
methionine to prevent the undesired oxidation of thiol side chains in the protein (see 
Figure 2.3A). 
NB: CTB 29 exists as a stable pentamer (ca. 58 kDa) which breaks down into 
monomers (ca. 12 kDa) if boiled or subjected to conditions used in the LC MS. SDS-
PAGE analysis of unboiled and boiled samples of CTB 29, examples of which can be 
seen in the Experimental section, confirmed the identity of CTB 29 and the prescence 
of the pentameric form following nickel purification. 
 
2.1.4 Thioredoxin 
Thioredoxin is an oxido-reductase protein found in many domains of life, and has 
various roles including disulfide bond reduction.159 Thioredoxin 31 from E. coli 
(which is commercially available) contains an N-terminal serine and is primed for 
oxidation by NaIO4 to give the corresponding glyoxyl-thioredoxin 32. Similarly to 
CTB, thioredoxin contains cysteine residues, which bear thiol side chains that are 
prone to undesired oxidation to generate sulfoxide-containing protein by-products. In 
order to develop a procedure for the selective oxidation of the N-terminus of 
thioredoxin, a screen of conditions with varying temperatures, concentration of 
NaIO4, and concentration of L-methionine, was carried out as outlined in Table 2.1. 
Thioredoxin 31 samples for oxidation were kept at final concentration of 80 µM in 
102 µL reaction solutions in 0.1 M PB, 0.1 M NaCl pH 7.0 buffer, and allowed to 
proceed in the dark. All samples were analysed by LC-MS and desalted prior to 
analysis. Conversion to glyoxyl-thioredoxin 31, as well as thiol oxidation, could be 
determined by LC-MS, examples of which are shown in Figure 2.5. 
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Table 2.1 Conditions screened for the oxidation of thioredoxin to glyoxyl-thioredoxin. Conversions to glyoxyl-
thioredoxin and undesired oxidation of thiol residues was assessed by ESI-MS analysis. 
Entry Final NaIO4 
concn (µM) 
Final L-
Met concn 
(µM) 
Temp. 
(oC) 
Time 
(min) 
Conversion to 
31 (%) 
Thiol 
ox (%) 
1 88 0 RT 15 >99 50 
2 88 0 RT 60 >99 >99 
3 400 800 RT 15 >99 50 
4 400 800 RT 30 >99 50 
5 800 800 RT 15 >99 80 
6 200 800 RT 15 >99 25 
7 300 600 4 4 >99 0 
 
 
 
 
 
 
 
Successful selective oxidation of the N-terminus of thioredoxin 31 was achieved as 
outlined in Table 2.1, Entry 7. Holding the reaction at 4 oC, along with keeping the 
protein, NaIO4 and L-methionine stock solutions on ice prior to performing the 
oxidation procedure, was found to be critical in avoiding undesired oxidation of thiol 
residues. This finalised set of conditions for thioredoxin 31 oxidation were taken 
from Table 2.1, Entry 7, and used to generate glyoxyl-thioredoxin 32 for 
downstream site-selective modification experiments (Figure 2.6A). Glyoxyl-
thioredoxin 32 primarily exists as the hydrate species 32-Hyd as judged by LC-MS 
(Figure 2.6B). Examples of LC-MS data observed for both thioredoxin 31 and 
glyoxyl-thioredoxin 32 are shown in Figure 2.6C and Figure 2.6D respectively.  
Figure 2.5 ESI-MS data of glyoxyl-thioredoxin 32 bearing different amounts of thiol oxidation following 
treatment with NaIO4. Calculated mass of 32-Hyd = 11661 Da, 11677 Da with thiol oxidation. 
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NB: Thioredoxin 31 was obtained from commercial sources as a lyophilised powder 
with ≥ 90% purity as judged by SDS-PAGE. Subsequent SDS-PAGE analyses of 
samples of thioredoxin 31, examples of which can be seen in Chapter 5, additionally 
confirmed the identity and purity of thioredoxin 31 used throughout this project. 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 (A) Periodate-mediated oxidation of thioredoxin 31 to glyoxyl-thioredoxin 32. (B) Structure of 
glyoxyl-thioredoxin 32, which is in equilibrium as both the “aldehyde” and “hydrate” form. (C) ESI-MS of 
thioredoxin 31. (D) ESI-MS of glyoxyl-thioredoxin, which is primarily seen as the “hydrate” form 32-Hyd. 
31 32 
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2.1.5 Green fluorescent protein 
Green fluorescent protein (GFP) is a 27 kDa protein from the jellyfish Aequorea 
victoria that, upon exposure to blue/uv light, emits green, fluorescent light.160-162 
This fluorescence results from the PTM of amino acids S65, Y66, and G67; 
following protein folding, these three amino acids undergo cyclisation, dehydration, 
and oxidation to yield an imidazolidinone chromophore responsible for the proteins 
characteristic fluorescence.163 The fluorescent properties of GFP have led to the 
protein becoming a staple tool in molecular biology,164 with applications as a marker 
for gene expression,161 in visualising subcellular localisation of biomolecules165,166, 
and in developing protein bioconjugation strategies.61 Indeed, the revolutionary 
discovery and development of GFP by Shimomura, Chalfie, and Tsien, led to them 
receiving the Nobel Prize in Chemistry in 2008.167-169 Unsurprisingly, variants of 
GFP frequently feature as protein scaffolds for the validation and development of 
methodology within the field of protein aldehyde bioconjugation, including PLP 
transamination,79 installation of fGly handles,93,170 development of PFTase mediated 
FAPP installation,98 and Tub tagging.105 For the development of protein aldehyde 
bioconjugation strategies during this project, a GFP variant containing an N-terminal 
serine was made available during this project; additionally, this GFP variant also 
bears an unnatural cyclooctyne-containing amino acid at position 39, meaning that 
this GFP variant could also be used as a model protein scaffold for testing the 
orthogonality of any subsequent protein aldehyde ligation with cyclooctyne groups 
alongside functional groups typically found within the canonical amino acid 
repertoire. The N-terminal serine, cylcooctyne containing GFP (Ser-
GFP(Y39CylcooctK), referred to as GFP 33 hereon in)i also contains cysteine 
residues; therefore, a modified procedure for the oxidation of thioredoxin was 
applied towards the oxidation of GFP 33 to glyoxyl-GFP 34, and this procedure was 
used to generate glyoxyl-GFP 34 for use throughout the project (Figure 2.7A, see 
Experimental for details on preparation). As with other protein α-oxo aldehydes, 
glyoxyl GFP predominantly exists in the hydrated form 34-Hyd (Figure 2B). 
Examples of LC-MS data observed for both GFP 33 and glyoxyl-GFP 34 are shown 
in Figure 2.7C and Figure 2.7D respectively. 
                                                          
i GFP 33 was kindly provided by Robin Brabham. 
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2.1.6 Hydrophilic acylated surface protein A 
Hydrophilic acylated surface proteins (HASPs) are a class of proteins with a 
currently unknown biological function that are expressed during the infective stages 
of the parasite Leishmania donovani.171 They are highly immunogenic, and form part 
of a visceral leishmaniasis vaccine currently undergoing clinical trials in humans.172 
HASPs are enzymatically, post-translationally dually acylated at the N-terminal 
region;173,174 specifically, HASPs undergo N-myristoylation, (covalent attachment of 
a C14 myristate group) at the amino group an N-terminal glycine, and S-
palmitoylation (covalent attachment of a C16 palmitate group) at the thiol of a 
cysteine at position 4.175 N-myristoylation is facilitated by the N-
myristoyltransferase (NMT) enzyme, whereas S-palmitoylation is facilitated by an 
unknown S-palmitoyltransferase. Although not entirely understood, both of these 
PTMs are thought to facilitate membrane trafficking of the HASPs.175 
Amongst other criteria, one of the absolute requirements for successful N-
myristoylation of a target protein by NMT is that the protein in question must 
contain an exposed N-terminal glycine (this is true for HASPs and other proteins that 
undergo N-myristoylation).176 As a result, HASPs (and other proteins that are targets 
for N-myristoylation) were postulated to be theoretically primed for installation of 
glyoxyl functionality via N-terminal biomimetic transamination using PLP 8. To test 
this hypothesis, the procedure for biomimetic transamination of myoglobin was 
Figure 2.7 (A) Periodate-mediated oxidation of GFP 33 to glyoxyl-GFP 34. (B) Structure of glyoxyl-GFP 34, 
which is in equilibrium as both the “aldehyde” and “hydrate” form. (C) ESI-MS of GFP 33. (D) ESI-MS of 
glyoxyl-GFP, which is primarily observed as the “hydrate” form 34-Hyd. 
33 34 33 
34 34-Hyd 34-Hyd 
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applied towards installing glyoxyl functionality into HASPA 35, a 9.5 kDa HASP. ii 
Successful transamination of HASPA 35 to glyoxyl-HASPA 36 (Figure 2.8A, see 
Figure 2.8B for schematic of equilibrium between the “aldehyde” and “hydrate” 
form, and Figure 2.8C-D for relevant ESI-MS data) was confirmed as judged by LC-
MS by the appearance of a peak at 9467 Da, corresponding to the hydrated form 36-
Hyd of glyoxyl-HASPA 36. An additional peak at 9490 Da was also observed post 
biomimetic transamination, which proved to be inert to subsequent site-selective 
modification. It was anticipated that this peak was a PLP-protein related by-product, 
as PLP related by-products of proteins have been previously reported in the 
literature.80 A peak at 9448 could either correspond to the “aldehyde” form of 
glyoxyl-HASPA 36, or unreacted HASPA 35. 
 
 
 
 
 
 
 
 
 
As seen in Figure 2.8D, a significant portion of HASPA 35 (as judged by LC-MS) is 
converted to the aforementioned unknown by-product following biomimetic 
transamination. Therefore, in an effort avoid this by-product, and reduce the time 
taken for aldehyde installation into HASPA 35, the N-terminal glycine was mutated 
into a serine for periodate-based oxidation to give HASAP(G1S) 37. A modified 
procedure for the oxidation of thioredoxin 31 was applied towards the oxidation of 
                                                          
ii HASPA 35 was kindly provided by Dr Sophie McKenna. 
Figure 2.8 (A) Biomimetic transamination of HASPA 35 to glyoxyl-HASPA 36 with PLP 8. (B) Structure of 
glyoxyl-HASPA 36, which is in equilibrium as both the “aldehyde” and “hydrate” form. (C) ESI-MS of HASPA 
35. (D) ESI-MS of glyoxyl-HASPA, which shows the “hydrate” form of the protein 36-Hyd, with additional 
peaks corresponding to unreacted HASPA or “aldehyde” glyoxyl HASPA (9448), and an anticipated HASPA-
PLP by-product (9490). 
35 8 36 
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HASPA(G1S) iii 37  (Figure 2.9A) to glyoxyl-HASPA 36 (see Figure 2.9B for 
schematic of equilibrium between the “aldehyde” and “hydrate” form). Both 
HASPA(G1S) 37 and glyoxyl-HASPA 36 were analysed and confirmed by LC-MS 
(Figure 2.9C and Figure 2.9D respectively), with the latter compared directly to the 
ESI-MS data obtained when generated glyoxyl-HASPA 36 via biomimetic 
transamination (Figure 2.9E). As evidenced in Figure 2.9E, generating glyoxyl-
HASPA 36 from periodate oxidation of HASPA(G1S) 37, as opposed to biomimetic 
transamination of HASPA 35, avoids formation of PLP-related by-products and 
gives a greater conversion overall to the desired α-oxo aldehyde. 
 
 
 
 
 
 
 
 
 
 
 
 
 
NB: During this project, 15N labelled HASPA 36 and 37 was also used. These 
species will be referred to as 36-15N and 37-15N. 
                                                          
iii HASPA(G1S) 37 was kindly provided by Dr Tessa Keenan. (see Reference 2 preparation of the 
HASPA protein). 
Figure 2 9 (A) Periodate-mediated oxidation of HASPA(G1S) 37 to glyoxyl-HASPA 36. (B) Structure of 
glyoxyl-HASPA 36, which is in equilibrium as both the “aldehyde” and “hydrate” form. (C) ESI-MS of 
HASPA(G1S) 37. (D) ESI-MS of glyoxyl-HASPA, which is primarily observed as the “hydrate” form 36-Hyd. 
(E) Comparison of ESI-MS data obtained for glyoxyl HASPA 36 generated from either biomimetic 
transamination of HASPA 35, or periodate-mediated oxidation of HASPA(G1S) 37. 
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2.1.7 Thiazolidine containing green fluorescent proteins 
Until recently, the α-oxo aldehyde handle had been restricted to the N-terminus of 
proteins, limiting the versatility of ligations targeting this handle. It was not until 
method development for the incorporation of thiazolidine amino acids such as 38 
into proteins, and subsequent thiazolidine metal-mediated decaging, that the α-oxo 
aldehyde handle could be installed at other sites on a target protein. Superfolder GFP 
(sfGFP) bearing thiazolidine (sfGFPN150ThzK) 39 and GFP bearing thiazolidine 
(GFPY39ThzK) 40 were made available during this projectiv (Figure 2.10A), and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
iv sfGFPN150ThzK 39 and GFPY39ThzK 40 were kindly provided by Robin Brabham (see Reference 2 
for preparation). 
Figure 2.10 (A) Installation of an unnatural thiazolidine side chain using unnatural amino acid mutagenesis to 
generate sfGFP(N150ThzK) 39 and GFP(Y39ThzK) 40. (B) Decaging of sfGFP(N150ThzK) 39. (C) Equilibrium 
of the ‘aldehyde’ and ‘hydrate’ form of sfGFP(N150GlyoxylK) 41. (D) Decaging of GFP(Y39ThzK) 42. (E) 
Equilibrium of the “aldehyde” and “hydrate” form of GFP(Y39GlyoxylK) 42. (F) ESI-MS of sfGFP(N150ThzK) 
39. (G) ESI-MS of sfGFP(N150GlyoxylK), which is primarily seen as the “hydrate” form 41-Hyd. (H) ESI-MS 
of GFP(Y39ThzK) 40. (I) ESI-MS of GFP(Y39GlyoxylK), which is primarily seen as the “aldehyde” form 42. 
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could be readily decaged using 1 molar equivalent of palladium (II) allyl chloride 
dimer ([PdCl(allyl)]2.
116 Decaging of sfGFP(N150ThzK) 39 (Figure 2.10B) yields 
sfGFP(N150GlyoxylK) 41, which predominantly exists in the ‘hydrate’ form 41-
Hyd (Figure 2.10C). Uniquely, decaging of GFP(Y39ThzK) 40 (Figure 2.10D) 
yields the α-oxo aldehyde-containing protein GFP(Y39GlyoxylK) 42 which, unlike 
other protein α-oxo aldehydes described in the literature (with the exception of 
glyoxyl-CTB 30), was noted to be observed primarily as the ‘aldehyde’ form 41 
(Figure 2.10E). Despite this phenomenon, GFP(Y39GlyoxylK) 41 appears to react 
readily in subsequent protein ligations,116 and does not show inactivity in a manner 
similar to that seen in the ‘aldehyde’ form of glyoxyl-CTB 30 158 Examples of ESI-
MS data observed for the caged and decaged GFPs are shown in Figure 2.10F-I. 
2.2 Conclusions 
Multiple proteins bearing α-oxo aldehyde handles at both terminal and internal 
locations have been prepared throughout this project as, in order to show the 
versatility of a given protein bioconjugation strategy, it is necessary to demonstrate a 
given ligation procedure on multiple protein scaffolds and at different sites for 
conjugation. For scaffolds SLYRAG 26 and CTB 29, strategies for α-oxo aldehyde 
incorporation were reported in the literature, and were subsequently used to generate 
α-oxo aldehyde containing protein scaffolds. For other protein scaffolds, α-oxo 
aldehyde installation was performed by either altering reported literature procedures 
(e.g. myoglobin 28), or by screening conditions for optimal aldehyde installation 
(e.g. thioredoxin 31). Altogether, these proteins provide a panel of eight protein 
scaffolds bearing α-oxo aldehydes which could be used to develop site-selective 
protein aldehyde bioconjugation strategies.  
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Chapter 3: Discovery of the Organocatalyst-mediated Protein Aldol 
Ligation 
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3.1 The accidental aldol 
During experimentation with CTB 29, an unexpected result was observed upon 
subjecting glyoxyl-CTB 30, before purification/desalting, to basic conditions. MS 
data collected for these experiments suggested a species with a mass identical to that 
of unoxidised CTB 29 was observed when the protein was incubated at 37 oC with 
shaking under sufficiently basic conditions. Notably, only one modification was 
made onto the protein and the result could not be achieved if the protein had, after 
oxidation, been desalted or purified. Given that desalting/purifying the glyoxyl-CTB 
30 following oxidation prevented the return of ‘unmodified CTB’, it was reasonable 
to conclude that the oxidation by-products were responsible for the unidentified 
protein modification. After consideration of the by-products present, a working 
hypothesis to explain this observation was proposed; theoretically, it was possible 
that the by-product acetaldehyde 43 reacts with the protein at the newly generated 
aldehyde position via an aldol-type reaction (Figure 3.1A), giving modified protein 
44 with an observed mass (Figure 3.1B) that is almost identical to that of unoxidised 
CTB 29. Such a hypothesis was considered entirely plausible, since both a 
Mukaiyama aldol reaction,128 and a direct aldol reaction involving 
thiazolidinediones133 have previously been described in the literature.  
 
 
 
 
 
 
 
 
 
 
Figure 3.1 (A) Hypothesised reaction of glyoxyl-CTB and acetaldehyde by-product. (B) Associated ESI-MS data 
obtained when subjected unpurified glyoxyl-CTB to sufficiently basic conditions. 
30 
43 
44 
86 
 
 
 
3.1.1 Testing the hypothesis 
To confirm whether an aldol-type ligation would be suitable for protein 
modification, glyoxyl-LYRAG 27 was subjected to excess acetaldehyde 43 in 0.1 M 
triethanolamine bicarbonate (TEAB) buffer at pH 8.5, and allowed to react overnight 
at 37 oC (Figure 3.2A). The TEAB buffer system was used as it was anticipated that 
basic conditions would be required to deprotonate the aldehyde substrates at the α-
carbon position to form enolates, and hence facilitate the aldol ligation. The reaction 
mixture was then analysed by LC-MS. Analysis of the LC-MS data reveal peaks 
corresponding to the [M+H]+ species of the anticipated aldol product 45. 
Gratifyingly, only one modification appeared to have taken place, as no other species 
that may have corresponded to uncontrolled modification of glyoxyl-LYRAG 27 
were present in the LC-MS trace (Figure 3.2B). 
 
 
 
 
 
As discussed previously, the anticipated aldol product contains an aldehyde 
functionality theoretically primed for further site-selective modification. The most 
common way of testing for aldehydes that have been incorporated into 
peptides/proteins in the literature is to use hydrazine or hydroxylamine reagents to 
form hydrazone or oxime bonds (respectively). Therefore, to test for aldehyde 
functionality, the pH of the crude reaction mixture containing anticipated aldol 
product 45 was lowered to pH 4 through addition of AcOH, and oxime ligation was 
attempted using aniline 46 as a catalyst, and aminooxy acetic acid 47 as shown in 
Figure 3.3A. The reaction was allowed to proceed overnight, and subsequently 
analysed by LC-MS. Conversion to the anticipated aldol-oxime product 48 was 
confirmed by the presence of the [M+H]+ peak at 752.34. Remaining glyoxyl-
LYRAG 27 also underwent modification to give oxime product 49, suggesting that 
the conditions tested were suitable for successful oxime ligation. (see Figure 3.3B for 
Figure 3.2 (A) Reaction of glyoxyl-LYRAG 27 and acetaldehyde 43 in 0.1 M TEAB pH 8.5 to give anticipated 
aldol product 45. (B) Obtained ESI-MS data for (A). 
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obtained MS data, and Figure 3.3C for associated structures and [M+H]+ ions of 
each species).  
 
 
 
 
 
 
 
 
 
 
With these preliminary results in mind, it was concluded that a strategy for site-
selective modification of proteins utilising an aldol reaction (of the described 
manner) was a viable concept, and warranted further investigation. 
 
3.1.2 Other aldehyde donors and reactions at neutral pH 
To further establish an aldol-type reaction for site-selective protein modification, 
aldehydes other than acetaldehyde 43 were investigated for their suitability as donor 
compounds (Figure 3.4A). Commercially available aldehydes propanal 50, butanal 
51, isobutyraldehyde 52, hexanal 53, and phenylacetaldehyde 54 were chosen as test 
donor substrates to accommodate a range of donor species bearing different 
substituents (alkyl vs aromatic, different chain lengths etc.) and differing α proton 
pKa values (α proton pKa of phenylacetaldehyde = 13, whereas pKa = 17 for the 
other aldehyde donors). The ligations between 1 mM glyoxyl-LYRAG 27 and the 
aldehydes 50-54 were carried out in TEAB pH 8.5 buffer using 10 molar equivalents 
(10 equiv.) of aldehyde substrate 50-54 (based on glyoxyl-LYRAG 27 
Figure 3.3 (A) Reaction of anticipated aldol product 45 and aminooxy acetic acid 47 using aniline 46 as a 
catalyst to give anticipated dually modified peptide 48. (B) Obtained ESI-MS data for (A). (C) Associated 
structures and [M+H]+ ions for each anticipated species observed in (B). 
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concentration), with the exception of phenylacetaldehyde 54 where only one molar 
equivalent was used (i.e. 1 mM instead of 10 mM). This was due to precipitation 
Figure 3.4 (A) Outline of anticipated aldol reaction between glyoxyl-LYRAG 27 and aldehyde donors 50-54., 
and structures of associated aldehyde donors 50-54 and anticipated aldol products 55-59. (B) Obtained ESI-
MS data for each anticipated aldol product 55-59. 
27 50-54 
50 51 52 53 54 
55 56 57 
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occurring in the reaction mixture when using a 10 mM loading of the donor, which 
was thought to arise from uncontrolled polymerisation of phenylacetaldehyde 54. 
Formation of the anticipated aldol products 55-59 using the commercially available 
aldehydes was confirmed by LC-MS analysis, with a conversion of >99% for 
aldehydes 50-52 and 54. The exception to this was when using hexanal 53 as the 
donor, which gave a lower conversion of 56%, possibly due to additional steric 
factors (an aldehyde substrate with a longer, more flexible alkyl chain will be more 
sterically hindered substrate, and is therefore a more challenging donor to use for 
modification), or due to decreased water solubility (resulting from the longer, more 
hydrophobic alkyl chain). Increasing the number of equivalents of hexanal 53 or 
longer reaction times would likely improve % conversion. Despite using only one 
molar equivalent of donor, the anticipated aldol ligation between glyoxyl-LYRAG 
27 and phenylacetaldehyde 54 proceeded to completion. The same results could not 
be achieved when attempting an anticipated aldol ligation between glyoxyl-LYRAG 
27 and butanal 51 in a 1:1 ratio, with a lower conversion of 61% obtained as judged 
by LC-MS. A possible explanation for these results is that phenylacetaldehyde 54 
contains an aromatic ring substituent, which would stabilise the carbon-carbon 
double bond formed in the enol tautomer of phenylacetaldehyde 54, leading a higher 
‘enol content’ of phenylacetaldehyde 54 compared with other aldehydes.177 Given 
that enol/enolate formation is required for an aldol-type mechanism to proceed, using 
a donor that naturally contains a higher ‘enol content’ would inevitably give higher 
rates of reaction due to increased enol/enolate availability, likely reducing the 
concentration of excess donor required to achieve total conversion to the anticipated 
aldol product. 
 
3.1.3 Anticipated aldol ligations at neutral pH 
In order to investigate the suitability of the anticipated aldol ligation in buffer 
systems closer to neutral pH, as opposed to basic pH, ligation between glyoxyl-
LYRAG 27 and aldehydes 51 and 54 were then performed in 25 mM PB at pH 7.0, 
and at pH 7.5. Conversion to the desired products 56 and 59 was achieved, although 
the conversion to 56 dropped significantly at a more neutral pH (39% and 42% for 
PB pH 7.0 and PB pH 7.5 respectively). Total conversion to 59 as judged by LC-MS 
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was observed despite the change in pH, further highlighting the increased reactivity 
of phenylacetaldehyde 54 in the anticipated aldol ligation. 
 
3.1.4 Tandem mass spectrometry analysis of anticipated aldol products 
Although the obtained LC-MS data contains the [M+H]+ species corresponding to 
the anticipated aldol product, the data provides no information on the connectivity of 
the observed reaction products, and therefore no information on the site-selectivity of 
the ligation. Tandem mass spectrometry (MS/MS) was therefore used to confirm 
whether any modifications of glyoxyl-LYRAG 27 were occurring site-selectively at 
the desired position i.e. at the N-terminus of the peptide. It is well documented that, 
for MS/MS, peptides fragment in a predictable manner to give smaller peptide 
fragments that can be assigned a letter (a, b, c, x, y, or z) and number (dependent on 
original peptide length) depending on the exact nature of fragmentation. It is then 
possible to assign the different peptide fragments to different m/z values observed in 
the MS/MS analysis, effectively ‘mapping’ the structure of the original peptide from 
which the fragments originated. In order to simplify analysis of modified peptide 
substrates by MS/MS analysis, the aldol products were treated as ‘Modification-
LYRAG’ peptides (i.e. LYRAG peptides which have been directly modified at the 
N-terminus. Figure 3.5 shows the initial MS/MS analysis of aldol product 56. 
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Figure 3.5 MS/MS data of aldol product 56. 
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The fragmentation of the 707.3 Da species, corresponding to the anticipated aldol 
product 56, was observed to be in good agreement with a site-selective aldol ligation 
occurring at the N-terminus of glyoxyl-LYRAG 27. 
The major fragment peak of 56 is 689.3 Da, corresponding to the loss of H2O from 
the aldol product (707.3-18 Da = 689.3 Da). This loss would likely result from 
fragmentation at the newly generated hydroxyl position, as alcohol groups are known 
to undergo rearrangement and subsequent fragmentation in MS/MS experiments. 
Given the position of hydroxyl substituent, it was postulated that subsequent MS/MS 
analyses of the 689.3 Da major fragment peak would result in fragmentation spectra 
where the x/y/z fragments remain the same as that of the initial fragmentation spectra 
of the 707.3 Da species, but the a/b/c fragments will all change by -18 Da. This was 
indeed found to be the case (Figure 3.6).  
 
 
 
 
 
 
 
 
 
These observations were considered to be consistent with the successful synthesis of 
aldol products such as 56. 
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Figure 3.6 MS/MS data of fragmentation of aldol product 56, followed by fragmentation of the resulting major 
fragment (689.3 Da).  
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3.1.5 Modifying myoglobin 
Having established that site-selective modification of glyoxyl-LYRAG 27 using 
small aldehyde substrates was possible via an aldol-type reaction, the ligation 
strategy was then extended to modifying glyoxyl-containing proteins. To investigate 
an aldol ligation on proteins, myoglobin 28 was used a model substrate. As described 
in Section 2.1.2, the N-terminal glycine of myoglobin 28 was oxidised via a 
transamination reaction with PLP 8 to give glyoxyl-myoglobin 13 in 25 mM PB pH 
6.5. Following removal of PLP 8, glyoxyl-myoglobin 13 was treated with different 
concentrations of donor 51 at pH 7.0 and pH 7.5, and conversion to the anticipated 
aldol product 60 was determined as judged by LC-MS (Table 3.1) 
Table 3.1 Screening of conditions for aldol reaction between 100 µM glyoxyl-myoglobin 13 and donor 51 with 
different concentrations of 51 at pH 7.0 and 7.5. Conversion determined as judged by LC-MS. 
Entry 51 concn (mM) pH Conversion to 60 (%) 
1 10 7.0 0 
2 25 7.0 22 
3 50 7.0 24 
4 100 7.0 N/A 
5 10 7.5 0 
6 25 7.5 24 
7 50 7.5 24 
8 100 7.5 N/A 
Figure 3.7A outlines the reactions described in Table 3.1, and Figure 3.7B shows the 
LC-MS data obtained for Entry 6 of Table 3.1.  
 
 
 
 
 
Figure 3.7 (A) Outline of reaction between glyoxyl-myoglobin 13 and donor 51 (B) LC-MS data obtained for 
reaction 100 µM glyoxyl-myoglobin 13 and 25 mM donor 51 in 25 mM PB pH 7.5  at 37 oC for 24 h. (see Table 
3.1, Entry 6.) 
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Although peaks corresponding to the anticipated aldol product 60 were present in 
some of the conditions screened described in Table 3.1, extremely low conversions 
of glyoxyl-myoglobin 13 to the anticipated aldol product 60 were achieved, despite 
using a large excess of donor 51. In some cases, such as Table 3.1 Entry 4 and Entry 
8, extremely high concentrations of donor 51 resulted in a loss of protein species 
when analysed by LC-MS. Changing the buffer system from PB pH 7.0 to PB pH 
7.5 had negligible effects on the % conversion obtained. 
3.1.6 Routes to optimisation 
It was evident that, from the results obtained as described earlier, significant 
optimisation was required in order to make the aldol ligation a viable strategy for 
site-selective protein bioconjugation. To achieve this, three strategies were 
considered:  
Strategy 1: Raise the pH of the reaction. A higher pH should facilitate deprotonation 
at the α-carbon position of the donor substrate, assisting in formation of the enolate 
required for the aldol reaction to proceed, and thus resulting in greater conversion to 
the desired product. However, this strategy is undesirable as it not only moves the 
ligation strategy away from the desired conditions of neutral pH, but could also lead 
to deprotonation of the ε-amino group of lysine residues under sufficiently basic 
conditions, which may lead to non-selective protein modification through 
nucleophilic attack of the ε-amino group of lysine at the carbonyl of the aldehyde 
donor (lysine bioconjugation is frequently performed at basic pH). 21,22 
Strategy 2: Increase the donor concentration. Successful protein bioconjugation 
usually requires an excess of reagent to drive the reactions to completion. Due to the 
large excess of donor compound already being used to obtain minimal protein 
modification, however, this was not considered a viable strategy for optimisation. 
Strategy 3: Use a catalyst. Other protein bioconjugation strategies have shown that 
addition of a catalyst can greatly facilitate the desired ligation, the most notable 
example arguably seen in aniline catalysed oxime ligations.121,123 Employing a 
catalyst in the protein aldol ligation could potentially lead to a similar success. This 
was considered to be the most viable strategy, and was therefore investigated further. 
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3.1.7 The Organocatalyst-mediated Protein Aldol Ligation 
For small molecules, the amino acid L-proline 61 is well-established as a catalyst for 
asymmetric aldol reactions. Dating back to the 1970s, the use of L-proline 61 as a 
catalyst was first reported independently both by the group of Eder, Sauer, and 
Weichert,178 and the group of Hajos and Parrish,179 in what is now known as the 
Hajos–Parrish–Eder–Sauer–Wiechert reaction. Major developments in proline 
catalysed asymmetric aldol reactions were then reported in the 2000s. List, Lerner, 
and Barbas demonstrated direct asymmetric aldol reactions between acetone 62 and 
aldehyde acceptors under non-inert, room temperature conditions could be 
performed using catalytic amounts (30 mol%) of L-proline 61 in DMSO. 180 Based 
on mechanistic observations of aldolase catalytic antibodies,181 an enamine 
mechanism for the proline catalysed aldol reaction was proposed, with the noted 
enantioselectivity of the reaction deduced to arise from a Zimmerman-Traxler type 
transition state (Figure 3.8A).180,182  Proline catalysed aldol reactions were further 
extended to direct, enantioselective cross aldol reactions of non-equivalent aldehydes 
by Northrup and Macmillan.183 The proline catalysed cross aldol strategy was also 
demonstrated in the enantioselective synthesis of protected carbohydrates including 
glucose, mannose and allose.184,185 Here, an enantioselective aldol reaction (catalysed 
by proline) between two α-oxy aldehydes was used to synthesise β-hydroxy 
aldehydes, which act as reagents in Lewis Acid mediated Mukaiyama Aldol 
condensations to yield the desired protected sugars. Critically, the β-hydroxy 
aldehyde intermediates synthesised via this method were found to be inert to further 
proline catalysed enolisation or enamine aldol additions, preventing uncontrolled 
polymerisation of α-oxyaldehyde starting materials whilst allowing for further 
functionalisation in a controlled manner using a different reaction (Figure 3.8B).185  
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Figure 3.8 (A) A Zimmerman-Traxler type transition state for enantioselective synthesis of β-hydroxy 
aldehyde products catalysted by L-proline 61. (B) Reactivity of the β-hydroxy aldehyde. 
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The use of L-proline 61 as catalyst for the OPAL was therefore investigated. In order 
to test the efficacy of L-proline 61 as a catalyst, an initial screen using glyoxyl-
LYRAG 27 and aldehyde 51 in PB pH 7.0, and PB pH 7.5, was performed. 
Traditionally, organocatalytic reactions involving catalysts typically employ catalytic 
amounts (e.g. 20 mol%). However, in the context of peptide/protein bioconjugations, 
concentration of organocatalyst used is usually much greater than this, as seen in 
aniline-catalysed hydrazone/oxime ligations.118,123 Therefore, two reaction protocols 
were attempted: one employing 20 mol % L-proline 61 (0.2 equiv.), and the other 
employing 20 equiv. (20 mM) of L-proline 61. The reaction of 1 mM glyoxyl-
LYRAG 27 and 10 mM butanal 51 was carried out using either 0.2 mM or 20 mM L-
proline 61 in PB pH 7.0 and PB pH 7.5 for 24 h at 37 oC, and the conversion to aldol 
product 56 was judged by LC-MS. The results are described in Table 3.2: 
Table 3.2 Screening of conditions for aldol reaction between 1 mM glyoxyl-LYRAG 27 and 10 mM donor 51 
with different concentrations of 61 at pH 7.0 and 7.5. Conversion determined as judged by LC-MS. 
Entry L-Proline 61 concn (mM) pH Conversion % 
1 0.2 7.0 33 
2 20 7.0 >99 
3 0.2 7.5 58 
4 20 7.5 >99 
Figure 3.9A outlines the reactions described in Table 3.2, and Figure 3.9B shows the 
LC-MS data obtained for Entry 4 of Table 3.2.  
 
 
 
 
 
 
 
Figure 3.9 (A) Outline of reaction between glyoxyl-LYRAG 27 and donor 51 using L-proline 61 as a catalyst 
(B) LC-MS data obtained for reaction 1 mM glyoxyl-LYRAG 27 and 10 mM donor 51 using 20 mM L-
proline 61 in 25 mM PB pH 7.5 for 24 h at 37 oC. (see Table 3.2, Entry 4). 
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The addition of 0.2 mM. L-proline 61 to the peptide aldol ligation did not appear to 
cause any significant improvement to conversion to aldol product 56 after 24 h (see 
3.1.3). The addition of 20 mM of L-proline 61, however, leads to total conversion of 
glyoxyl-LYRAG 27 to aldol product 56 as judged by LC-MS analysis under 
identical conditions at both pH 7.0 and pH 7.5, demonstrating the catalytic effects of 
L-proline 61 in this particular reaction. 
The introduction of L-proline 61 within the context of protein modification was next 
investigated. Aldol reactions between 100 µM glyoxyl-myoglobin 13 and 25 mM 
butanal 51 were performed with either a 10 mM or 25 mM loading of L-proline 61 at 
37 oC. The reactions were monitored after 1 h, 2 h, 4 h, and 6 h of reaction time, and 
conversion to the anticipated aldol product 60 was confirmed by LC-MS analysis 
(see Table 3.3). 
Table 3.3 Screening of conditions for the reaction between 100 µM glyoxyl-myoglobin 13 and 25 mM donor 51 
in PB pH 7.5 with different concentrations of 61 at different time intervals. Conversion determined by LC-MS. 
Entry L-Proline 61 concn (mM) Reaction time (h) Conversion (%) 
1 10 1 30 
2 10 2 50 
3 10 4 65 
4 10 6 75 
5 25 1 44 
6 25 2 63 
7 25 4 82 
8 25 6 >99 
 
Figure 3.10A outlines the reactions described in Table 3.3, and Figure 3.10B shows 
the LC-MS data obtained for Entry 8 of Table 3.3. 
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As seen in the peptide aldol ligations, the use of L-proline 61 in the anticipated aldol 
reaction between glyoxyl-myoglobin 13 and butanal 51 was found to vastly improve 
conversion to the anticipated aldol product 60 as judged by LC-MS analysis, with 
full conversion observed within 6 h when using a 25 mM loading of L-proline 61.  
3.1.8 Trypsin digest experiments on modified myoglobin 
To determine that the observed modification of glyoxyl-myoglobin 13 was occurring 
at the desired position i.e. the N-terminus, a proteolytic digest using trypsin, 
followed by LC-MS/MS analysis, was performed. Trypsin is a serine protease that 
cleaves proteins at the carboxyl end of lysine and arginine residues (unless they are 
followed by a proline),186 generating smaller peptide units (Figure 3.11A). With the 
knowledge of the amino acid sequence of myoglobin 28, peptide units generated 
from a trypsin digest of myoglobin 28 can be predicted, based on the position of 
lysine and arginine residues within the proteins sequence. The first occurrence of a 
lysine or arginine residue in the sequence of myoglobin 28 (reading from the N-
terminus to the C-terminus) is lysine 16 (K16). Cleavage by trypsin at this position 
would result in the ‘N-terminal’ peptide unit GLSDGEWQQVLNVWGK. Similarly, 
a trypsin digest of glyoxyl myoglobin 13 would give the N-terminal peptide unit 
glyoxyl-LSDGEWQQVLNVWGK. If the anticipated aldol product 60 has been 
synthesised, then a trypsin digest of the aldol product 60 would give the N-terminal 
peptide unit ‘Modification-LSDGEWQQVLNVWGK’ with a calculated [M+H]+ of 
1887 Da (Figure 3.11B). MS/MS analysis of this peptide unit could then be used to 
confirm that the modification was occurring at the desired position i.e. at the N-
terminus of the protein. A trypsin digest was therefore performed on the anticipated 
aldol product 60 (synthesised using the conditions described in Table 3.3, confirmed 
Figure 3.10 (A) Outline of reaction between glyoxyl-myoglobin 13 and donor 51 using L-proline 61 as a catalyst  
(B) LC-MS data obtained for reaction 100 µM glyoxyl-myoglobin 13 and 25 mM donor  51  using 25 mM L-
proline 61 in 25 mM PB pH 7.5 at 37 oC for 6 h. (see Table 3.3, Entry 8.) 
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by LC-MS). Following separation and analysis of the tryptic peptides by LC-MS, a 
species corresponding to 1886.9 Da was observed (Figure 3.11C).  
 
 
 
 
 
 
 
 
This peak was subjected to MS/MS analysis, and the resulting peaks were assigned 
to potential fragments that would theoretically result from the N-terminal fragment 
of aldol product 60, as seen in Figure 3.11: 
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Figure 3.11 (A) Schematic of tryptic digest of aldol product 60 to give peptide fragments. (B) Structure of the N-
terminal fragment theoretically generated from tryptic digest of anticipated aldol product 60. (C) Species at 
1886.9 Da observed in LC-MS analysis of trypsin digest of anticipated aldol product 60, which potentially 
corresponds to the anticipated N-terminal fragment described in (B). 
Figure 3.12 MS/MS of anticipated N-terminal fragment of aldol product 60 resulting from trypsin digest 
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The major fragment observed from the initial MS/MS was found to be a peak at 
1869.8 Da. Similar to the MS/MS analysis of aldol products, the major fragment 
peak corresponds to a loss of 18 Da, and presumably results from fragmentation at 
the newly generated hydroxyl position of the aldol product. As a result, MS/MS 
analyses of this major fragment peak should result in fragmentation spectra where 
the predicted x/y/z fragments remain the same compared to predicted fragmentation 
spectra of the OPAL product 60, but the predicted a/b/c fragments will all change by 
-18 Da. As seen in Figure 3.13, this was indeed found to be the case: 
 
 
 
 
 
 
 
 
 
 
 
Overall, the resulting fragments from the 1869.8 Da fragment confirm both the 
presence of the β-hydroxy aldehyde group, and that the aldol modification has 
occurred site-selectively at the glyoxyl position of glyoxyl-myoglobin 13. 
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Figure 3.13 MS/MS, followed by MS/MS of the major fragment of the anticipated N-terminal fragment of aldol 
product 60 resulting from trypsin digestion. 
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3.1.9 UV/Vis data 
As previously discussed, the haem group of myoglobin exhibits a strong absorbance 
at λ = 410 nm, which can be used as an indicator of protein integrity after 
modifications are made to the protein.79,128,130 The UV/vis spectra of unmodified 
myoglobin 28 and OPAL product 60 were therefore recorded, and compared as 
shown in Figure 3.14. 
 
 
 
 
 
 
 
 
 
 
 
 
The UV/vis spectrum of OPAL product 60 was found to be of an excellent match to 
that of unmodified myoglobin 28, suggesting that the protein integrity, and the haem 
group itself, remained unchanged post modification. 
3.2. Further development of the OPAL strategy 
From what began as an undesired side reaction, the OPAL has proved to be a 
suitable procedure for site-selective labelling of α-oxo aldehyde containing proteins. 
This novel ligation strategy was first validated using the α-oxo aldehyde containing 
peptide glyoxyl-LYRAG 27 and commercially available small molecule aldehyde, 
and the site-selectivity of the reaction was confirmed using a combination of LC-MS 
and MS/MS analysis. Furthermore, the presence of β-hydroxy aldehyde functionality 
resulting from aldol ligation was confirmed by downstream oxime ligation using the 
Abs 
Figure 3.14 UV-Vis measurements of myoglobin 28 (red line) and aldol product 60 (blue line). 
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catalyst aniline 46 and aminooxy acetic acid 47. By incorporating the catalyst L-
proline 61 into the bioconjugation protocol, the aldol ligation (deemed the 
Organocatalyst mediated Protein Aldol ligation, abbreviated as “OPAL”) could be 
efficiently carried out at neutral pH, allowing for quantitative labelling of peptide 
and protein α-oxo aldehydes with small molecule aldehydes within 24 h at pH 7.5. 
The site-selectivity of the OPAL on myoglobin 28 was confirmed by performing 
trypsin digestion of the aldol product 60, followed by MS/MS analysis of the 
resulting peptide fragments. Finally, UV/Vis analysis of the modified myoglobin 
species 60 confirmed the haem group was intact post modification, suggesting the 
protein integrity was maintained. 
Overall, the OPAL, as described in Chapter 3 offers notable advantages over other 
protein bioconjugation strategies, particularly in its ability to synthesise 
hydrolytically stable conjugates via C-C bond formation at neutral pH without 
compromising protein integrity. A significant drawback of the OPAL procedure 
described in this section, however, are the long reaction times and a high 
concentration of probe required for efficient labelling. Although many previously 
reported bioconjugation strategies frequently use long reaction times and large 
excesses of reagent to force ligations to completion, there has recently been an 
increasing push towards bioconjugation strategies that use equimolar or near 
equimolar concentrations of probe to protein. Additionally, from a practical 
perspective; the longer a protein modification takes the longer the protein spends 
outside of its optimal storage conditions, and the higher the concentration of label 
required the more rigorous the purification needed following modification. 
Consideration of these factors was deemed to be particularly important if the protein 
in question is a target for further downstream site-selective modifications via the β-
hydroxy aldehyde handle, where the target protein will spend even longer outside of 
its optimal storage conditions.  
To further develop the OPAL as an effective bioconjugation strategy, it was clear 
that optimisation of the reaction conditions would be required. Many protein 
bioconjugation strategies described in the literature have benefitted from alterations 
to their reactive partners; for protein aldehyde ligations this has been most evident in 
the Pictet Spengler series of bioconjugations (higher rate constants in the iso-Pictet 
Spengler ligation, more applicable at pH closer to neutral in the HIPS),88,89,125 and 
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has also been reported in the ABAO ligation (higher rate constants).132 In a similar 
vein, aniline-catalysted hydrazine/oxime ligations have been the subject of major 
optimisation through research into alternative catalysts that offer superior ligation 
kinetics to aniline 46 .119,139 Therefore, it was evident that the most fruitful areas to 
research for optimisation of the OPAL would be the identity of both the catalyst and 
donor used in the ligation protocol. 
3.3 Conclusions 
To conclude, in the form described within this Chapter, the OPAL proved to be a 
suitable method for the site-selective modification of peptide and protein α-oxo 
aldehyde acceptors, using α carbon-containing aldehydes as donors. Protein 
modification via this method was facilitated using the highly water soluble, 
commercially available catalyst L-proline 61, and is thought to proceed by an 
enamine type mechanism. Finally, the OPAL does not compromise protein integrity 
post modification, leads to carbon-carbon bond formation between protein and 
probe, and occurs readily at neutral pH. 
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Chapter 4: Site-selective protein modification via an optimised 
OPAL strategy 
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4.1 Choice of organocatalyst 
Since the disclosure of L-proline 61 as an organocatalyst for the aldol reaction, 
numerous different catalysts have since been reported that offer improvements in 
catalytic activity, enantioselectivity/diastereoselectivity of product formation, and 
catalyst solubility. It was therefore envisioned that using a different catalyst to L-
proline in the OPAL may lead to a ligation protocol with improved reaction kinetics 
i.e. higher conversions to the desired OPAL product on a faster timescale. In contrast 
to other aldol reactions described in the literature, stereochemical control of the 
OPAL products synthesised by a given catalyst was deemed unimportant; as long as 
a given compound could theoretically participate in enamine-type catalysis, it could 
be deemed to be a potential catalyst for the OPAL. This would, however, lead to an 
enormous amount of compounds to screen in the optimisation of the OPAL, as any 
primary or secondary amine (which can participate in initial imine formation) would 
theoretically be a catalyst for the OPAL. Therefore, potential catalysts were also 
required to have desirable properties, such as having good water solubility, and being 
commercially available. Catalysts were also chosen on the basis of whether or not 
they would offer an insight into what properties make a given compound a more (or 
less) effective organocatalyst compared to L-proline 61  within the context of the 
OPAL. Based on this, a panel of 10 secondary amines (including L-proline 61) were 
chosen to be investigated in their ability to catalyse the OPAL procedure. This panel 
of catalysts includes pyrrolidine 63, piperidine 64, morpholine 65, L-prolinamide 66, 
2-azetidine carboxylic acid 67, D-proline 68, homomorpholine 69, (S)-(–)-5-(2-
pyrrolidinyl)-1H-tetrazole 70 (referred to as proline tetrazole 70 hereon in), and 
piperazine 71. Catalysts 63-71, shown in Figure 4.1 (alongside L-proline 61), are 
water soluble, commercially available, and display subtle yet potentially important 
differences to that of L-proline, such as different side chains, ring size, and amino 
group pKa. 
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4.1.1 Practical considerations of catalysts 
During acquisition of the kinetic data for the OPAL, it was noted that stock solutions 
of some of the catalysts prepared deviated significantly from pH 7.5, giving 
solutions of up to pH 11. For this particular screen, such catalysts included 
pyrrolidine 63, piperidine 64, morpholine 65, L-prolinamide 66, and piperazine 71. 
Therefore, the pH of stock solutions of all catalysts were confirmed by pH probe or 
pH test paper, and adjusted to pH 7.5 using concentrated HCl if required. 
4.1.2 Initial screening of different organocatalysts 
For many protein bioconjugations, performing kinetic studies has proved to be a 
reliable way of assessing the effectiveness of using alternative catalysts and/or 
alternative reactive partners for a given ligation strategy. As established in Chapter 
1, this has typically been done using two small molecules/peptides that contain the 
reactive groups used in the ligation strategy on proteins, along with any required 
catalyst for the reaction at a set concentration (catalyst loading). Second order rate 
constants could then be obtained for the ligation, with the reactions assumed to be 
bimolecular processes between the two reactive partners. With previously 
established kinetic studies for protein bioconjugation strategies in mind, the panel of 
10 commercially available secondary amines were screened for their ability to 
catalyse the OPAL between glyoxyl-LYRAG 27 (acceptor mimic) and butanal 51 
(donor mimic), and second order rate constants were determined for each catalyst at 
1 mM, 10 mM, and 25 mM loadings. Kinetic data was obtained in a manner 
consistent with previous literature 42,43; this method obtains kinetic data using an LC-
MS-based approach, and was deemed to be ideal for the obtaining kinetic data for 
Figure 4.1 Panel of commercially available secondary amines used as potential catalysts for the OPAL. 
61 63 64 65 66 
67 68 69 
70 
71 
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the OPAL which, as described in Chapter 2 and 3, was primarily established using 
LC-MS analysis. 
4.1.3 Kinetic data obtained and comparison of organocatalysts  
Figure 4.2 outlines the reaction performed to obtain second order rate constants for 
the OPAL:  
 
 
 
 
Table 4.1 shows the experimentally observed second order rate constants for each 
catalyst at a set catalyst loading (as outlined in Figure 4.2, see Appendix for details 
on obtaining the kinetic data).  
 
 
 
 
 
 
 
 
 
 
From the kinetic data obtained for the 10 catalysts, several observations could be 
made. In all cases, having a higher catalyst loading was beneficial towards increasing 
the second order rate constant for the reaction between glyoxyl-LYRAG 27 and 
Figure 4.2 Reaction of glyoxyl-LYRAG 27 and butanal 51 using one of the 10 commercially available 
secondary amines 61 and 63-71 to catalyse the reaction. 
Table 4.1 Second order rate constants obtained for the reaction of glyoxyl-LYRAG 27 and butanal 51 using 
different loadings of secondary amines 61 and 63-71 
27 51 56 
61, 63-71 
61 63 64 65 66 
67 68 69 70 71 
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butanal 51; this was to be expected, as a higher concentration of catalyst will 
inevitably lead to a higher concentration of active enamine species present at any 
given time, leading to higher conversions of product on a shorter timescale 
(compared to using lower concentrations of catalyst). Strikingly, the second order 
rate constants obtained vary noticeably depending on the catalyst used. Piperidine 64 
shows by far the lowest catalytic activity, requiring a 25 mM loading to achieve 
similar rates to that of L-proline 61 at a 1 mM loading. Indeed, the reaction between 
glyoxyl-LYRAG 27 and butanal 51 using a 1 mM loading of piperidine 64 led to 
such low conversions as judged by LC-MS that an accurate rate constant could not 
be determined  on the timescale used for obtaining the kinetic data for the OPAL 
Pyrrolidine 63, 2-azetidine carboxylic acid 67, and D-proline 68 display similar rates 
to that of L-proline, whilst slightly higher rate constants were observed for 
morpholine 65, homomorpholine 69, and piperazine 71. The highest rate constants of 
the 10 catalysts were observed when using L-prolinamide 66, and proline tetrazole 
70, with a 1 mM loading of 66 or 70 displaying similar rate constants to that of L-
proline at a 25 mM loading. Trends relating to specific features of the catalysts 
investigated, when compared to L-proline 61, could also be identified. The presence 
of a carboxylic acid side chain, which is thought to be of major importance in 
controlling the stereochemistry of aldol products synthesised in small molecule 
organic synthesis,180 was found to have little impact on the obtained second order 
rate constants, as evidenced when comparing the data set for catalysts 63, 67, and 68 
to catalyst 61. Likewise, changing the stereochemistry of the carboxylic acid side 
chain did not lead to any significant changes in obtained second order rate constants, 
as evidenced when comparing L-proline 61 to D-proline 68. Changing the ring size to 
a four membered ring as seen in catalyst 67 had little effect on the second order rate 
constants obtained. Catalysts 65, 69, and 71 yielded higher rate constants compared 
to L-proline 61, suggesting that the presence of a heteroatom on the ring assisted in 
facilitating catalysis. Significantly higher rate constants were obtained when 
substituting the carboxylic acid group of L-proline 61 for a primary amide or 
tetrazole group as seen with catalysts 66 and 70 respectively. Despite having twice 
the number of free amino groups, catalyst 71 did not yield substantially higher 
second order rate constants to that of L-proline 61 in comparison to catalysts 66 and 
70. Overall, the rate constants obtained for all catalysts in the reaction between 
glyoxyl-LYRAG 27 and butanal 51 were found to be comparable to rate constants 
109 
 
 
 
observed for previously reported uncatalysed/catalysed hydrazine/oxime ligation. In 
particular, the second order rate constants in Table 4.1 indicate that using L-
prolinamide 66 or proline tetrazole 70 over L-proline 61 would lead to an increase in 
rate of OPAL, and thus a decrease in reaction times required for full conversion to 
OPAL products.  
4.2 Using aryl donors 
Although noticeable improvements to the rate of the OPAL were achieved when 
exchanging L-proline 61 for L-prolinamide 66 or proline tetrazole 70, the observed 
second order rate constants were low by literature standards, 1,141,187 ranging within 
the region of 10-2-10-1 M-1 s-1. Therefore, to improve the rate of the OPAL further, 
the identity of the donor used was next investigated. Previous experiments described 
in Chapter 3 established phenylacetaldehyde 54 as the more reactive of the 
commercially available donors tested, and was therefore used as a model donor 
substrate for subsequent kinetic studies. Due to practical considerations (i.e. not 
having to correct the pH of the stock solution), and due to showing enhanced 
catalytic activity as seen in Table 4.1, proline tetrazole 70 was used as the catalyst, 
with an additional screen using L-proline 61 as the catalyst undertaken to provide 
comparative data on the effects of the rate of the OPAL when changing both the 
catalyst and donor. Second order rate constants for the reaction between glyoxyl-
LYRAG 27 and phenylacetaldehyde 54 were then determined for the two catalysts at 
1 mM, 10 mM, and 25 mM in an identical manner as described in section 4.1. 
4.2.1 Aryl donors yield higher rate constants  
Figure 4.3 outlines the reaction performed to obtain second order rate constants for 
the OPAL:  
 
 
 
 
Figure 4.3 Reaction of glyoxyl-LYRAG 27 with phenylacetaldehyde 54 using L-proline 61 or proline tetrazole 
70 as an organocatalyst. 
27 54 59 
61 or 70 
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Table 4.2 shows the experimentally observed second order rate constants for the 
reaction outlined in Figure 4.3, using either L-proline 61 or proline tetrazole 70 as a 
catalyst. For comparison, the second order rate constants obtained for L-proline 61 
and proline tetrazole 70 using butanal 51 (see Table 4.1) are also shown. 
 
 
 
 
 
 
In comparison to butanal 51, significantly higher second order rate constants are 
observed when using phenylactealdehyde 54 as a donor, with rate constants ranging 
between 1-24 M-1s-1 depending on the catalyst and catalyst loading. Similarly to 
kinetic studies with butanal 51, proline tetrazole 70 displays greater catalytic activity 
compared to that of L-proline 61. In comparison to previously reported protein 
aldehyde ligation kinetic studies, the second order rate constants obtained for the 
OPAL were found to be comparable to specific aniline-catalysed oxime ligations at 
pH 4.0 123 and pH 7.0,122 small molecule iso-Pictet Spengler ligations at pH 4.5,88 
small molecule SPANC ligations in H2O/MeCN,
188 and small molecule ABAO 
ligations at pH 4.5 132 (see Section 1, Table 1.1).These rate constants also compare 
favourably to small molecule oxime ligations performed at neutral pH,143 and to 
other protein bioconjugation strategies such as the SPAAC or the Staudinger 
ligation.141 
4.3. Putting the two together 
Following the kinetic studies outlined in Section 4.1 and 4.2, the use of proline 
tetrazole 70 compared to L-proline 61 as a catalyst, and phenylacetaldehyde 54 
compared to butanal 51 as a donor was investigated within the context of protein 
modification. For these experiments, glyoxyl-thioredoxin 27 was chosen as a model 
protein substrate. Glyoxyl-thioredoxin 32 was subsequently treated with four 
Table 4.2 Second order rate constants obtained for the reaction of glyoxyl-LYRAG 27 with either butanal 51 (R 
= CH2CH3) or phenylacetaldehyde 54 (R = Ph) using different loadings of L-proline 61 or proline tetrazole 70. 
61 70 61 70 
51 54 
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different combinations of catalyst and donor in 25 mM PB pH 7.5 buffer at 37oC for 
1 h as outlined in Figure 4.4A. Conversions to the desired OPAL products were 
judged by LC-MS analysis (Figure 4.4B).  
 
 
 
 
 
 
 
 
 
 
Consistent with the previously acquired kinetic data, proline tetrazole 70 displayed 
greatly enhanced catalysis compared to L-proline 61 in the OPAL. Similarly, 
phenylacetaldehyde 54 showed substantially higher reactivity compared to butanal 
51, with significantly higher conversions observed within the 1 h period when using 
phenylacetaldehyde 54, despite using 200 molar equivalents less of 
phenylactealdehyde 54 (500 µM final concentration) compared to butanal 51 (10 
mM final concentration). The difference in reactivity of catalyst and donor is 
especially apparent when comparing the catalyst/donor combination of L-proline 
61/butanal 51 to the proline tetrazole 70/phenylacetaldehyde 54 combination, with 
no conversion to the OPAL product observed for the former, and quantitative 
conversion observed for the latter. Overall, proline tetrazole 70 and 
phenylacetaldehyde 54 exhibited significantly greater reactivity in the OPAL 
compared to L-proline 61 and butanal 51 respectively, leading to greater conversions 
of the desired OPAL product within the 1 h timeframe, along with requiring 
32 
51 or 54 
61 or 70 
72 (R = CH2CH3) or 73 
(R = Ph) 
61 51 61 54 
70 51 70 54 
72 73 
72 73 
Figure 4.4 (A) Reaction 50 µM glyoxyl-thioredoxin 32 with either 10 mM butanal 51 or 500 µM 
phenylacetaldehyde 54 using L-proline 61 or proline tetrazole 70 as a catalyst. (B) Observed conversion to the 
desired OPAL product 72 or 73 for each catalyst/donor combination as judged by LC-MS analysis. 
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significantly lower concentrations of donor to achieve high conversions to the OPAL 
product. 
 
4.3.1 Rational for enhanced catalyst and donor activity 
The enhanced reactivity displayed by proline tetrazole 70 and phenylacetaldehyde 54 
in comparison to L-Proline 61 and butanal 51 could be rationalised by previously 
reported observations made in the small molecule aldol literature. For proline 
tetrazole 70, greater compatibility with water and hydrated aldehydes has been 
previously reported. 189 Focusing on conversion to the aldol product, the 
intermolecular reaction between chloral 74 and cyclopentanone 75, using proline 
tetrazole 70 as a catalyst, (Figure 4.5A) gives an 85% yield of the desired aldol 
product 76 when performing the reaction in the presence of 100 mol% water. In 
contrast, the reaction fails to proceed if no water is added, but gives aldol product in 
an 83% yield if chloral monohydrate is used as the acceptor. Replacing proline 
tetrazole 70 with L-proline 61 significantly reduced the yield of the desired aldol 
product 76 (<10%) regardless of whether chloral 74 or chloral monohydrate 77 was 
used. 189 An additional explanation for the enhanced reactivity of proline tetrazole 70 
displayed over L-proline 61 is the tendency for L-proline 61 to form bicyclo-
oxazolidinone species 78 with aldehyde substrates e.g. pivaldehyde 79 during a 
given aldol reaction (Figure 4.5B). These “parasitic” species are thought to sequester 
active catalyst species, preventing enamine formation and thus reducing catalyst 
efficiency. Proline tetrazole 70 does not participate in such reactions, and, 
subsequently, more catalyst is available for enamine formation and downstream 
aldol product synthesis, leading to a more efficient catalyst. 190 
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For phenylacetaldehyde 54, a greater tendency for 54 to form enamines than other 
aldehyde donors has previously been described in the literature. 191 Equilibrium 
constants (Keq) for the equilibria between carbonyl compounds and their respective 
enamines (using O-TBDPS-derived prolinol 80) were determined by NMR 
spectroscopy, using proton peak areas of the carbonyl, catalyst and enamine species 
in a given system. Equilibrium constants for enamine formation between prolinol 80 
and phenylacetaldehyde 54 were significantly higher than those observed when using 
alkyl aldehydes such as isoburtyraldehyde 52 (Figure 4.6), suggesting 
phenylacetaldehyde 54 shows a much greater tendency to form enamines than alkyl 
aldehyde donors (likely explained by carbon-carbon double bond stabilising effects 
provided by the phenylacetaldehyde aromatic ring substituent), and therefore shows 
significantly enhanced reactivity when used in the synthesis of aldol products. 191 
 
Figure 4.5 Rational for enhanced activity displayed by proline tetrazole 70 over L-proline 61 in the OPAL. 
(A) Proline tetrazole 70 shows enhanced reactivity in the presence of water/hydrated aldehydes compared 
to L-proline 61. (B) L-proline 61 participates in parasitic bicyclo-oxazolidinone formation, reducing 
catalyst availability and overall reactivity in aldol ligations. 
75 
70 
74 or 77 
76 
74 74 77 
79 61 78 
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4.3.2 Comments on stereochemistry 
The stereochemistry of small molecules is often of immense importance in 
governing their chemical properties, effects in biological processes, and ultimately 
their downstream applications. Diastereomers are known to exhibit different 
chemical properties to each other, such as different reactivity and different retention 
times in separation techniques. The enantiomers of a given compound can induce 
profoundly different outcomes when used in a biological context. For example, the 
drug thalidomide, which interconverts between enantiomers under biological 
conditions and was used to treat morning sickness in the 1950s, has sedative 
properties (resulting from the (R) enantiomer) but also causes birth defects (resulting 
from the (S) enantiomer).192 Unsurprisingly, asymmetric reactions that give a high 
percentage of one diastereomer and/or high levels of enantiomeric excess of a given 
compound of interest are highly prized in organic synthesis. Organocatalysed aldol 
reactions in particular have garnered significant interest within the field of 
asymmetric synthesis and asymmetric catalysis. 
Stereochemistry is a factor of great importance when considering synthetic routes 
towards a desired product in small molecule organic synthesis, and stereochemical 
control of a given synthetic strategy is often the focal point of many publications 
within the field of asymmetric synthesis/catalysis. For protein bioconjugation, 
Figure 4.6 Rational for enhanced activity displayed by phenylacetaldehyde 54. Phenylacetaldehyde 54 shows a 
greater tendency to form enamines than other aldehyde donor species, increasing the active concentration of 
reactive enamine species available for aldol ligation, enhancing the overall rate of reaction. 
54 
52 
80 
80 
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however, the stereochemical outcome of the products is rarely a focal point, with 
only a handful of publications acknowledging the stereochemistry of the products 
synthesised using a given strategy.17,128,130,131,133 A possible reason for this is that the 
stereochemistry of the bond between the non-functional linker segment of a 
conjugate and between a protein (a large, dynamic biomolecule which can constantly 
adopt different conformations) is arguably unimportant given that it is unlikely to 
affect protein/probe functionality, and is therefore not discussed. Alternatively (or 
additionally), lack of discussion on stereochemistry in protein bioconjugation may be 
due to the fact that it is difficult to control, or cannot be controlled. Protein 
bioconjugation must be performed in aqueous media i.e. water, which can greatly 
interfere with the stereoselectivity certain reactions. The organocatalysed aldol 
reaction for example has been shown to lead to mixtures of diastereomers when 
performed in water. 193 
NB: The field of organocatalysed aldol reactions where water is used as an 
additive/solvent has seen a great deal of discussion. For more information, readers 
are directed to published material. 194-196 
For the OPAL, it was decided that the stereochemistry of the products was of 
interest, given that (unlike any previously reported protein bioconjugation strategies) 
the bioconjugation was being catalysed by enantiomerically pure organocatalysts, 
which may impact of the stereochemical outcome of the bioconjugates synthesised. 
Therefore, the stereochemistry of the OPAL was investigated via NaIO4 oxidation of 
Ser-Ala dipeptide 81 to the glyoxyl-alanine 82, followed by an aldol reaction with 
phenylactealdehyde 54 using L-proline 61 as a catalyst to synthesise aldol product 
(2,4,4-trihydroxy- 3-phenylbutanoyl)-L-alanine 83 (Figure 4.7A).  Complete 
conversion to aldol product 83 was confirmed by LC-MS analysis, then characterised 
through NMR and HPLC studies (Figure 4.7B). The NMR and HPLC data obtained 
for this small molecule model indicated a mixture of four diastereomers the ratio 
a:b:c:d = 1: 0.91: 0.89: 0.72 (as obtained from relative area values from HPLC). This 
lack of stereochemical control was in agreement with other previously described 
aqueous aldol reactions, and it was therefore anticipated that OPAL modifications of 
proteins would lead to a mixture of diastereomers. 
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v Synthesis of dipeptide 81 and subsequent NMR/HPLC characterisation of aldol product 83 was 
performed by Dr Darshita Budhadev (see Reference 2 for full characterisation). 
Figure 4.7 (A) Outline of synthesis of aldol product 83. (B) HPLC data of aldol product 83, highlighting a 
mixture of diastereoisomers of 83. (C) Zoomed in portion of 1H NMR of aldol product 83, highlighting a mixture 
of diastereoisomers 83. 
81 82 83 
61, 54 
1.0 
0.89 
0.72 
0.91 
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4.4 Aryl donor synthesis 
Having established an improved OPAL strategy using phenylacetaldehyde 54, 
synthesis of probes containing α-aryl aldehyde functionality suitable for the OPAL 
were next investigated. Probes bearing Boc-protected oxazolidines were constructed 
using SPPS on resin from readily available building blocks and linker 84 (see 
Chapter 8, Experimental) for peptide synthesis for synthesis of linker). Figure 4.8 
shows the generic structure of the Boc-protected oxazolidine, resin bound probes 
(where R = functionality of choice e.g. fluorescent group, affinity tag). 
 
 
 
 
 
 
Simultaneous resin cleavage and unmasking of the resin bound Boc-protected 
oxazolidine to give 1,2 amino-alcohol protected probes could then be achieved using 
TFA (Figure 4.9A). The α-aryl probes constructed contain a polyethylene glycol 
spacer unit to both increase the water solubility of the probe, and reduce steric bulk 
at the reactive linker section of the probe. The 1,2 amino alcohol protected probes 
could then be converted to the desired α-aryl containing probes via rapid periodate 
oxidation (Figure 4.9B) to yield the α-aryl probes. vi 
 
 
 
 
 
                                                          
vi Linker 84 was kindly provided by Dr Darshita Budhadev (see Reference 2 for details of synthesis). 
84 
Figure 4.8 Outline of resin bound, Boc-protected oxazolidine probes for the OPAL 
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Throughout this report, different chemical probes are represented as different 
symbols depending on the identity of R group shown, as shown in Figure 4.10 (see 
Chapter 8 for full details on probe preparation). 
 
 
 
 
 
 
 
 
 
Figure 4.9 (A) Simultaneous resin cleavage and Boc-protected oxazolidine cleavage using TFA to give the 
amino-alcohol protected OPAL probes (R = functionality of choice). (B) Periodate oxidation of amino-alcohol 
protected OPAL probes to reveal the α-aryl containing OPAL probes. 
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Figure 4.10 Structures of the four α-aryl OPAL probes 85-88 and their representative symbols used 
throughout the project. 
85 
86 
87 
88 
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4.5 Protein modification 
With α-oxo aldehyde containing proteins, compatible chemical probes and a 
validated procedure in hand, the optimised OPAL strategy was next investigated 
within the context of protein modification. It was anticipated that conditions used in 
the kinetic studies for the OPAL could be used as the basis for site-selective protein 
modification. For an OPAL with proline tetrazole 70 and aryl probes 85-88, this 
would give conditions of 50 μM α-oxo protein, 150 μM probe, and 25 mM proline 
tetrazole 70 in 25 mM PB pH 7.5 at 37 oC for 30 min. Protein bioconjugations, 
however, are well known to proceed at a more sluggish rate than their peptide 
counterparts, requiring higher concentrations of reagent or longer reaction times to 
achieve similar conjugation results. Therefore, for initial OPAL experiments 
between glyoxyl-thioredoxin 32 and fluorescent probe 85, the concentration of probe 
used was increased from 150 μM to 500 μM, and a 4 µL reaction between 50 µM of 
glyoxyl-thioredoxin 32 and 500 µM fluorescent probe 85 was performed using 25 
mM proline tetrazole 70 in 25 mM PB pH 7.5 for 30 min at 37 oC as outlined in 
Figure 4.11A. Total conversion to fluorescent thioredoxin 89 was observed as judged 
by LC-MS analysis, as shown in Figure 4.11B. 
 
 
 
 
 
 
 
 
Next, the OPAL was performed on glyoxyl-thioredoxin 32 on a 40 µL scale, using 
500 µM of fluorescent probe 85 or 500 µM of azide probe 87, 25 mM proline 
tetrazole 70 in 25 mM PB pH 7.5 for 30 min at 37 oC. This did not, however, lead to 
complete conversion to either fluorescent thioredoxin 89 or azide labelled 
Figure 4.11 (A) Outline of reaction between glyoxyl-thioredoxin 32 and probe 85 using proline tetrazole 70 as 
a catalyst. Masses quoted are calculated masses, mass in brackets = 32-Hyd. (B) LC-MS data for the  reaction 
of 50 µM glyoxyl-thioredoxin 32 and 500 µM donor 85 using 25 mM proline tetrazole70 in 25 mM PB pH 7.5 
for 30 min at 37 oC . 
32 
70 
85 
89 
89 
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thioredoxin 90 as judged by LC-MS analysis. Allowing the reactions to proceed for a 
further 30 min (1 h total) resulted in complete conversion to the desired modified 
proteins as judged by LC-MS analysis (Figure 4.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This procedure was subsequently used for the site-selective fluorescent labelling of 
glyoxyl-[15N]HASPA 36-15N and biotinylation of glyoxyl-GFP 34 (Figure 4.13). 
 
 
 
 
 
32 
32 
70 
85 
89 
89 
70 
90 
87 
90 
Figure 4.12 (A) Outline of reaction between glyoxyl-thioredoxin 32 and probe 85 using proline tetrazole 70as a 
catalyst. Masses quoted are calculated masses, mass in brackets  = 32-Hyd (B) LC-MS data obtained for reaction 
50 µM glyoxyl-thioredoxin 32 and  500 µM donor 85 using 25 mM proline tetrazole 70 in 25 mM PB pH 7.5 for 
1 h at 37 oC .(C) Outline of reaction between glyoxyl-thioredoxin 32 and probe 87 using proline tetrazole 70as a 
catalyst. Masses quoted are calculated masses, mass in brackets = 32-Hyd (D) LC-MS data obtained for reaction 
50 µM glyoxyl-thioredoxin 32 and  500 µM donor 87 using 25 mM proline tetrazole 70 in 25 mM PB pH 7.5 for 
1 h at 37 oC . 
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In some cases, particularly when using older probes as (see section 4.5.1), or when 
using sterically bulky folate probe 88, a higher loading of probe was required to 
achieve full conversion to the desired OPAL product. With this knowledge in mind, 
site-selective modification of glyoxyl-thioredoxin 32, glyoxyl-myoglobin 13, 
glyoxyl-GFP 34, and glyoxyl-HASPA 36 via the OPAL was carried out using 1 mM 
of fluorescent probe 85, biotin probe 86, or azide probe 87 (1.5 mM of folate probe 
88), with a 25 mM loading of proline tetrazole 70, in 25 mM PB pH 7.5 at 37 oC for 
1 h, with protein concentrations ranging from 50-250 μM (0.5-2.5 mg mL-1). 
Successful synthesis of constructs 93-96 was confirmed and analysed by LC-MS 
(Figure 4.14, see Chapter 8, Experimental for details of modification procedures). 
These results in particular highlight the versatility of the OPAL, as different protein 
α-oxo aldehydes and α-aryl donors can be used successfully in the ligation protocol. 
Figure 4.13 (A) Outline of reaction between glyoxyl-[15N]HASPA 36-15N and probe 85 using proline 
tetrazole 70 as a catalyst. Masses quoted are calculated masses, mass in brackets = 36-15N-Hyd (B) LC-MS 
data obtained for reaction 250 µM glyoxyl-[15N]HASPA 36-15N and 500 µM donor 85 using 25 mM proline 
tetrazole 70 in 25 mM PB pH 7.5 for 1 h at 37 oC .(C) Outline of reaction between glyoxyl-GFP 34 and probe 
86 using proline tetrazole 70 as a catalyst. Masses quoted are calculated masses, mass in brackets = 34-Hyd (D) 
LC-MS data obtained for reaction 62 µM glyoxyl-GFP 34 and  500 µM donor 86 using 25 mM proline tetrazole 
70 in 25 mM PB pH 7.5 for 1 h at 37 oC . 
36-15N 
70 
91 
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In comparison to using L-proline 61 and alkyl aldehyde donor 51, site-selective 
protein modification using proline tetrazole 70 and α-aryl donors 85-88 gave faster 
reaction times (from 6 h to 1 h) and reduced donor concentrations (from 10-25 mM 
to 0.5 - 1.5 mM) required to achieve full conversion to the desired OPAL product as 
judged by LC-MS, offering a significantly improved OPAL protocol. 
 
4.5.1. Notes on probe stability and long term storage 
During the course of this project, it was found that 1,2 amino alcohol protected 
probes and α-aryl probes 85-88 could be stored long term as lyophilised powders at -
20 oC. The lyophilised chemical probes 85-88 were found to be highly water soluble 
and could be stored as 50 mM stock solutions in water at -20 oC for at least 3 months 
(typically as 5 μL aliquots). Stock solutions in this form could then be defrosted and 
used when required. Throughout the project, defrosted stock solutions of probes 85-
88 were kept at 4 oC and were typically used within four days for bioconjugation 
reactions. It was noted that, after 3 months of storage in solution at -20 oC, a minor 
decrease in reactivity of probes 85-88 towards protein modification could be 
observed. Probes 85-88 stored for longer than 6 months in solution at -20 oC could 
Figure 4.14 Site-selective modification of protein α-oxo aldehydes using different combinations of protein α-
oxo aldehydes and α-aryl probes. 
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still be successfully used for site-selective protein modification, but procedures could 
require higher concentrations of probe to achieve complete conversion to the desired 
protein bioconjugates after 1 h of incubation at 37 oC. Therefore, if incomplete 
conversion to the desired modified protein was noted for a given bioconjugation 
when using old probe, an additional 0.5-1 mM of probe could be added to a given 
bioconjugation reaction, and allowed to react for a further 30 min at 37 oC to achieve 
quantitative conversion. 
 
4.5.2 Protein integrity 
As discussed in section 3.1.9 the haem group of myoglobin exhibits a strong 
absorbance at λ = 410 nm, and could be used as an indicator of protein integrity after 
modifications are made to the protein. The UV/vis spectra of unmodified myoglobin 
28, glyoxyl-myoglobin 13 and biotinylated myoglobin 97 were therefore recorded, 
and compared at 410 nM (Figure 4.15). 
 
 
 
 
 
 
 
 
The UV/vis spectrum of OPAL product 97 was found to be of an excellent match to 
that of unmodified myoglobin 28, suggesting that the protein integrity, and the haem 
group itself, remained unchanged post modification. 
 
 
Abs 
G = Myoglobin 28 
B = Glyoxyl myoglobin 13 
R = Biotinylated myoglobin 97 
Figure 4.15 UV-Vis measurements of myoglobin 28 (green line), glyoxyl-myoglobin 13 (blue line) and aldol 
product 97 (red line). 
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4.5.3 Modification of glyoxyl-CTB by the OPAL 
As described previously in Chapter 2, glyoxyl-CTB 30 is a challenging glyoxyl-
protein substrate to modify due to inactivation by intramolecular cyclisation. 
Multiple attempts to site-selectively modify glyoxyl-CTB 30 via the OPAL were 
performed throughout the course of this project. Unfortunately, unsuccessful, 
uninterpretable data, or minimal modification to give the desired OPAL product was 
observed in all cases, with the most successful OPAL results for glyoxyl-CTB 30 
shown in Figure 4.16A and Figure 4.16B using fluorescent probe 85. 
 
 
 
 
 
 
 
Allowing the reaction described in Figure 4.15 to proceed longer, or supplementing 
the reaction with more catalyst, or using high donor concentrations, did not lead to 
any improvements in conjugation to yield fluorescent CTB 98. These results further 
demonstrate the additional challenges associated with modifying protein α-oxo 
aldehydes containing adjacent proline residues such as glyoxyl-CTB 30. 
4.5.4 Comments on OPAL product stability 
Protein bioconjugation strategies should ideally yield conjugates that are 
hydrolytically stable and do not undergo uncontrolled breakdown. In an effort to 
assess the stability of the OPAL products, a desalted aliquot of azide labelled 
thioredoxin 90 was incubated in 25 mM PB pH 7.5 at 37 oC over the course of 72 h 
with LC-MS data for the sample collected at 24 h intervals (Figure 4.17). 
 
Figure 4.16 (A) Outline of reaction between glyoxyl-CTB 30 and probe 85 using proline tetrazole 70 as a 
catalyst. Mass quoted = calculated masses, mass in brackets = 30-Hyd (B) LC-MS data obtained for reaction 
100 µM glyoxyl-CTB 30 and  2 mM donor 85 using 25 mM proline tetrazole 70 in 25 mM PB pH 7.5 for 1 h at 
37 oC 
30 
70 
85 
98 30 
98 
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No hydrolysis of azide labelled thioredoxin 90 to give glyoxyl-thioredoxin 32 was 
observed as judged by LC-MS. Additionally, OPAL modified protein samples could 
be stored at 4 oC for several days following purification by desalting, and used at a 
later date for further site-selective modification experiments. On a related note, 
purified samples of modified peptides 56 and 59 could be stored as lyophilised 
powders at -20 oC for at least 1 month, with minimal hydrolysis of the aldol product 
observed upon solubilisation into buffer.  
4.6 Modification of internal protein α-oxo aldehydes 
With confirmation of the OPAL as a viable method for site-selective modification of 
proteins bearing N-terminal α-oxo aldehyde, the strategy was next investigated in its 
compatibility with internal α-oxo aldehyde handles (Figure 4.18A). Following Pd-
mediated decaging, sfGFP(N150GlyoxylK) 41 and GFP(Y39GlyoxylK) 42 were 
subjected to OPAL conditions using 1.5 mM of azide probe 87, with a 25 mM 
loading of proline tetrazole 70 in 25 mM PB pH 7.5, at 37 oC 1 h, with 
sfGFP(N150GlyoxylK) 41 at a final concentration of 100 µM, and 
GFP(Y39GlyoxylK) 42 at a final concentration of 150 µM, yielding internally azide 
labelled sfGFP 99 and internally labelled GFP 100 (Figure 4.18B). Additionally, to 
demonstrate compatibility with other probes, 100 µM sfGFP(N150GlyoxylK) 41 
was also site-selectively modified using biotin probe 86 under identical conditions to 
give internally biotinylated sfGFP 101. 
 
 
 
Figure 4.17 Structure of OPAL product azide tagged thioredoxin 90, and associated MS data after periods of 
incubation at 37 oC to determine hydrolytic stability. 
90 
90 90 90 
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4.6.1 Labelling of GFP in cell lysate and selective protein pulldown 
Having established the OPAL as a method for the site-selective modification of 
purified proteins (either from commercial or recombinant sources), the ligation 
procedure was next investigated in its compatibility to proceed in complex biological 
mixtures. To demonstrate this, cell lysate containing GFP(Y39ThzK) 42 was first 
subjected to Pd-mediated decaging, followed by site-selective modification via the 
OPAL using proline tetrazole 70 and biotin probe 86. Excess probe was removed 
using 10kDa MWCOs to give a “post OPAL” cell lysate containing internally 
biotinylated GFP 102 (Figure 4.19). 
70 
99 100 
101 
Figure 4.18 (A) Pd-mediated decaging of thiazolidine-containing proteins followed by the OPAL. 
(B) Site-selective modification of proteins bearing internal glyoxyl handles using azide probe 87 or 
biotin probe 86. 
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Following removal of excess probe 86, the lysate was then loaded onto a monomeric 
avidin column and unbound material was washed off with PBS. Material tagged with 
biotin i.e. internally biotinylated GFP 102 was then eluted off the monomeric avidin 
agarose column using an elution buffer comprising of a 2 mM biotin solution in 
PBS. The monomeric avidin agarose column post lysate loading and post PBS 
washing, along with the fractions collected during the protein pulldown procedure, 
were examined for fluorescence (Figure 4.20). Given that the Pd-mediated decaging, 
OPAL-mediated biotinylation, and elution procedure were performed at pH 7.4-7.5, 
the integrity and therefore fluorescence of GFP should be retained post modification. 
In total, one 2 mL fraction of flowthrough was collected (Fraction FT), six fractions 
of 2 mL washes with 1 x PBS were collected (Fractions 1-6), and 14 fractions of 1 
mL washes with 2 mM biotin in 1 x PBS pH 7.4 were collected (Fractions 7-20), as 
shown in Figure 4.20. 
 
 
 
 
 
 
Figure 4.19 Pd-mediated decaging and OPAL biotinylation of GFP(Y39ThzK) 42 in cell lysate using 25 mM 
proline tetrazole 70 and 1.25 mM biotin probe 86. 
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As seen in Figure 4.20, fluorescence was retained following loading of the ‘post 
OPAL’ cell lysate onto the monomeric avidin agarose column and washing the 
column with PBS, suggesting successful binding of internally biotinylated GFP 102. 
Of the wash fractions 1-6 collected, only fraction 1 displayed fluorescence, 
suggesting the presence of unbound GFP material. Of the elution fractions 7-20, 
fractions 8-13 clearly display fluorescence, suggesting the recovery of internally 
biotinylated GFP. This was accompanied with the expected loss fluorescence 
displayed by the monomeric avidin agarose column due to elution of bound GFP. To 
assess the purity of eluted fractions containing internally biotinylated GFP 102 
following selective protein pulldown, fractions 7-11 along with 1 and 6 (to assess 
6 x wash 
1 x PBS, 
pH 7.4 
Load Post 
OPAL 
lysate 
Figure 4.20 Schematic of loading cell lysate containing internally biotinylated GFP 102 onto monomeric avidin 
agarose column. The column is then washed with PBS. Fluorescent imaging pre and post washing demonstrates 
retention of GFP fluorescence. Fractions from purification of cell lysate containing internally biotinylated GFP 
102 using a monomeric avidin agarose column were then collted. FT = Flowthrough. Fractions 1-6 = Washed 
with 1 x PBS pH 7.4. Fractions 7-20 = Elution with 2 mM biotin in 1 x PBS pH 7.4. Left: Fluorescent imaging 
of collected fractions. Right: White light imaging of collected fractions. 
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purity/GFP presence), were subjected to SDS-PAGE analysis. Samples of the 
original cell lysate prior to Pd-mediated decaging, and of the ‘post-OPAL’ lysate, 
were also subjected to SDS-PAGE analysis for a direct comparison of GFP purity 
before and after OPAL modification and avidin purification (Figure 4.20) 
 
 
 
 
 
 
 
 
 
 
As shown in Figure 4.21, the cell lysate and ‘post-OPAL’ lysate contain a complex 
mixture of biomolecules. Fraction 1 displays GFP with impurities as evidenced by 
the faint bands above and below the band at ca. 30 kDa (other impurities may have 
been removed in the fraction FT). No material is seen in fractions 6 and 7. Fractions 
8-11 clearly show purified GFP protein, with no other bands corresponding to the 
impurities seen in the lysate samples or wash samples present. Overall, these results 
demonstrate that both Pd-decaging of proteins bearing thiazolidine groups, and site-
selective modification of proteins via the OPAL strategy, could be successfully 
carried out in complex biological media without compromising protein integrity, and 
that selective protein pulldown can be achieved through site-selective biotinylation 
and subsequent purification using a monomeric avidin agarose column. 
 
 
Figure 4.21 SDS-PAGE analysis of cell lysate samples and fractions of interest collected from purification of 
cell lysate containing internally biotinylated GFP 102 using a monomeric avidin agarose column. L = Ladder. 
CL = Cell lysate (before addition of allylpalladium(II) chloride dimer). PO = Post OPAL (following removal of 
excess affinity tag 86 and directly before loading onto the monomeric avidin agarose column). Collected 
fractions follow same numerical labelling as seen in Figure 4.19. 
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4.7 Future work 
With regards to optimising the OPAL, the focus was primarily centred on the 
identity of the catalyst and donor used in the ligation procedure. Through screening a 
series of commercially available secondary amines and enolisable aldehydes, 
substantial optimisation of the original OPAL procedure was achieved, with 
significant reductions in reaction times and donor concentrations required for total 
conversion to OPAL products from α-oxo aldehyde bearing starting materials. 
Rigorous kinetic analysis of this panel of catalysts and substrates with a model α-oxo 
aldehyde acceptor yielded a range of second order rate constants, the highest of 
which was displayed in the reaction of glyoxyl-LYRAG 27 and phenylacetaldehyde 
54 using a 25 mM loading of proline tetrazole 70. For these conditions, a second 
order rate constant of ~24 M -1s-1 was obtained, which compares favourably to 
protein aldehyde bioconjugation strategies previously reported in the literature.1 
Further improvements to the OPAL procedure could potentially be found through 
screening of additional catalysts and donors; currently, only 10 different secondary 
amine catalysts and only two species of aldehyde donor have been investigated. 
Numerous catalysts have been developed and reported in the literature for use in 
small molecule aldol reactions, such as peptide-based catalysts, resin bound 
catalysts, and enzyme-based catalysts. Other amino acids (aside from L-proline 61) 
may also show catalytic activity. Aldehyde donors bearing functional groups other 
than purely alkyl and aryl substituents (e.g. halogens, heteroatoms) may offer 
superior kinetics when used within the context of the OPAL, and may be worth 
investigating. There are, however, hundreds of different combinations of catalyst and 
donor that could be screened, and to investigate every single combination via the 
methods described in this Chapter would be exceptionally time consuming. 
Therefore, large scale screening of different catalysts and donors would likely 
require a different set of methodology, such as resin-based strategies for determining 
optimal sequence for PLP/RS transamination for example. 81,83 
Throughout its development, the OPAL displayed good compatibility with all 
protein scaffolds regardless of positioning of the α-oxo aldehyde and the donors 
investigated. The one exception to this was when using glyoxyl-CTB 30 as the α-oxo 
aldehyde acceptor. For protein scaffolds bearing hindered α-oxo aldehyde handles, 
such as glyoxyl-CTB 30, it may be beneficial to investigate different lengths of the 
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linker component of the donors used for protein bioconjugation. An increased linker 
length would increase the spacing between the reactive component and bulky, 
functional moiety of the donor, which may help reduce steric clashes between the 
protein and donor during a given ligation, thus leading to improved kinetics and 
conversion yields. Another area that would be worthwhile investigating would be the 
buffer composition used in the OPAL procedure. Throughout the design and 
development of the OPAL, the choice of buffer has consistently been kept as a 25 
mM PB buffer solution at pH 7.5. However, it has become increasingly apparent 
within the protein bioconjugation literature that buffer composition and the addition 
of salts can have significant effects on the rate of a given ligation. This is particularly 
notable for π-clamp mediated cysteine bioconjugation, where enormous rate 
enhancement can be achieved by supplementing the reaction with salts such as 
ammonium sulfate. 43 Therefore, investigating the effect of buffer salt composition 
within the context of the OPAL would potentially lead to further improvements in 
the kinetics of ligation. 
The selective biotinylation of GFP in cell lysate demonstrated that both Pd-decaging 
of thiazolidine-bearing amino acid side chains and site-selective modification of 
proteins via the OPAL strategy could be successfully carried out in complex 
biological media. Importantly, the entire labelling procedure could be performed at 
neutral pH, maintaining GFP fluorescence (and therefore protein integrity), was site-
selective for the protein α-oxo aldehyde over other cell lysate material, and yielded 
hydrolytically stable, C-C linked bioconjugate. The next stage in this venture would 
be to apply the OPAL in the labelling of live cells – this would truly assess the 
bioorthogonality of the OPAL. 
To further investigate the stability of OPAL products, it would be worthwhile 
screening a range of different storage conditions. In particular, observing the stability 
of OPAL products in human plasma would be of great importance if the OPAL 
strategy were to be used in the synthesis of ADCs, or other conjugates designed for 
in vivo use. 
Finally, site-selective protein modification via aldol-type chemistry could be further 
improved through investigation into metal-based catalysts and more sophisticated 
donors. Aldol reactions catalysed by metals feature prominently in small molecule 
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literature, and such procedures could potentially have applications in aldol-based 
site-selective protein modification. Designing more sophisticated donors could also 
lead to an improved aldol-type bioconjugation procedure. With the understanding 
that the OPAL follows an enamine-type mechanism of reaction, it is reasonable to 
postulate that one of the major mechanistic barriers in synthesis of the aldol product 
is the required formation of an imine, which subsequently tautomerises to the 
reactive enamine, between the catalyst and donor. This is because the reaction media 
used for the OPAL is entirely aqueous, which would result in the rapid hydrolysis of 
any imine formed between catalyst and donor. Circumventing this issue, either by 
designing donors that incorporate both catalyst and reactive aldehyde species to 
allow for intramolecular (as opposed to intermolecular) imine formation, or by 
designing sufficiently reactive donors containing “preformed enamine” functionality, 
could lead to an overall improved ligation procedure for site-selective modification 
of protein aldehydes. 
4.8 Conclusion 
In conclusion, the OPAL has been validated as a straightforward, organocatalyst 
mediated bioconjugation strategy that uses commercially available catalysts, and 
easily accessible probes for the rapid site-selective modification of a range of α-oxo 
aldehyde containing proteins at neutral pH to give hydrolytically stable 
bioconjugates. This ligation procedure was designed through kinetic analysis of 
different organocatalysts and aldehyde donors within the context of an 
organocatalyst mediated aldol reaction suitable for protein bioconjugation as a 
framework. Proteins containing N-terminal and internal α-oxo aldehydes, and donors 
bearing different probes, including fluorescent tags, affinity handles, bioorthogonal 
handles, and targeting agents, were found to be compatible with the OPAL, 
demonstrating the flexibility of the ligation procedure. The selectivity and 
effectiveness of the OPAL for protein bioconjugation was demonstrated in the 
selective labelling, pulldown, and purification of α-oxo aldehyde bearing GFP 
directly from a cell lysate. 
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Chapter 5: Site-selective dual modification of proteins 
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5.1 Beyond single modifications of proteins 
As established in Chapter 3, the OPAL yields protein bioconjugates containing an 
aldehyde handle, which theoretically could participate in further site-selective 
modification via another previously report protein aldehyde ligation strategy.1 
Several strategies for dual/multi-functionalisation of proteins have previously been 
reported, 197 and are split into two categories: strategies that modify two amino acids 
in a given protein, and strategies that first modify a given protein with a probe 
containing an orthogonal handle, followed by modification of that incorporated 
handle. However, in comparison to strategies for single site-selective modification 
(which are becoming more prevalent in the literature), strategies for the site-selective 
dual modification of proteins and beyond are somewhat scarce. Development of 
strategies for site-selective multi-functionalisation of proteins would be of immense 
benefit to furthering the field of protein bioconjugation, given that certain 
applications require dual/multi-functional protein constructs; studying structural and 
dynamic properties of proteins via Förster Resonance Energy Transfer (FRET) for 
example requires installation of two fluorescent groups into a target protein.63 
Alternatively, the ability to site-selective modify target protein multiple times would 
allow for the design of more complex protein bioconjugates, such as those with 
fluorescent and affinity properties, or enable the conjugation of functionalised 
proteins to moieties such as surfaces or other proteins. Site-selective 
dual/multifunctionalisation of proteins would also greatly lend itself to designing 
next generation ADCs. The drug-antibody ratio (DAR) of ADCs is of critical 
importance in determining certain parameters of a given ADC. ADCs with 
sufficiently low DARs may show reduced therapeutic activity, whereas ADCs with 
sufficiently high DARs potentially suffer detrimental effects to protein structure, 
stability, and antigen binding.198 For example, the ADC comprising an anti-CD30 
monoclonal antibody caC10 and monomethyl auristatin E with a DAR of 4:1 
required lower doses than ADC with a DAR of 2:1, and was found to have 
comparable in vivo activity to that of ADC with DAR 8:1 but twice the maximum 
tolerated dose in mice and a 3-fold reduction in clearance time.199 Controlling DAR 
during current generation ADC synthesis is hampered by the non-specific 
bioconjugation strategies however, giving a heterogeneous mixture of ADCs with 
variable DARs. Strategies enabling site-selective dual/multi-functionalisation could 
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potentially offer a solution to this hurdle in designing next generation therapeutics 
(see Reference 14 for discussions on current and next generation strategies for 
preparation of ADCs). Therefore, in an effort to design methodology that could be 
suitable for such applications, site-selective modification of OPAL products via the 
β-hydroxy aldehyde was investigated.  
5.1.1 The β-hydroxy aldehyde handle 
As discussed throughout Chapters 3 and 4, the β-hydroxy aldehyde product of the 
OPAL displays no reactivity in further aldol reactions. This was in agreement with 
observations originally made on small molecule aldol products,185 and was despite 
the molar excess (compared to the concentration of peptide/protein acceptor) of both 
catalyst and probe used in the OPAL procedure. However, as established in Section 
3.1.1, the β-hydroxy aldehyde can undergo modification via a different protein 
aldehyde ligation strategy, such as oxime ligation. Therefore, the compatibility of the 
β-hydroxy aldehyde for site-selective protein aldehyde bioconjugation was 
investigated using previously reported protein aldehyde ligation strategies. For initial 
investigation into the suitability of the β-hydroxy aldehyde handle for further site-
selective modification, the ligation between aldol-modified peptide 59, and small 
molecule reactive partners 103 for oxime ligation, 104  for an iso-Pictet Spengler 
ligation, 88 and 104 vii for an ABAO ligation 132 was carried out. These three ligation 
strategies were chosen for investigation over other potential protein aldehyde ligation 
strategies as they had previously been established to show good ligation kinetics, and 
compatibility with a range of aldehyde handles (see Table 1.1 in Chapter 1). As all 
three ligation strategies have an optimal pH of pH 4.5, all reactions were performed 
in NaOAc pH 4.5 buffer as outlined in Figure 5.1A. LC-MS data was collected for 
each ligation to assess conversion to the dually modified peptides 106-108 (Figure 
5.1B). 
 
 
 
                                                          
vii Indole 104 was kindly provided by Dr Darshita Budhadev (prepared according to Reference 2). 
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In all cases, site-selective modification of the β-hydroxy alkyl aldehyde to the 
desired dually modified peptide 106, 107, or 108 was observed. Conversion yields 
were low, however, despite using long reaction times and large concentrations of 
reaction partner. Attention was therefore turned to improving the conjugation yield 
of oxime ligation by addition of aniline which, as described in Chapter 1.3.1, can act 
as a nucleophilic catalyst for oxime ligation via an imine-based mechanism. The 
reaction between aldol modified peptide 59, and aminooxy 103 was therefore 
performed in the presence of 100 mM aniline in NaOAc at pH 4.5. A notable 
increase in conjugation yields was observed, resulting in a 61% conversion to 106. 
Figure 5.1 (A) Outline of reaction between aldol-modified peptide 59 and small molecule reactive partners 106, 
107, or 108. (B) LC-MS data obtained for each reaction of 0.1 mM aldol modified peptide 59 with small 
molecule 106, 107, or 108 in 0.2 M NaOAc, pH 4.5 for 18 h at 37 oC. 
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5.1.2 Reversal of pH dependence 
The optimal pH of non-catalysed and catalysed oxime ligations has previously been 
reported as pH 4.5.1,139 Acidic pH, however, is incompatible with certain biological 
applications and bioconjugation certain protein scaffolds; GFP, for example, 
denatures and loses its characteristic fluorescence under acidic conditions.200 
Kinetics of non-catalysed oxime ligation at neutral pH are generally sluggish, with 
rate constants typically in the region of 10-3 M-1 s-1, but can be improved through 
addition of aniline, making the ligation suitable for bioconjugation at neutral pH. 
Therefore, an additional screen of aniline–catalysed oxime ligation of aldol-modified 
peptides 56 and 59 and aminooxy 103 was performed in 0.2 M PB at pH 7.5 using 
aniline 46 as a catalyst as outlined in Figure 5.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 (A) Outline of reaction between aldol modified peptides 56 or 59 with aminooxy 103 using 
aniline 46 as a catalyst. (B) LC-MS data obtained for each reaction of  0.1 mM of aldol modified peptides 56 
or 59 with 10 mM aminooxy 103 using 100 mM aniline 46 in 0.2 M PB pH 7.5 for 18 h at 37 oC.  
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56 [M+H]+ = 707.36 Da 
59 [M+H]+ = 755.36 Da 
 
106 [M+H]+ = 860.42 Da 
109 [M+H]+ = 812.42 Da 
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In both cases, the conjugation yields obtained at pH 7.5 were higher than those 
obtained at pH 4.5, suggesting that pH 7.5 was the more optimum pH for the aniline-
catalysed oxime ligation, demonstrating an unexpected reversal in pH dependence in 
comparison to other aniline-catalysed oxime ligations reported in the literature. It 
was decided this phenomenon warranted further investigation. To achieve this, 
previously reported aniline-based catalyst 18, along with 110 and 111, 119,152 were 
investigated for activity in the aniline-catalysed oxime ligation of aldol-modified 
peptides 56 and 59 and aminooxy 103 both at pH 4.5 and pH 7.5 (Figure 5.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
N.B: LC-MS data was not collected for experiments using catalyst 111 at pH 4.5, as 
the catalyst precipitates under acidic conditions. In some experiments, small peak at 
740 Da is observed in all cases – see Chapter 7 for an explanation as to the identity 
of this peak and why it was present. 
Figure 5.3 Outline of investigation into pH effect on the outcome of oxime ligation on aldol-modified peptides 
56 or 59. Conjugation yields to give dually modified peptide 106 or 109 were obtained as judged by LC-MS. 
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The trend of improved conjugation yields at pH 7.5 as opposed to pH 4.5 was again 
evident during the screening of the alternative aniline catalysts, with higher 
conversions to the desired dually modified peptides obtained at pH 7.5. To confirm 
this phenomenon on proteins, an aniline-catalysed oxime ligation was also 
performed between OPAL-modified myoglobin 60 and aminooxy 103 at pH 4.5 and 
pH 7.5 using aniline 46 as a catalyst (Figure 5.4). 
 
 
 
 
 
 
 
 
 
 
 
 
For the ligation of OPAL-modified myoglobin 60, no dually modified protein 
product 112 was observed at pH 4.5, whereas a 52% conversion to the dually 
modified protein product 112 was observed at pH 7.5, further confirming the reversal 
in pH dependence of aniline-catalysed oxime ligation in this particular system. 
5.1.3 Hypothesis of pH dependence 
The pH dependence of aniline-catalysed oxime ligation for the β-hydroxy aldehyde 
containing peptides/proteins, where neutral pH was seemingly favoured over acidic 
pH, differs significantly from the established pH dependence of aniline-catalysed 
60 
60 60 
112 
103 
46 
Figure 5.4 (A) Outline of reaction between OPAL-modified myoglobin 60 and aminooxy 103 using aniline 46 as 
a catalyst at pH 4.5 or pH 7.5. Masses quoted = calculated masses. (B) LC-MS data obtained for reaction at pH 
4.5 (left) or pH 7.5 (right) for 18 h at 37 oC between 100 µM aldol myoglobin 60 and 10 mM aminooxy 103 
using 100 mM aniline 46. 
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oxime ligation typically observed for other aldehyde handles. In previously reported 
literature, aniline-catalysed and uncatalysed oxime ligations have always yielded 
superior kinetics at acidic pH (pH 4.5), regardless of the efficiency a given aniline 
catalyst displays in oxime ligation at neutral pH (pH 7.0).121,123 As shown in Figure 
5.3 and 5.4 however, the reverse was true when using the β-hydroxy aldehyde 
handle. The current working hypothesis for this reversal of pH dependence relates to 
anticipated intramolecular H-bonding contributions from the hydroxyl functional 
group of the β-hydroxy aldehyde handle, and takes inspiration from previously 
reported aniline catalyst oxime ligations, and imine formation of o-hydroxyaryl 
aldehyde. Firstly, it has increasingly been shown that rate enhancements in aniline-
catalysed oxime ligations at neutral pH can be achieved if the aniline catalyst used 
contains an ortho proton donor functional group (e.g. a carboxylic acid as seen in 
catalyst 113).152 Catalysts bearing an ortho proton donor are thought to alter the pKa 
of the aniline amino group, and facilitate the rate determining step at neutral pH 
(dehydration of the intermediate hemiaminal)201 through a cyclic transition state 
(Figure 5.5A).143 It is thought the most efficient catalysts for catalysed oxime 
ligations have a pKa value close to that of the solution pH 143; indeed, protonated 
aniline 46 and aldehyde-aniline imines have pKa values of 4.6 and 2.6 respectively, 
which are similar values to the optimal pH of 4.5 for aniline catalysed oxime 
ligations.121,202 Therefore, at higher pH values (i.e. pH 7.0) catalysts with ortho 
proton donors are theorised to be more active than catalysts without ortho proton 
donors due to the higher aniline amino pKa values. Secondly, it has previously been 
suggested that imine formation of glycine 114 with o-hydroxyaryl aldehydes,203 such 
as salicylaldehyde 115 and PLP 8, is stabilised in aqueous solution by intramolecular 
H-bonding between the iminium nitrogen and ortho phenoxide group (Figure 5.5B). 
Additionally, the presence of the ortho phenoxide groups causes a significant 
increase in the determined pKa of the aforementioned iminium ions. 203 Based on 
these observations, it is possible that the hydroxyl group of the β-hydroxy aldehyde 
handle acts as a pseudo ortho proton donor during imine formation, as outlined in 
Figure 5.5C, resulting in a higher-than-usual pKa value of the aldehyde-aniline 
iminium ion . This in turn would result in aniline-catalysed oxime ligations of the β-
hydroxy aldehyde displaying higher reactivity at higher pH values than expected. 
Alternatively (or additionally), the presence of a pseudo ortho proton donor may also 
facilitate the rate determining dehydration step at neutral pH. Therefore, improved 
142 
 
 
 
conjugation yields at the β-hydroxy aldehyde would occur at neutral pH compared to 
acidic pH due to these factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 A) Hypothesised effects of anilines bearing ortho proton donors on dehydration step of imine 
formation between an aldehyde and aniline catalyst. (B) Hypothesised pKa elevation of imine formed between an 
aromatic aldehyde bearing ortho proton donors and an aniline catalyst. (C) Hypothesised effects of contributions 
from the ortho hydroxyl of the β-hydroxy aldehyde on aniline catalysis. 
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5.1.4 Tandem mass spectrometry of dually modified peptide 
To ensure site-selective modification was occurring at the β-hydroxy aldehyde 
position, MS/MS of the anticipated dually modified species was performed. Figure 
5.6 shows the initial MS/MS analysis of dually modified 109. 
 
 
 
 
 
 
 
 
 
 
 
 
Although several peptide fragments corresponding to the anticipated dually modified 
109 were observed, the major peak observed from the initial MS/MS was found to be 
a peak at 635.1 Da. For dually modified 109, this fragment would likely occur from 
fragmentation of the C-C bond between the aldol-oxime segment and β-hydroxy 
segment of the peptide. As a result, further MS/MS analysis of the peak at 635.1 Da 
should give a fragmentation pattern that can be predicted based on this hypothesis. 
Figure 5.7 shows the MS/MS analysis of the peak at 651.3 Da. 
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Figure 5.6 (A) MS/MS data of dually modified peptide 109. 
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The fragmentation pattern obtained for the fragment corresponding to 635.1 Da were 
considered to be consistent with the successful synthesis of the aldol-oxime dually 
modified peptide 109 in a site-selective manner.  
5.1.5 Hydrolytic stability of dually modified peptides 
To investigate the hydrolytic stability of the OPAL-oxime products, dually modified 
β-hydroxy oxime peptide 109 was synthesised, purified, lyophilised, and incubated 
in either 0.2 M NaOAc pH 4.5 buffer or in 0.2 M PB pH 7.5 buffer at 37 oC. The 
stability of both the aldol and oxime bond of peptide 109 was monitored by LC-MS. 
Figure 5.8 shows the results of incubating peptide 109 after 1 day, 2 days, 4 days, 
and 30 days at either pH 4.5 or pH 7.5. 
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NB: A small peak at 740 Da is observed in all cases – see Chapter 7 for an 
explanation as to the identity of this peak and why it was present. 
At both pH 4.5 and pH 7.5, no hydrolysis of the aldol bond of the OPAL-oxime 
product to glyoxyl-LYRAG 27 was observed. Additionally, minimal hydrolysis of 
the dually modified peptide 109 to aldol-modified peptide 59 was observed at pH 
7.5. However, notable hydrolysis of the dually modified peptide 109 to aldol-
modified peptide 59 was observed at pH 4.5, with 3%, 10%, 15% and 80% 
conversion to aldol modified peptide 59 after 1 day, 2 days, 4 days, and 30 days of 
incubation at 37 oC. These results suggest that dually modified OPAL-oxime 
products show good hydrolytic stability in environments at neutral pH, but would 
undergo slow hydrolysis back to the OPAL product in acidic environments, whilst 
OPAL products i.e. 59 show excellent hydrolytic stability at both pH 4.5 and pH 7.5. 
5.1.6 Site-selective dual protein modification via an OPAL-oxime strategy 
Having established a pH dependence for the aniline-catalysed oxime ligation of β-
hydroxy aldehyde scaffolds, the synthesis of dually, site-selective modified protein 
bioconjugates via a tandem OPAL-oxime procedure was investigated. Using azide 
106 
Figure 5.8 Stability testing of dually modified peptide 106, and associated LC-MS data for periods of incubation 
at pH 4.5 or pH 7.5. Calculated [M+H]+ of 106 = 860.42 Da, calculated [M+H]+ of 59 = 755.36 Da. 
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labelled myoglobin (stored in 5 mM PB pH 7.5), conditions for aniline-catalysed 
oxime ligation between 100 µM azide labelled myoglobin 116 and commercially 
available aminooxy biotin 117 in 50 mM PB, pH 7.5, were screened, with varying 
concentrations of aniline catalysts, varying concentrations of aminooxy biotin, and 
varying reaction times. The conditions, along with the observed conversions (as 
judged by LC-MS) to the dually modified protein species 118 for each set of 
conditions, are shown in Table 5.1 
Table 5.1 Screening of conditions for aniline catalysed oxime ligation of azide labelled myoglobin 116 using 
aminooxy biotin 117. 
 
Figure 5.9A outlines the reaction described in Table 5.1 Entry 9, and Figure 5.9B 
shows the LC-MS data obtained for Entry 9 of Table 5.1. 
 
Entry Catalyst Catalyst 
loading (mM) 
Biotin 117 
(mM) 
Reaction 
time (h) 
Conversion 
to 118 (%) 
1 - - 15 18 0 
2 110 10 15 18 0 
3 110 100 15 18 Precipitates 
4 111 10 15 18 0 
5 111 100 15 18 Precipitates 
6 110 10 50 18 16 
7 111 10 50 18 0 
8 18 10 15 18 47 
9 18 10 15 42 65 
10 18 10 30 18 38 
11 18 20 15 18 50 
12 18 20 15 42 68 
13 18 20 30 18 38 
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NB: An unidentified peak at 17172 Da has been theorized to correspond to a 
protein-PLP by-product, as it has frequently been noted in samples of glyoxyl-
myoglobin 13 post transamination. This peak was not taken into consideration when 
calculating conversions to the dually modified protein species 118.  
Despite their compatibility with previously reported small molecule oxime ligations, 
along with oxime ligations of aldol-modified peptides 56 and 59, catalysts 110 and 
111 showed poor activity in the ligation between azide labelled myoglobin 116 and 
aminooxy biotin 117. Greater catalytic activity was observed when using p-anisidine 
18, with a maximum of 65% and 68% conversion to the desired dually modified 
protein obtained when using a 10 mM and 20 mM catalyst loading respectively. 
Doubling the loading of catalyst 18 had minimal effect on the obtained conjugation 
yields whereas, surprisingly, conjugation yields dropped when increasing the 
concentration of aminooxy biotin 117. A current working hypothesis for this 
observation is that the increased concentration of aminooxy biotin influences the pH 
of the reaction medium (as stock solutions of aminooxy biotin 117 are initially 
acidic, and must be neutralised with NaOH), resulting in a more acidic solution, and 
thus leading to a slower rate of oxime ligation. 
The conditions in Table 5.1, Entry 12 were then used for the site-selective 
modification of fluorescently labelled thioredoxin 89 with aminooxy biotin 117, 
using p-anisidine 18 as a catalyst (Figure 5.10A). A 75% conversion to fluorescent, 
biotinylated thioredoxin was observed after 42 h of incubation in 50 mM PB, pH 7.5, 
at 37 oC as judged by LC-MS analysis (Figure 5.10B). 
Figure 5.9 (A) Outline of reaction between azide labelled myoglobin 116 and aminooxy biotin 117 using p-
anisidine 18 as a catalyst. Masses quoted = calculated masses. (B) LC-MS data obtained for the reaction of 100 
µM azide labelled myoglobin 116 and 15 mM aminooxy biotin 117 using 10 mM p-anisidine in 50 mM PB pH 
7.5, 10 % DMSO, for 42 h at 37 oC. 
116 
117 
117 
18 
118 
118 
116 
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5.2 SDS-PAGE and Western Blot analysis of dually modified protein constructs 
Alongside mass spectrometry, protein bioconjugates can be further characterised 
using other analytical techniques depending on the groups attached during the 
ligation procedure as discussed in Section 1. Samples of azide labelled, biotinylated 
thioredoxin 120 were therefore subjected to SDS-PAGE analysis and Western Blot 
analysis (Antibiotin-alkaline phosphatase antibody detection) to detect for successful 
biotinylation, along with thioredoxin 31, glyoxyl-thioredoxin 32, and azide labelled 
thioredoxin 90 as controls, as shown in Figure 5.11 
 
 
 
 
 
 
 
Coomassie staining of thioredoxin 30, glyoxyl-thioredoxin 31, azide labelled 
thioredoxin 90, and azide labelled, biotinylated thioredoxin 120 confirm the presence 
Figure 5.10 (A) Outline of reaction between fluorescent thioredoxin 89 and aminooxy biotin 117 using p-
anisidine 18 as a catalyst. Mass quoted = calculated masses. (B) LC-MS data obtained for the reaction of 100 µM 
fluorescent thioredoxin 89 and 15 mM aminooxy biotin 117 using 10 mM p-anisidine 18 in 50 mM PB pH 7.5, 
10 % DMSO, for 42 h at 37 oC. 
89 
18 
117 
119 
119 
89 
Figure 5.11 SDS-PAGE analysis (left) and Western Blot analysis (right, antibiotin alkaline phosphatase 
antibody detection) of thioredoxin 30, glyoxyl-thioredoxin 31, azide labelled thioredoxin 90, and azide 
labelled, biotinylated thioredoxin 120. L = Ladder (molecular weight marker). 
30 31 90 120 
30 31 90 120 30 31 90 120 L L 
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of each protein respectively. As anticipated, only biotinylated protein 120 was 
detected in the Western Blot experiment 
To further demonstrate the ability to dually, site-selectively modify proteins via an 
OPAL-oxime procedure, fluorescent, biotinylated thioredoxin 119 was also 
subjected to SDS-PAGE analysis and Western Blot analysis, along with fluorescent 
visualisation. Thioredoxin 30, glyoxyl-thioredoxin 31, and fluorescently labelled 
thioredoxin 89 were also used and analysed as control samples. (Figure 5.12). 
 
 
 
 
 
 
 
Coomassie staining of thioredoxin 30, glyoxyl-thioredoxin 31, fluorescently labelled 
thioredoxin 89, and fluorescently labelled, biotinylated thioredoxin 119 confirm the 
presence of each protein respectively. As anticipated, only fluorescent proteins 89 
and 119 were detected in the fluorescent imaging experiment, and only biotinylated 
protein 119 was detected in the Western Blot experiment (detecting for biotin). 
To further demonstrate the versatility of dual, site-selective protein bioconjugation 
via an OPAL-oxime strategy, aminooxy PEG 2kDa 121, was synthesised as 
previously described 204 and used to site-selectively modify fluorescently labelled 
myoglobin 93. The dually labelled protein 122 was subsequently analysed using 
SDS-PAGE analysis and fluorescent visualisation, along with myoglobin 28, 
glyoxyl-myoglobin 13, fluorescently labelled myoglobin 93, and mono-PEGylated 
myoglobin 123 as controls. (Figure 5.13). 
 
 
30 31 89 119 L 30 31 89 119 L 30 31 89 119 L 
30 31 89 119 
Figure 5.12 SDS-PAGE analysis (left) and Western Blot analysis (right, antibiotin alkaline phosphatase antibody 
detection) of thioredoxin 30, glyoxyl-thioredoxin 31, fluorescent thioredoxin 89, and fluorescent, biotinylated 
thioredoxin 119. L = Ladder (molecular weight marker). 
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Coomassie staining of myoglobin 28, glyoxyl-myoglobin 13, mono-PEGylated 
myoglobin 123 (which also contains unreacted glyoxyl-myoglobin 13), fluorescently 
labelled myoglobin 93, and fluorescently labelled, PEGylated myoglobin 122 (which 
also contains unreacted fluorescently labelled 93) confirm the presence of each 
protein respectively. As anticipated, only samples containing fluorescently labelled 
proteins 93 and 122 were detected in the fluorescent imaging experiment. For protein 
samples treated with aminooxy PEG 2k 121 two protein bands were observed, with 
the upper band corresponding to a single addition of the polymer unit to the protein. 
The results obtained for this experiment were consistent with samples containing 
both unmodified protein (13 or 93) and PEGylated protein (123 or 122 respectively). 
It was notable, in this set of experiments, that the lower of the two protein bands in 
samples treated with aminooxy PEG 2k 121 runs slightly lower than expected 
compared to samples containing unmodified protein that have not been treated with 
aminooxy PEG 121. To investigate this phenomenon, three samples of myoglobin 
28, glyoxyl myoglobin 13, and fluorescently labelled myoglobin 93 were treated 
28 13 13 + 123 L 93 
28 13 
93 
121 
123 122 
93 + 122 28 13 13 + 123 L 93 93 + 122 
Figure 5.13 SDS-PAGE analysis (left) and fluorescent imaging (right) of myoglobin 28, glyoxyl-myoglobin 13, 
PEGylated myoglobin 123 (upper band in Lane 4, lower band = 13) fluorescent myoglobin 93, and fluorescent, 
PEGylated myoglobin 122 (upper band, lower band = 93). L = Ladder (molecular weight marker). 
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with aminooxy PEG 2k 121 , allowed to sit at 37 oC for 3 h, and then analysed by 
SDS PAGE analysis as shown in Figure 5.14. These samples were also observed at a 
slightly lower molecular weight than expected, suggesting this phenomenon was an 
artefact of SDS-PAGE analysis when analysing samples containing both protein and 
aminooxy PEG 2kDa 121 (Figure 5.14). 
 
 
 
 
 
 
 
 
 
5.3 Future work 
Although notable site-selective modification of OPAL products can be achieved 
through aniline-catalysed oxime ligation at neutral pH, the reaction does not go to 
completion, requires long reaction times, and requires a large excess of aminooxy 
reagent. This is likely because of three reasons: 1) Oxime ligations are sluggish by 
nature. 2) the β-hydroxy aldehyde handle suffers notable steric hindrance from the 
functionality attached from previous the OPAL procedure, and 3) the β-hydroxy 
aldehyde is less reactive in comparison previously described aldehyde handles (such 
as α-oxo aldehydes). For a more efficient dual, site-selective protein bioconjugation 
strategy, it may be beneficial to investigate a different reaction for the second step. A 
good candidate for the second step of the tandem bioconjugation strategy would be 
the SPANC; this ligation procedure mechanistically follows the same initial pathway 
as aniline-catalysed oxime ligation, but offers vastly superior ligation kinetics, and is 
regularly performed at neutral pH. Alternatively, designing a ligation procedure 
28 13 13 + 123 L 93 93 + 122 A B C 
Figure 5.14 Coomassie stained SDS-PAGE analysis of myoglobin constructs, and associated 
myoglobin-PEG related controls. A = 28 treated with 121 for 3h. B = 13 treated with 121 for 3h. C = 93 
treated with 121 for 3h. 
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which displays significant selectively/reactivity with β-hydroxy aldehyde handles 
over other aldehyde handles could potentially lead to a highly efficient tandem 
bioconjugation strategy. Further exploration of aniline catalysts within the context of 
oxime ligation of β-hydroxy aldehydes may prove fruitful in optimisation of an 
OPAL-oxime strategy for dual, site-selective biconjugation. Finally, the observed 
stability of the oxime bond of the β-hydroxy oxime products warrants further 
investigation. This stability at pH 7.5 and slow hydrolysis at pH 4.5 of the oxime 
bond may be of use in applications where conjugates remain stable at neutral pH but 
release bound cargo at acidic pH, such as ADC design.  
 
5.4 Conclusion 
In conclusion, it has been demonstrated that dually, site-selective modified protein 
bioconjugates can be synthesised at neutral pH via a tandem OPAL-oxime 
procedure. This was achieved by first using the OPAL to site-selectively modify α-
oxo aldehyde containing proteins, and then site-selectively modifying the resulting 
β-hydroxy aldehyde handle via aniline-catalysed oxime ligation. Remarkably, 
aniline-catalysed oxime ligation of β-hydroxy-aldehyde handles was found to 
proceed more readily at neutral pH in comparison to acidic pH, in a direct reversal of 
pH dependence previously reported for aniline-catalysed oxime ligation of aldehyde 
handles. Aminooxy reagents bearing functional moieties including therapeutically 
relevant PEG, and affinity handles, were found to be compatible with site-selective 
modification of a number of OPAL bioconjugate scaffolds. Bi-functionalisation of 
protein bioconjugates was confirmed by LC-MS analysis, along with characterisation 
by SDS-PAGE/fluorescent visualisation/Western Blot analysis where appropriate. 
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Chapter 6: Post translational modification mimics of myristoylated 
and palmitoylated proteins 
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6.1 Myristoylation and palmitoylation of HASPs 
Following the sequencing of the human genome,205,206 it was discovered that an 
estimated 20,000-25,000 protein-encoding genes are present in the human genome. 
However, it is thought the number of proteins present in human proteome is 
significantly higher. A major contributing factor to this increase in complexity from 
genome to proteome is thought to be the PTM of proteins, which (depending on the 
PTM) are responsible for roles such as protein localisation, biomolecule interactions, 
and activity regulation. One of the greatest challenges faced in studying the role of 
specific PTMs is obtaining protein samples bearing the desired PTMs in sufficient 
purity and in large quantities. For conventional molecular biology, the recombinant 
production of proteins bearing specific PTMs, such as complex glycans, typically 
requires eukaryotic cell strains such as yeast or mammalian (prokaryotic cell strains 
lack the organelles to perform these kinds of PTMs). Eukaryotic cells are much more 
challenging to culture than prokaryotic cells, and (depending on the PTM) can lead 
to heterogeneous mixtures of proteins bearing different PTMs at multiple sites, 
making the study of one particular PTM at a designated site on a given protein 
immensely challenging. 
Due to significant advances in synthetic biology and protein bioconjugation over the 
last two decades, it is now possible to site-selectively install chemical functionalities 
at a particular protein site, generating homogenously modified protein constructs.15,19 
Alongside chemical probes such as drugs, fluorescent moieties and affinity tags, 
protein bioconjugation can also be used to design chemical ‘mimics’ of proteins 
bearing specific PTMs. This is typically achieved through recombinant expression of 
the desired protein in a prokaryotic cell strain system, followed by site-selective 
modification to install the chemical PTM mimic of interest at the site where the 
natural PTM would occur. This methodology offers significant advantages in the 
production of proteins bearing PTMs over conventional molecular biology 
methodology; recombinant expression is usually less time consuming and higher 
yielding when using prokaryotic cell strains as opposed to eukaryotic cell stains, and 
the heterogeneity associated with type of PTM/PTM location can be avoided through 
the use of site-selective bioconjugation chemistry. Chemical installation of PTM 
mimics through protein bioconjugation has been primarily investigated within the 
context of sulfur chemistry.30 In particular, dehydroalanine has been utilised in the 
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synthesis of a vast array of PTM protein mimics, including lysine/arginine 
methylation, glycosylation, and phosphorylation.17,18,32 Aldehyde handles have also 
been exploited in the synthesis of chemical mimics of N-glycans on antibodies, 16 
and methylated lysine mimics on histones. 114 
As discussed in Chapter 5, proteins can exhibit multiple PTMs at once, and would 
require protein bioconjugation strategies that allow for dual/multifunctionalisation to 
enable their chemical synthesis. It was therefore envisioned that an OPAL-oxime 
strategy could be used for designing proteins bearing two PTMs. However, given the 
close proximity of the OPAL and oxime modification, the OPAL-oxime strategy 
would likely only be suitable for designing chemical PTM mimics where the two 
PTMs were naturally close in space. Bearing this in mind, attention was turned 
towards applying the OPAL-oxime strategy for mimicking dual acylation of 
hydrophilic acylated surface proteins (HASPs). As discussed in Section 2.1.6, 
HASPs such as HASPA 35 are highly immunogenic proteins present in all human 
infective Leishmania parasites that are expressed during the infective stages of the 
parasite. They are enzymatically dually lipidated at the N-terminal region, which is 
thought to facilitate their binding to plasma membranes.175 The N-myristoylation of 
HASPA can be achieved in vitro to give N-myristoylated HASPA 124, as the NMT 
required is known, allowing for generation of mono-acylated HASPA species.207 
However, the S-palmitoyltransferase required for the second acylation of HASPs, 
generating dually acylated HASPA 125, is currently unknown, meaning that in vitro 
dual acylation of HASPA, and obtaining dually acylated HASPA 125 species for 
further study is not possible. Given the close proximity of these two modifications, it 
was hypothesised that an OPAL-oxime strategy using a suitable C14 probe 126 to 
generate a chemically “myristoylated” species 127, and a suitable C16 probe 128 to 
generate a chemically, dually lipidated HASPA mimic 129 could be achieved, and 
therefore help facilitate the study of post-translationally modified HASPA (Figure 
6.1). 
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35 36 
124 
126 
127 
128 
129 
125 
Figure 6.1 Enymatic and chemical post-translational modification of HASPA 35. The left hand side shows the 
enzymatic route for the N-myristoylation of HASPA 35 (catalysed by a known NMT), followed by S-
palmitoylation of N-myristoylated HASPA 124 (catalysed by a currently unknown S-palmitoyltransferase). The 
right hand side shows the proposed chemical route constructing lipidated mimics of HASPA 35, starting with 
aldehyde installation to generate glyoxyl-HAPA 36, followed by OPAL with donor 126 to generate the 
chemically myristoylated HASPA 127 mimic, followed by oxime ligation with aminooxy 128 to generate 
dually lipidated HASPA 129 mimic. 
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6.1.1 Validation of chemical myristoylation 
To begin with, the OPAL modification with the C14 aldehyde myristyaldehyde 126 
to generate mono lipidated HASPA mimics was investigated. Unlike previously 
described aldehyde donors, myristaldehyde 126 was found to very insoluble in water 
or buffered solutions; this was undoubtedly due to the hydrophobic nature of the C14 
chain. Therefore, the solubility of myristaldehyde 126 in MeCN, t-BuOH, and 
DMSO, was investigated; these three solvents have previously been successfully 
employed as co-solvents for other protein aldehyde bioconjugation strategies 
reported in the literature.128,130,133 At a final concentration of 25 mM, myristaldehyde 
proved to be insoluble in both a 1:1 H2O:MeCN solvent system, and a 1:1 H2O:t-
BuOH solvent system, but was found to be soluble in a 1:1 H2O:DMSO. DMSO was 
therefore used as the co-solvent of choice of subsequent chemical myristoylation 
experiments. To confirm whether a chemical myristoylation strategy via the OPAL 
could be achieved, the aldol reaction between glyoxyl-LYRAG 27 and 
myristaldehyde 126, using L-proline 61 as a catalyst, performed in 25 mM PB, pH 
7.5, for 24h at 37 oC, was investigated. DMSO was used both to prepare 
myristaldehyde 126 stock solutions, and as a co-solvent for the reaction. Three 
chemical myristoylation reactions of glyoxyl-LYRAG 27 to give chemically 
myristoylated peptide 130 were performed, with differing amounts of DMSO content 
used in each experiment (Figure 6.2) 
 
 
 
 
 
 
 
 
 
Figure 6.2 (A) Chemical myristoylation of glyoxyl-LYRAG 27 using myristaldehyde 126 and L-proline 61 as a 
catalyst in solvent systems containing different amounts of DMSO. (B) Results for the chemical myristoylation 
of glyoxyl-LYRAG 27 in solvent systems with different DMSO content. Calculated [M+H]+ of 130 = 847.52 Da 
27 126 
61 
130 
130 
130 27-Hyd 
27-Hyd 
27-Hyd 
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Successful chemical myristoylation of glyoxyl-LYRAG 27 was confirmed by LC-
MS and MS/MS analysis with a 14% conversion to 130 observed when performing 
the reaction in 10% DMSO, and a 42% conversion to 130 observed when performing 
the reaction in 25% DMSO. For the reaction performed in 25% DMSO, a very small 
amount of doubly lipidated peptide was observed at 1059.96 Da was observed 
(<2%), and an unknown peak at 1099.84 Da was also observed. No conversion to the 
desired chemical myristoylated peptide 130 was observed when performing the 
reaction in 5% DMSO. The results from the chemical myristoylation of glyoxyl-
LYRAG 27 suggested that the DMSO content of the reaction was a limiting factor in 
the rate of the ligation. This will undoubtedly be related to the insolubility of the 
myristaldehyde 126 reagent; the higher the DMSO content of the reaction, the higher 
concentration of myristaldehyde 126 reagent in solution available for reaction with 
the glyoxyl-LYRAG peptide 27. 
 
6.1.2 Chemical myristoylation of HASPA 
The chemical myristoylation procedure was next extended towards the modification 
of HASPA. Conditions for chemical myristoylation of HASPA were first screened 
using glyoxyl-HASPA generated from HASPA bearing an N-terminal glycine as 
outlined in Table 6.1. 
NB: In all cases of chemical lipidation of HASPA, peaks at M -18 were noted in the 
LC-MS experiments, which likely corresponds to the aldol condensation product 
with a loss of H2O. This was only found for chemical lipidation via the OPAL and 
was not noted in any other OPAL modifications with probes 85-88. It was 
hypothesised that this dehydration was related to the hydrophobicity of the attached 
lipid chain, which is in close proximity to the β-hydroxy group. 
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Table 6.1 Outline of conditions screened for the chemical myristoylation of glyoxyl-HASPA 36 (generated from 
PLP 8 transamination of HASPA 35). * Conversion calculation based on 35, 36-Hyd, anticipated PLP by 
product, and 127 peak intensity. ** Incomprehensible data obtained. 
Entry Protein 36 
(µM) 
Myristaldehyde 
126 (mM) 
% 
DMSO 
Conversion to 
127 (%) 
1 120 25 50 15* 
2 120 5 65 50* 
3 120 15 65 63* 
4 120 25 65 63* 
5 120 15 90 N/A** 
6 120 25 90 N/A** 
7 30 15 70 N/A** 
8 60 15 70 N/A** 
9 240 15 70 53%* 
10 480 15 70 71%* 
Figure 6.3A outlines the reaction described in Table 6.1, Entry 10, and Figure 6.3B 
shows the LC-MS data obtained for Entry 10 of Table 6.1. 
 
 
 
 
 
 
Conditions for successful chemical myristoylation as outlined in Entry 10 of Table 
6.1 were then applied towards chemical myristoylation of glyoxyl-HASPA 61 
generated from HASPA(G1S) 37 bearing an N-terminal serine. This was also applied 
to 15N labelled glyoxyl-HASPA 36-15N (Figure 6.4). Full conversion to the desired 
Figure 6.3 (A) Chemical myristoylation of glyoxyl-HASPA 36 (generated from PLP 8 transamination of 
HASPA 35). (B) LC-MS data obtained for Table 6.1, Entry 10. Peak at 9491 Da was anticipated to be a PLP-
related by-product. Calculated mass of 127 = 9657 Da 
36 
61 
126 
127 
127 
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chemically myristoylated HASPA 127 and 127-15N was achieved as judged by LC-
MS. 
 
 
 
 
 
 
 
 
 
 
 
 
6.1.3 Isolation of chemically myristoylated protein 
In order to carry out downstream applications of the chemically myristoylated 
HASPA (e.g. modification of the β-hydroxy aldehyde, protein NMR), removal of the 
excess myristaldehyde 126 and high DMSO content post reaction was first required. 
To achieve this, multiple 60 µL chemical myristoylation reactions were pooled to 
give an estimated protein content of 640 µg (based on initial concentration of the 
unmodified HASPA(G1S) 37 stock). The pooled reactions were then diluted with 
water to give solutions <20% DMSO. This solution was then desalted using multiple 
PD Minitrap G-25 columns (GE Healthcare), and the desalted protein was 
lyophilised to give the chemically myristoylated HASPA 127 as a white powder. The 
protein could then be stored at -80 oC until required for downstream use. Typically, a 
Figure 6.4 (A) Chemical myristoylation of glyoxyl-HASPA 36 (generated from NaIO4 oxidation of 37) with 
myristaldehyde 126 using L-proline 61 as an organocatalyst. (B) Chemical myristoylation of glyoxyl-HASPA 36-
15N (generated from NaIO4 oxidation of 37-15N) with myristaldehyde 126 using L-proline 61 as an 
organocatalyst. (C) LC-MS data obtained for (A). Calculated mass of 127 = 9657 Da. (D) LC-MS data obtained 
for (B). Calculated mass of 127-15N = 9787 Da. 
36 
61 
127 
36-15N 
61 
127-15N 
126 
126 
127-15N 
127 
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25% protein recovery (determined by SDS-PAGE analysis,viii based on initial 
concentration of the unmodified HASPA(G1S) 37 stock) was obtained when 
following this procedure. 
6.1.4 NMR characterisation of chemically myristoylated HASPA 
 NMR spectroscopy was used to characterise the chemically myristoylated HASPA 
125, and to assess the similarity of its structural and solution based properties to that 
of enzymatically N-myristoylated HASPA 122 (the characterisation of which has 
been previously reported).207 Following NMR characterisation of chemically 
myristoylated HASPA 125, heteronuclear single quantum coherence (HSQC) spectra 
revealed the chemical mimic 125 to be highly similar to that of the enzymatically N-
myristoylated HASPA 122. These data demonstrated that chemical myristoylation of 
HASPA effectively mimics that of enzymatically N-myristoylated HASPA.ix 
NB: For a detailed discussion on protein NMR of HASPs, readers are directed to 
reference 207. 
 
 
 
 
 
 
 
 
 
 
                                                          
viii Information on the protein concentration determined was kindly provided by Dr Tessa Keenan. 
ix N-myristoylated HASPA 124 was provided by Dr Sophie McKenna. The HASPA NMR experiment and 
characterisation/processing was performed by Dr Michael Plevin (see Reference 2 for details). 
Figure 6.5 Regions of 2D (1H, 15N) HSQC NMR spectra of [15N]labelled HASPA. Comparison of 
unmodified 35 (grey) and enzymatically myristoylated (red) HASPA 124 (left). Comparison of unmodified 
37 (grey) and chemically myristoylated (red) HASPA 127 (right). (1H,15N) Resonance assignments are 
indicated. Unassigned peaks are denoted by asterisks. 
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6.2 Dual chemical lipidation of HASPA 
With a procedure in place for the chemical myristoylation of HASPA, further 
modification of the chemically myristoylated HASPA 127 with a second alkyl chain 
via the β-hydroxy aldehyde handle was investigated. First, a suitable C16 aminooxy 
reagent 128 was synthesised for use in the oxime ligation (see Experimental). 
Palmitoyl aminooxy 128 was then prepared as a 25 mM stock solution in DMSO for 
use in the modification of chemically myristoylated HASPA 127-15N samples. 
Reactions of the isolated samples were performed in 100 mM PB, pH 6.5, 70% 
DMSO at 37 oC, using 100 mM aniline 46 as a catalyst (Figure 6.6A). Conversions 
after 48 h and 96 h of reaction time were judged by LC-MS analysis (Figure 6.6B). 
 
 
 
 
 
 
 
 
 
 
Despite using long reaction times and high concentrations of palmitoyl aminooxy 
128, poor conversions to the desired dually modified HASPA were obtained, with a 
maximum conversion of 30% obtained after 4 days. During the reaction, notable 
precipitation had occurred, which was hypothesised to be the reason for the low 
conversion observed. This precipitation was established to be due to the palmitoyl 
aminooxy 128 reagent; control experiments of incubating 128 in 100 mM PB, pH 
Figure 6.6 (A) Oxime ligation of chemically myristoylated HASPA 127-15N with palmitoyl aminooxy 128 using 
aniline 46 as a catalyst in a PB/DMSO solvent system. (B) LC-MS data obtained for (A) after 48 h (left) and 96 h 
(right). Calculated mass of 129 = 9787 Da. Calculated mass of 129-15N = 10026 Da. 
127-15N 
46 
129-15N 
128 
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6.5, 70% DMSO at 37 oC with 100 mM aniline 46 led to precipitation after 18 h. 
Therefore, to avoid precipitation issues and low conversions to the dually modified 
protein, EtOH was next investigated as a co-solvent for the second alkylation step of 
HASPA. EtOH is miscible with water, and has previously been used as a solvent for 
reactions involving palmitoyl aminooxy 128. 208 Initially, reactions of chemically 
myristoylated HASPA with palmitoyl aminooxy 128 were set up in 100 mM PB pH 
6.5, 70% EtOH at 37 oC with 100 mM of aniline;333 these conditions however led to 
immediate precipitation of phosphate salts. Reducing the concentration of PB from 
100 mM to 25 mM circumvented this issue, and reactions of chemically 
myristoylated HASPA with palmitoyl aminooxy 128 were performed up in 25 mM 
PB pH 6.5, 70% EtOH at 37 oC using 100 mM aniline as a catalyst (Figure 6.7A). 
Conversions after 48 h and 96 h of reaction time under these conditions were judged 
by LC-MS analysis (Figure 6.7B). 
 
 
 
 
 
 
 
 
 
 
 
As shown in Figure 6.7, significantly higher conversions to dually modified HASPA 
were obtained when using EtOH as a co-solvent compared to using DMSO, with a 
maximum of 75% conversion obtained after 4 days of incubation. 
127-15N 
46 
129-15N 
128 
Figure 6.7 (A) Oxime ligation of chemically myristoylated HASPA 127-15N with palmitoyl aminooxy 
128 using aniline 46 as a catalyst in a PB/EtOH solvent system. (B) LC-MS data obtained for (A) after 48 
h (left) and 96 h (right). Calculated mass of 129 = 9787 Da. Calculated mass of 129-15N = 10026 Da. 
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6.2.1 Liposome binding of chemically lipidated HASPA 
As discussed earlier, the HASP lipidation is postulated to facilitate binding to the 
plasma membrane. To investigate this, liposome sedimentation assays of chemical 
myristoylated HASPA 127 and dually lipidated HASPA 129 (along with unmodified 
HASPA(G1S) 37 (as a control) were performed to assess the proteins ability to bind 
to membranes. x SDS PAGE analysis (Figure 6.8) revealed no liposome binding by 
HASPA(G1S) 37 throughout a 30 h time period, whereas liposome binding was 
observed with lipidated HASPA 127 and 129 (see lanes P in Figure 6.8). The results 
of this in vitro system suggest that the addition of a lipid chains to HASPs facilitate 
binding of the protein to membranes, supporting the hypothesis that these PTMS 
assist trafficking of HASPSs to the plasma membrane in vivo.175 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
x The liposome preparation, binding assays, and characterisation were performed by Dr Tessa 
Keenan (see Reference 2 for details). 
Figure 6.8 SDS-PAGE analysis of liposome sedimentation assay of unmodified HASPA 37, chemically 
myristoylated HASPA 127 and dually lipidated HASPA 129. The supernantant (S) and resuspended liposome 
pellet (P) were analysed. (M = Molecular weight marker, ladder). 
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6.3 Future work 
Through aldehyde installation and subsequent OPAL, chemical mimics of N-
myristoylated HASPA have been described. This “chemical myristoylation” 
procedure offers certain benefits over that of the natural, enzymatic procedure of N-
myristoylation. First, chemical myristoylation does not require NMT, avoiding both 
the requirement of expressing/purifying recombinant NMT and the necessity of 
removing the enzyme post N-myristoylation of HASPA. Secondly, chemical 
myristoylation utilises myristaldehyde 126 as the source of the myristyl group. At 
the time of writing, myristaldehyde 126 is significantly more commercially available 
compared to that of myristoyl coA used in the enzymatic N-myristoylation 
procedure, making chemical myristoylation more attractive of the two procedures 
from a scaling and costing perspective. Finally, chemical myristoylation lends itself 
to lipidation of other protein targets. Enzymatic N-myristoylation is limited to certain 
proteins due to substrate specificity of NMT. Alongside the absolute requirement of 
an N-terminal glycine, as many as 17 N-terminal residues can be involved in 
determining whether or not a protein (or peptide) will undergo N-myristoylation.176 
This selectivity is understandably important in nature to avoid offsite N-
myristoylation of other intracellular proteins; from a bioconjugation perspective 
however, it limits NMTs applicability towards myristoylation of other protein 
targets. The only requirement for chemical myristoylation is a glyoxyl handle, which 
can be installed both at the N-terminus and at internal positions of protein, 
suggesting this procedure could be applied to protein targets which do not/cannot 
undergo conventional myristoylation. 
 
The chemical myristoylation procedure described in this chapter for the chemical 
myristoylation of HASPA does, however, have notable drawbacks. The 
myristaldehyde 126 substrate is an alkyl donor, requiring high concentrations of 
donor similar to that of butanal 51. As a result, an exceptionally large percentage of 
DMSO co-solvent was required to solubilise donor 126, which in turn was also 
required to obtain full conversion to the chemically myristoylated HASPA 127. 
Employing α-aryl aldehyde based myristyl donors would likely reduce the required 
donor concentration. Alternatively, different organocatalysts, such as L-proline 61 
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derivatives bearing long alkyl chains, may prove more compatible with the chemical 
myristoylation procedure. Different buffer composition may also lead to an 
improved chemical myristoylation procedure. 
With respect to isolation of the chemically myristoylated HASPA, although the 
procedure described in this chapter does allow for purification/isolation of 
chemically myristoylated HASPA, the process of diluting samples to >20% DMSO, 
purification by multiple PD MiniTrap G-25 columns (GE Healthcare), and 
lyophilisation to obtain the protein for downstream applications is time consuming 
costly in terms of resources, and leads to poor protein recovery. The isolation step of 
the chemical myristoylation process in particular would benefit from significant 
optimisation (although part of this would be reliant on optimisation of the reaction 
conditions). Since the HASPA bears a histidine tag, nickel affinity chromatography 
would likely be a good candidate for purifying the chemically myristoylated proteins 
species. Alternatively, a more standard method of dialysis may also be applicable 
towards isolation of chemically myristoylated HASPA 127. 
The β-hydroxy aldehyde handle of the chemically myristoylated HASPA 127 proved 
to be compatible with aniline-catalysed oxime ligation for the addition of a second 
long alkyl chain, using 100 mM aniline 46 as the catalyst and palmitoyl aminooxy 
128 as the aminooxy reagent. Similarly to other dual bioconjugations described in 
Chapter 5, aniline-catalysed oxime ligation of chemically myristoylated HASPA 
suffers from slow ligation kinetics, and requires high concentrations to obtain >70% 
conversions to the dually alkylated HASPA. The palmitoyl aminooxy reagent 128 
also proved to be a challenging substrate to work with requiring a high percentage of 
EtOH co-solvent to solubilse 128. Different buffer compositions, or using the 
SPANC ligation (which has previously been utilised for labelling glyoxyl-peptides 
with C16 chains) 146 may potentially lead to a more efficient procedure for 
conjugation of the second alkyl chain to chemically myristoylated HASPA 126. 
Alternatively, dually modified HASPA species could be generated by first installing 
the ThzK unnatural amino acid at position 4 of HASPA(G1S) 37 (the site that 
undergoes S-palmitoylation in nature), subjecting the protein to Pd-mediated 
decaging and subsequent periodate oxidation to reveal α-oxo aldehyde handles at 
both position 1 and 4 of HASPA, followed by OPAL using L-proline 61 and 
myristaldehyde 126 to simultaneously install two long alkyl chains into HASPA. 
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This procedure is arguably more attractive than the current procedure of installing 
the second chain at the β-hydroxy aldehyde position, as it would be a one pot 
procedure, and would avoid the necessity of using both the less reactive β-hydroxy 
aldehyde group and the highly insoluble palmitoyl aminooxy reagent 128. 
6.4 Conclusions 
To conclude, a strategy for the chemical myristoylation and dual lipidation of 
HASPA has been described. Following installation of glyoxyl functionality, HASPA 
could be “chemically myristoylated” in vitro via the OPAL using L-proline 61 as the 
organocatalyst and myristaldehyde 126 as the donor to give the N-myristoylated 
HASPA mimic 127. This chemically myristoylated mimic 127 displayed near 
identical structural and solution properties to that of enzymatically myristoylated 
HASPA 124 as determined by NMR spectroscopy. Chemically myristoylated 
HASPA 127 could then be further modified via the β-hydroxy aldehyde handle using 
palmitoyl aminooxy 128 to synthesise a HASPA bearing two long chain alkyl 
groups. Finally, both mono and dually chemically lipidated HASPA were found to 
show improved binding to liposomes in comparison to unmodified HASPA 37, 
reaffirming the hypothesis of HASP lipidation facilitating membrane binding. 
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Chapter 7: Beyond the OPAL and closing remarks 
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7.1 Discovery of a retro-aldol mediated breakdown of OPAL products 
The OPAL procedure synthesises a hydrolytically stable C-C bond between protein 
and conjugate, which is a major advantage over other protein bioconjugation 
strategies, such as hydrazone/oxime ligation for example which are prone to 
hydrolysis.140 For certain applications, however, controlled hydrolysis/release of the 
covalently attached moiety is desirable; this is highly apparent in ADCs, which are 
required to release their payload upon arrival at the targeted site. Traditional methods 
of bioconjugate cleavage include the use of hydrazones (hydrolysed over time under 
acidic conditions)209 and disulfides (cleaved by high intracellular levels of thiols 
such as glutathione).210 However, these methods require the use of labile linkers, 
which can lead to uncontrolled/off site release of conjugate in vivo (as seen in the 
ADC Mylotarg, which uses a hydrazone linker).211 Alternative strategies focus on 
incorporating a peptide linker into the chemical probe which can undergo in vivo 
enzymatic cleavage as seen in cathepsin cleavable linkers, providing a more stable 
alternative linker. 212 
In the context of the aldol reaction, the C-C bond cleavage of the β-hydroxy carbonyl 
product to generate two carbonyl species (i.e. the reverse of the aldol reaction) is 
known as the retro-aldol reaction. The primary focus of retro-aldol research has been 
in the study of aldolase enzymes. In nature, aldolases can catalyse both the forward 
and retro-aldol processes, feature in several biologically important pathways such as 
sugar metabolism, 213 and are classified into two different categories based on their 
mechanism of action; Class I aldolases utilise an enamine based mechanism which is 
thought to involve a catalytically active lysine residue, whereas Class II aldolases 
operate via a metal-mediated process utilising a transition metal such as Zn2+. In 
organic synthesis, natural and engineered aldolases have been used as catalysts to 
promote both C-C bond forming aldol reactions and C-C bond breaking retro-aldol 
reactions.214,215 In particular, the retro-aldol C-C bond cleavage of methodol has seen 
much interest within the context of computationally designing and engineering 
protein biocatalysts. 215-217 Small molecule induced retro-aldol reactions for metal-
mediated C-C activation has also been described in the literature.218,219 
As discussed earlier, the protein bioconjugates synthesised via the OPAL are 
hydrolytically stable and do not breakdown. It was envisaged, however, that it might 
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be possible to induce retro-aldol breakdown of the OPAL products by some other 
means, such as treating the bioconjugate with a small molecule catalyst. Bearing this 
in mind, attention was drawn towards the aniline-catalysed oxime ligations 
performed on aldol-modified peptides (Figure 7.1A). As discussed in Chapter 5, in 
some cases a small peak at 740 Da, which was hypothesised to correspond to a 
singly modified oxime-LYRAG species 137 was identified in these samples. This 
was initially thought to occur from using stock samples of aldol-modified peptide 
that contained small amounts of unreacted glyoxyl-LYRAG 27. However, the peak 
intensity of oxime peptide 137 was noted to be different in each sample depending 
on the catalyst and pH used; in particular, a significant peak corresponding to oxime 
peptide 137 was noted in the LC-MS analysis of the aniline-catalysed oxime ligation 
of aldol modified peptide 59 at pH 7.5 using catalyst 18, whereas no such species 
was present when using catalyst 110 (Figure 7.1B). This suggests that, during the 
dual modification, breakdown of the aldol-modified peptides back to glyoxyl-
LYRAG 27, followed by oxime ligation, may have occurred in order to generate 
oxime peptide 137 (Figure 7.1C).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1 (A) Outline of aniline catalysed oxime ligation of aldol product 59 to generate dually modified 
peptide 106 and byproduct oxime product 137. (B) LC-MS data obtained when using catalyst 18 or catalyst 110 
at pH 7.5, showing the presence of the anticipated byproduct 137 present when using catalyst 18 but not when 
using catalyst 110. (C) Proposed pathway for generation of oxime product 137. 
137 
137 106 
59 
103 
106 106 
18 110 
59 
27 
137 
Possible by-product? 
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It was therefore hypothesised that incubating OPAL products with an aniline catalyst 
without the addition of an aminooxy nucleophile may lead to breakdown of the 
OPAL products to the α-oxo aldehyde species, thus inducing cleavage of the 
otherwise stable C-C bond and regenerating the original α-oxo aldehyde species via 
a retro-aldol mediated process. To investigate this hypothesis, aldol product 59 was 
incubated with each of the aniline catalysts 18, 46, 110, and 111 (or with no catalyst 
as a control) in either pH 4.5 or pH 7.5 buffer for 18 h at 37 oC, with the outcome 
analysed by LC-MS (Figure 7.2). Notably different results were obtained depending 
on the pH used and choice of catalyst. For example, incubation of aldol product 59 
with aniline 46 at pH 4.5 lead to no breakdown of aldol product 59. However, 
analysis by LC-MS of the incubation of aldol product 59 with aniline 46 at pH 7.5 
revealed the appearance of a peak at 653 Da, which would correspond to the 
hydrated glyoxyl-LYRAG 27-Hyd. Based on peak intensity, a maximum of 52% 
conversion to glyoxyl-LYRAG 27 was observed when using catalyst 18 at pH 7.5. 
Similar to oxime ligation of the β-hydroxy aldehyde of OPAL products, this 
breakdown appears to be facilitated at pH 7.5 in comparison to pH 4.5 (Figure 7.2).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Outline of investigation into pH effect on the outcome of aniline-catalysed breakdown of aldol 
product 59. Conversions glyoxyl-LYRAG 27 were obtained as judged by LC-MS. 
59 
18, 46, 110, 111 
46 18 110 111 
27 
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NB: An additional aniline catalyst, p-phenylenediamine (previously described for 
aniline catalysed oxime ligation), 123 was also screened for retro-aldol activity, 
along with catalysis in oxime ligation of aldol product 59. However, data obtained 
when using this catalyst yielded multiple unknown species when judged by LC-MS, 
and was subsequently not investigated further. 
The results shown in Figure 7.2 suggest that significant, controlled breakdown of 
OPAL products could be achieved through incubation with catalyst 18 (and, to a 
lesser extent, with catalyst 46), which likely occurs through a retro-aldol mediated 
process.  
7.1.1 Mechanism for the retro-aldol mediated breakdown of OPAL products 
There are isolated examples of small molecule-mediated retro-aldol reactions,218,219 
with the primary focus of research into retro-aldol chemistry focused within the area 
of engineering Class I aldolases to catalyse the breakdown of small molecule β-
hydroxy carbonyls.220 The retro-aldol mediated cleavage of C-C bonds through these 
retro-aldolases is hypothesised to occur through initial imine formation between the 
ε-amino group of a catalytically active lysine residue in the aldolase active site and 
the β-hydroxy carbonyl of the aldol molecule.215 Previously reported studies of 
aldolases have determined that this catalytic lysine residue resides in a hydrophobic 
pocket of the enzyme, resulting in a “highly perturbed” ε-amino pKa value of ~6 (in 
contrast to the typical pKa of ~9-10 seen in other lysine residues).221 The similarity 
in this pKa value compared to the pKa of aniline (pKa = 4.6) and p-anisidine (pKa = 
5.3) and the propensity for anilines to form imines may explain why these molecules 
are effective at promoting a retro-aldol mediated C-C cleavage of aldol modified 
peptides. Based on these previous observations, a potential mechanism for the 
aniline-catalysed retro-aldol mediated breakdown of OPAL products was proposed, 
and is shown in Figure 7.3. 
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7.1.2 Controlling the pathway to oxime ligation or retro-aldol 
As shown in Chapter 5, the addition of an aniline catalyst was found to be essential 
for facilitating the oxime ligation of OPAL products. In particular, catalyst 18 was 
especially effective at catalysing this process at pH 7.5. During these experiments no 
observed breakdown of OPAL products back to the protein α-oxo aldehyde (or to 
singly oxime modified product) was observed. However, as shown in Figure 7.2, 
catalyst 18, along with catalyst 46 (which was used to generate dually lipidated 
HASPA 129), were found to be effective at promoting breakdown of aldol-modified 
products 59. Taking both the results described in this Chapter and in Chapters 5 and 
6 into account, it was hypothesised that an additional factor in addition to catalyst 
loading, catalyst choice, and pH choice, must influence whether or not retro-aldol 
mediated breakdown of OPAL products occurred. Notably, it has previously been 
shown for the π-clamp mediated site-selective bioconjugation42 of cysteines that 
alteration of the buffer salt composition can dramatically impact on the outcome of 
bioconjugation.43 Throughout this thesis, the aniline-catalysed oxime ligation of 
peptide aldol products was consistently performed in 200 mM buffer, whereas 
aniline-catalysed oxime ligation of protein aldol products was consistently 
performed in 50 mM buffer (the exception being for synthesis of dually lipidated 
HASPA 129 which was performed in 25 mM buffer). To check the potential impact 
of buffer salt concentration on the outcome of retro-aldol mediated breakdown of 
OPAL products, aldol product 59 was incubated with catalyst 18 at pH 7.5 with 
different concentrations of PB salts, and conversion to glyoxyl-LYRAG 27 was 
judged by LC-MS (Figure 7.4). 
 
 
Figure 7.3 Proposed mechanism for the aniline-catalysed retro-aldol mediated breakdown of OPAL products. 
Imine formation between the β-hydroxy aldehyde, followed by decomposition and hydrolysis, leads to 
breakdown of the OPAL product to regenerate an α-oxo aldehyde species. (B = unspecified base). 
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NB: Addition of an aniline catalyst to the reaction medium can sometimes alter pH 
of a given reaction (particularly in weakly buffering solutions). The actual pH for 
these reactions was therefore assessed by pH probe, and found to be pH 7.4-7.6 in 
all cases. 
As shown in Figure 7.4, significantly higher conversion to glyoxyl-LYRAG 27 was 
observed when using higher concentrations of PB salts, suggesting that the aniline 
catalysed retro-aldol mediated breakdown of OPAL products was facilitated in 
systems with higher concentrations of PB salts. Comparisons of Figure 7.2 and 
Figure 7.4 suggest that this was limited up to 100 mM of PB, as moving from 100 
mM PB salts to 200 mM PB salts had a negligible effect on conversion to glyoxyl-
LYRAG 27 These results would explain why retro-aldol mediated breakdown was 
observed during aniline-catalysed oxime ligation experiments of aldol product 59 
(performed with 200 mM PB) but not in aniline-catalysed oxime ligation 
Figure 7.4 Outline of investigation into the effects of concentration of buffer salts used in the retro-aldol 
mediated breakdown of 59 using catalyst 18. Conversion to glyoxyl-LYRAG 27 was assessed as judged by 
LC-MS. 
59 
18 
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experiments of OPAL described in Chapter 5 (performed with 50 mM PB) or in the 
dual lipidation of HASPA described in Chapter 6 (performed with 25 mM PB). 
7.1.3 C-C bond cleavage of protein bioconjugates 
Finally, to begin to investigate retro-aldol mediated cleavage of functionalised 
OPAL products, fluorescently labelled thioredoxin 89 (25 µM) was incubated with 
catalysts 18, 46, 110, and 111, in 0.2 M PB pH 7.5 at 37 oC (0.2 M, as opposed to 0.1 
M, PB was chosen in an attempt to maximise conversion). The anticipated 
breakdown to glyoxyl-thioredoxin 32 was judged by LC-MS after 18 h or 42 h 
intervals, as outlined in Table 7.1. 
Table 7.1 Outline of screening catalysts in the retro-aldol mediated breakdown of fluorescently labelled 
thioredoxin 89. 
Entry Catalyst Time (h) Conversion to glyoxyl-
thioredoxin 32 (%) 
1 46 18 24* 
2 18 18 45* 
3 110 18 18* 
4 111 18 Precipitate** 
5 - 18 0* 
6 18 42 57* 
 
* A small, additional peak at 11676 Da was also present in all samples treated for 
retro-aldol, which currently has not been identified. ** In this particular set of 
experiments, a small amount of precipitate was observed, and for this reason the 
data was not analysed. 
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Figure 7.5 shows the results from Table 7.1, Entry 6: 
 
 
 
 
 
 
Similar to retro-aldol mediated reactions of aldol product 59, catalyst 18 was found 
to be most effective at promoting retro-aldol mediated breakdown of fluorescently 
labelled thioredoxin 89 to glyoxyl-thioredoxin 32, with a 57% conversion to 
glyoxyl-thioredoxin 32 observed after 42 h of incubation. These results demonstrate 
that cleavage of an otherwise stable C-C linked OPAL bioconjugate can be achieved 
through aniline catalysis, and that the original protein α-oxo aldehyde can be 
regenerated in the process. 
7.2 Variants on aldol bioconjugation 
Throughout Chapters 3-6 it has been demonstrated that protein α-oxo aldehydes can 
be site-selectively dually modified first through an organocatalyst-mediated process 
that uses a proline-derived catalyst, followed by another organocatalyst-mediated 
process that uses an aniline-derived catalyst, in a two-step tandem process. 
Intriguingly, in small molecule literature, the use of both a proline-derived 
organocatalyst and an aniline-derived organocatalyst in the context of aldol reactions 
leads to different process known as the Mannich reaction.222 As discussed in Chapter 
1, a Mannich ligation strategy for modifying proteins has been previously reported; 
this ligation strategy is selective for surface exposed tyrosine residues through a 
three component reaction involving both aniline-type and aldehyde-type reagents, 
resulting in formation of stable C-C bond between the substrates and the ortho 
position of the tyrosine phenol side chain.223 Similar bioconjugations involving 
preformed imines and phenols/tyrosine containing peptides and proteins has also 
been reported.224 Whilst the reported Mannich ligation is selective for surface 
Figure 7.5 (A) Outline of the retro-aldol mediated breakdown of OPAL product 89 using catalyst 18. (B) LC-
MS data obtained for Table 7.1, Entry 6. 
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exposed tyrosine residues it does not distinguish between multiple surface exposed 
tyrosine residues, leading to heterogeneous protein constructs.223. Both ortho 
positions (with respect to the hydroxyl group) of the tyrosine phenol side chain can 
be modified, particularly for small peptides, further leading to heterogeneous product 
formation.224 
7.2.1 A ‘modified Mannich’ bioconjugation 
It is clear from the published literature that it is possible to take phenol (i.e. tyrosine) 
containing peptides/proteins, and chemically modify them selectively with aldehyde 
and aniline reagents. Additionally, since the publication of the three component 
Mannich ligation (nearly 15 years ago), significant advancements have been made 
within the field of protein bioconjugation; in particular, incorporation of handles 
such as aldehydes into proteins has advanced significantly.1 Therefore, it should 
theoretically be possible to take aldehyde containing peptides/proteins, and 
chemically modify them selectively with phenol and aniline reagents via an 
alternative ‘modified-Mannich’ ligation strategy. By installing one aldehyde into the 
protein and having the ‘aldehyde’ component of the reaction as the limiting agent, 
product heterogeneity should be avoided. Additionally, by using functionalised 
phenol and aniline reagents in this reaction, it should be possible to achieve dual 
functional modification of the protein in question via a one-step process (Figure 7.6). 
 
 
 
 
 
 
 
 
 
Figure 7.6 Comparison of the three component Mannich bioconjugation strategy to the hypothesised modified 
Mannich bioconjugation strategy. 
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To investigate this hypothesis, two modified-Mannich ligations between the model 
peptide glyoxyl-VARLG 132 (chosen because it does not contain any tyrosine 
residues which may interfere with the initial validation stages), commercially 
available aniline 133 and substituted phenol reagents 134 or 135 were performed in 
0.1 M PB pH 6.5 for 24 h at 37 oC. Conversion to the anticipated Mannich products 
136 and 137 respectively was assessed as judged by LC-MS analysis (Figure 7.7).  
 
 
 
 
 
 
 
 
 
 
 
 
As shown in Figure 7.7, conversion to the anticipated Mannich products was 
observed in both cases (these species were then identified as the desired Mannich 
products through MS/MS analysis, see Figure 7.8-7.11). However, only a 12% 
conversion to Mannich product 136, or a significant amount of unanticipated by-
product produced alongside Mannich product 137, was observed in these 
experiments. These results suggest that significant optimisation would be required in 
order to make the modified Mannich ligation a viable strategy for bioconjugation. 
 
132 
133 
134 
135 
133 
132 
132-Hyd 
136 
137 
? 
136 
137 
Figure 7.7 (A) Outline of reaction of glyoxyl-VARLG 132 with aniline 133 and phenol 134. Calculated 
[M+H]+ of product 136 = 814.44 Da. (B) LC-MS data obtained for (A). (C) Outline of reactyion of glyoxyl-
VARLG 132 with aniline 133 and phenol 135. Calculated [M+H]+ of product 137 = 844.45 Da. (D) LC-MS 
data obtained for (C). 
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Figure 7.8 MS/MS data of Mannich product 136. 
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Figure 7.9 MS/MS data of fragmentation of Mannich product 136, followed by fragmentation of the resulting 
major fragment (677.4 Da). 
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Figure 7.11 MS/MS data of fragmentation of Mannich product 136, followed by fragmentation of the resulting 
major fragment (707.4 Da). 
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7.2.1 A catalyst free aldol ligation 
The results described in Figure 7.7 both show low conversions to the desired 
Mannich product, but for different reasons; for the reaction with phenol 134, this was 
due to significant quantities of starting material remaining, but for the reaction with 
phenol 135, this was due to the presence of significant quantities of an unanticipated 
species at 725.43 Da. Incidentally, the m/z value of this species corresponds to the 
mass of glyoxyl-VARLG 132 + the mass of phenol 135 (+1 Da for [M+H]+), and 
MS/MS analysis of this species yields a fragmentation pattern similar that described 
for aldol-modified peptides (modification identified at the N-terminus, highly intense 
peak of species -18 Da, which upon fragmentation yields x/y/z fragments 
corresponding to the “VARLG” peptide in a similar manner to Mannich product 137, 
see Figure 7.12 and Figure 7.13). Modifications of aldehydes in aqueous solvents 
with phenol reagents that act as enolate equivalents have previously been reported,225 
and it was therefore hypothesised that phenol 135 may be participating as a 
preformed enolate equivalent in an aldol-type direct conjugation with glyoxyl-
VARLG 132. Such a ligation would be of significant interest within the field of 
bioconjugation, as the procedure would lead to C-C bond formation between phenol 
and biomolecule. To validate this hypothesis, glyoxyl-VARLG 132 was incubated 
with different concentrations of phenol 135 in 0.1 M PB pH 6.5 for 24 h at 37 oC, 
and conversion to the anticipated phenol-peptide product 138 was assessed by LC-
MS analysis (Figure 7.14). 
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Figure 7.12 MS/MS data of hypothesised phenol-peptide product 138. 
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Figure 7.13 MS/MS data of fragmentation of phenol-peptide product 138, followed by fragmentation of the 
resulting major fragment (707.4 Da). 
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As shown in Figure 7.14, almost complete conversion (95%) to the hypothesised 
phenol-peptide product 138 can be achieved using only 1 molar equiv. of phenol 
135, with total conversion achieved when using 5 molar equiv. of phenol 135. 
7.2.2 Controlling reaction pathways through pH 
The effect of pH of both the modified Mannich bioconjugation and the unanticipated 
phenol-mediated ligation was next investigated. The three-component Mannich 
bioconjugation has  been reported to have an optimal reactivity observed at pH 5.5-
6.5 and poor reactivity observed above pH 8.223 It has been hypothesised that at pH 
6.5 (the optimal pH) a cyclic transition state between the phenol and aldehyde-
aniline imine can be formed, which simultaneously activates both the aldehyde-
aniline imine and the phenol aromatic towards product formation. 223 On peptides 
however Mannich bioconjugations have also been reported to proceed over a much 
wider pH range, with reactions proceeding at a pH as low as 2 and as high as 10. 224 
It was therefore hypothesised that both the modified Mannich ligation procedure and 
the unanticipated phenol-mediated ligation procedure could proceed at different pH 
values i.e. neutral pH. Therefore, the modified Mannich ligation between glyoxyl-
VARLG 132, aniline 133, and phenol 135, along with the phenol-mediated ligation 
between glyoxyl-VARLG 132 and phenol 135, was performed in 0.1 M PB pH 7.5 
132 
135 
138 
132-Hyd 
138 138 138 
Figure 7.14 (A) Outline of reaction of glyoxyl-VARLG 132 with different concentrations of phenol 135. 
Calculated [M+H]+ of anticipated phenol-peptide product = 725.38 Da. (B) LC-MS data obtained for each 
loading of phenol 138 after 24 h of reaction. 
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for 24 h at 37 oC to test this hypothesis. Similar reactions were also performed in 0.1 
M NaOAc pH 4.5 to provide a comparison of performing both reactions at neutral 
and acidic pH. Both reactions were analysed by LC-MS, as shown in Figure 7.15 
 
 
 
 
 
 
 
 
 
 
 
 
NB: For the reaction of glyoxyl-VARLG 132 with aniline 133 and phenol 135 at pH 
4.5, an intense peak at 515.38 Da was observed. It was unclear as to where this peak 
originated from – it was hypothesised that it could possibly be the peptide VARLG 
which may have originated from decomposition during the reaction or from 
fragmentation of product 137 during ESI-MS analysis. 
The results of performing the modified Mannich and phenol-mediated 
bioconjugation protocols varied significantly depending on if they were performed at 
pH 4.5 or pH 7.5. For the modified mannich bioconjugation protocol, a greater 
proportion of Mannich-peptide product 137 compared to phenol-peptide product 138 
was observed at pH 4.5, with phenol-peptide product 138 dominating at pH 7.5. For 
the phenol-mediated bioconjugation protocol, a 60% conversion to phenol-peptide 
product 138 was observed at pH 4.5, whereas full conversion to phenol-peptide 
Figure 7.15 (A) Outline of reaction of glyoxyl-VARLG 132 with aniline 133 and phenol 135 at pH 4.5 or pH 
7.5, with each outcome analysed by LC-MS. (B) Outline of reaction of glyoxyl-VARLG 132 with phenol 135 at 
pH 4.5 or pH 7.5, with each outcome analysed by LC-MS. 
132 
132 
133 
135 
135 
138 
137 
137 
138 
132-Hyd 
138 138 
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product 138 was noted at pH 7.5. The results shown in Figure 7.15A suggest that for 
the modified mannich bioconjugation protocol, it would be possible to facilitate 
mannich bioconjugation (and avoid phenol bioconjugation by-products in this case) 
by performing the reaction at pH 4.5 as opposed to pH 6.5 or pH 7.5. Additionally, 
the results shown in Figure 7.15B suggest that the phenol-mediated bioconjugation 
strategy proceeds efficiently at pH 7.5 
7.2.3 Dissecting the phenol-based ligation 
In the interest of designing ligation strategies that operate at neutral pH, the phenol-
mediated bioconjugation protocol was subjected to further investigation. As seen in 
Figure 7.8, phenol 134 and phenol 135 show significantly different reactivity 
towards ligation with glyoxyl-VARLG 132. These results suggest that the choice of 
phenol reagent and substituent position appears to greatly impact whether or not 
modification of glyoxyl-VALRG 132 occurs. Therefore, to dissect the intricacies of 
the ligation, a series of small molecule aromatics were screened for their activity in 
the site-selective modification of glyoxyl-VARLG 132 (Figure 7.16). These 
compounds were chosen primarily to investigate the importance of the phenol OH 
group and the effects of substitution on the aromatic ring on the outcome of the 
phenol-based ligation. 
 
 
 
 
 
 
 
Figure 7.17A outlines the reactions of 1 mM of glyoxyl-VARLG 132 in 0.1 M PB 
pH 7.5, 5% DMSO, at 37 oC for 24 h with 5 mM of aromatics 139-144. Conversion 
to modified peptide species was then assessed by LC-MS analysis, with different 
aromatics displaying different reactivity towards glyoxyl-VARLG 132 (Figure 
139 140 141 
142 143 144 
Figure 7.16 Aromatics screened for reactivity with glyoxyl-VARLG 132. 
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7.17B, green tick indicates reaction of aromatic with glyoxyl-VARLG 132, whereas 
red cross indicates no reaction with glyoxyl-VARLG 132 was observed). Structures 
of the anticipated aromatic-peptide products 145-147 that were observed in the 
screen of aromatic compounds 139-144, along with relevant LC-MS data, are shown 
in Figure 7.17C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*NB: For the reaction with aromatic 139 and aromatic 144, it was hypothesised that 
multiple phenol-peptide products would be possible, as aromatic 139 and 144 have 
additional possible ortho positions (with respect to phenol OH) available for 
132 139-144 
139 140 141 142 143 144 
Figure 7.17 (A) Outline of reaction of glyoxyl-VARLG 132 with aromatics 139-144 to give anticipated modified 
peptide products. (B) Structure of aromatics 139-144 screened in (A). A green tick below the structure indicates 
that some degree of modification with glyoxyl-VARLG 132 occurred, whereas a red cross indicates that no 
reaction with glyoxyl-VARLG 132 was observed whatsoever. (C) Structures of anticipated aromatic peptide 
products 145, 146, and 147 observed when using aromatic 139, 140 and 144 respectively. LC-MS data for these 
experiments is also shown. Calculated [M+H]+ of 145 = 681.35 Da, calculated [M+H]+ of 146 = 693.39 Da, 
calculated [M+H]+ of 147 = 725.34 Da 
145 
(100 
146 147 
145* 
146 
147 132-Hyd 132-Hyd 
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ligation. However, all the products generated would show up as the same mass when 
analysed by ESI-MS. It would therefore require an additional analytical technique 
(i.e. NMR) to determine the actual connectivity and product distribution seen for the 
peak at 681.51 Da in Figure 7.17C. Therefore, although the peaks at 681.51 Da and 
725.46 Da have been labelled as product 145 and 147 respectively, in this instance, 
these peak likely comprises of a mixture of products. 
As seen in Figure 7.17, successful modification of glyoxyl-VARLG 132 with each of 
aromatics 139-144 varied greatly depending on which compound was used. Total 
conversion was achieved when using resorcinol 139 (NB: a small unidentified peak 
at 626.66 Da was also observed), with a lower conversion of 49% observed when 
using phenol 144, and a significantly lower conversion of 14% observed when using 
phenol 140. No modification occurred when using aromatics 141-143, with only 
unreacted glyoxyl-VARLG 132 observed in each case. The results of the screen of 
aromatic compounds 139-144 described in Figure 7.9 provides significant insights 
into the ligation strategy described thus far. Firstly, a phenol group was found to be 
absolutely vital for successful modification, as using aromatics 141 and 142, which 
do not contain phenol groups, lead to no modification of glyoxyl-VARLG 132. 
Substitution of the aromatic ring was also found to be of major importance in 
dictating the outcome of the ligation; phenols bearing strongly electron donating 
groups (such as phenol 135, phenol 139, and phenol 139) were found to give high 
conversions to the desired phenol-peptide product, whereas phenols bearing weakly 
electron donating groups (such as phenol 140) or those containing electron 
withdrawing groups (such as phenol 143 and phenol 144) were found to give low 
conversions to the desired product. Finally, the presence of a carboxylic acid group 
ortho to the hydroxyl group of the phenol was found to have significant effects on 
the outcome of the ligation, with only a 49% conversion to the desired product 
observed when using phenol 144, and no conversion observed when using phenol 
143. These results were deemed particularly interesting, as both compounds have the 
required phenol group and both contain a strongly electron donating group in the 
meta position, but only conversion with phenol 144 was achieved. Phenols that 
contain ortho carboxylic acid groups are known to participate in intramolecular 
hydrogen bonding. Given that the phenol group is vital for successful ligation, it was 
hypothesised that the presence of an ortho hydrogen bonding group to the phenol 
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group may lead to “consumption” of the phenol moiety, preventing it from 
participating as an enol equivalent in aldol-type ligations. This would explain why 
phenol 143 (which has only one phenol group and can theoretically participate in 
intramolecular hydrogen bonding to the adjacent carboxylic acid group) was 
unreactive towards glyoxyl-VARLG 132 but why phenol 144 (which has two phenol 
groups present, one of which will not participate in intramolecular hydrogen 
bonding) was reactive towards glyoxyl-VARLG 132. 
7.2.4 Hypothesised mechanism for the catalyst-free aldol bioconjugation 
The use of phenols as enol/enolate equivalent has been previously documented in the 
literature. For example, one of the most well-known examples of phenols acting as 
enolate equivalents is in the Kolbe-Schmitt carboxylation, which can be utilised to 
synthesise salicylic acids.226,227 Phenols as enolate equivalents have also been 
reported in the modification of aldehydes.225 It was therefore hypothesised that the 
phenol reagents described thus far would also operate via a similar mechanism in the 
modification of α-oxo aldehydes as shown in Figure 7.18. This mechanism would 
explain the absolute requirement of a phenol for successful conjugation, and also 
explain improved conjugation yields obtained at pH 7.5 compared to pH 4.5 (higher 
pH = higher proportion of deprotonated phenol, thereby increasing the active content 
of phenol). 
 
 
 
 
 
 
7.2.5 Towards catalyst free protein bioconjugation 
Finally, to begin to demonstrate the aforementioned phenol ligation was compatible 
with site-selective protein bioconjugation, the reaction between 75 µM of glyoxyl-
myoglobin 13 and 1 mM of phenol 135 in 0.1 M PB pH 7.5, 10% DMSO, at 37 oC 
Figure 7.18 Proposed mechanism for the phenol-mediated ligation of α-oxo aldehydes. Following 
deprotonation, phenol acts as an enolate equivalent and participates in nucleophilic attack of the α-oxo 
aldehyde. Tautomerisation followed by protonation generates the final phenol product. 
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for 1 h was performed as outlined in Figure 7.19A. Conversion to the anticipated 
modified myoglobin 148 was assessed as judged by LC-MS (Figure 7.19B).  
 
 
 
 
 
 
As shown in Figure 7.19, a 79% conversion to the anticipated phenol-myoglobin 
product 148 was observed. This result suggests that suitable phenol reagents such as 
135 can be used to in protein bioconjugation. Further studies, such as UV/Vis 
analysis and trypsin digestion experiments, would be required to fully characterise 
this product, and determine the suitability of using phenol reagents in this manner for 
site-selective protein bioconjugation. Additionally, one could anticipate that by using 
a suitably functionalised phenol compound, one could enable highly efficient, 
catalyst free, site-selective protein bioconjugation of protein aldehydes in a similar 
manner to the OPAL. This phenol-induced ligation of protein aldehydes (or 
‘PHILIPA’ for short) could provide an efficient, straightforward way to site-
selectively modify protein aldehydes via a hydrolytically stable C-C bond at neutral 
pH without the need for large concentrations of small molecule organocatalyst 
(Figure 7.20). 
 
 
 
 
 
 
148 
13-Hyd 
148 
13 
135 
Figure 7.19 (A) Outline of reaction between glyoxyl-myoglobin 13 and phenol 135 (B) LC-MS data obtained for 
reaction of 75 µM 13 and 1 mM phenol 135 in 0.1M PB pH 7.5 (10% DMSO) at 37 oC for 1 h. 
Figure 7.20 Proposal of a novel protein bioconjugation strategy for the site-selective modification of 
protein α-oxo aldehydes using phenols at neutral pH to generate C-C linked bioconjugates. 
190 
 
 
 
7.3 Concluding statement 
In conclusion, the work described in this thesis has led to the development of a novel 
protein bioconjugation strategy, the Organocatalyst-mediated Protein Aldol Ligation 
(abbreviated to “OPAL”). Following its serendipitous discovery, the OPAL was 
validated on model peptide and protein systems, and optimised through rigorous 
kinetic analysis of different small molecule organocatalysts and aldehyde donors. 
Throughout this project, the OPAL has proved to be a robust, versatile, and powerful 
C-C bond forming bioconjugation strategy, which offers site-selective modification 
of a range of protein aldehydes at both internal and N-terminal positions. Alongside 
palladium-mediated decaging of thiazolidine-bearing proteins, compatibility and 
selectivity of the OPAL was demonstrated through selective labelling and protein 
pulldown of GFP within cell lysates, which maintains its fluorescence as a result of 
modification and purification at neutral pH. In addition, the newly generated β-
hydroxy aldehyde handle that results from OPAL modification was found to be 
amenable to site-selective modification via a different protein aldehyde 
bioconjugation strategy. Screening of aniline-catalysed oxime ligations on aldol-
modified peptides revealed an unexpected switch in pH dependence, in which neutral 
pH was favoured over acidic pH. This information was then used in the synthesis of 
dually modified protein bioconjugates via an OPAL-oxime at neutral pH. The OPAL 
was then applied in the chemical mimicry of N-terminal myristoylation of the 
Leishmania protein HASPA, and was demonstrated to mimc structural and solution 
based properties of its enzymatically N-myristoylated counterpart via 
characterisation by protein NMR. The tandem OPAL-oxime strategy was also 
utilised to generate a dually lipidated HASPA species previously inaccessible 
through conventional enzymatic methods, which was further used to explore the 
effects of HASPA lipidation and membrane binding. Finally, an aniline-catalysed 
retro-aldol mediated process for the controlled breakdown of OPAL products, along 
with a ‘catalyst free’ aldol-type bioconjugation, was discussed. It is hoped the work 
described in this thesis will further contribute towards the bioconjugation toolbox in 
chemical biology, assist in the study of lipidated proteins such as HASPs, and 
facilitate research towards the discovery of new organocatalyst mediated and catalyst 
free bioconjugation strategies for wide ranging applications in chemical biology. 
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General procedures and materials 
Unless otherwise specified, all chemical reagents were obtained from commercial 
sources and used without further purification. Myoglobin from equine heart (M1882) 
and Thioredoxin from Escherichia coli (T0910) were purchased from Sigma and 
used without further purification. Sequencing Grade Modified Trypsin V5111 was 
purchased from Promega. Pierce™ Monomeric Avidin Agarose was purchased from 
ThermoFisher Scientific. 
Small molecule NMR spectroscopy 
1H and 13C NMR spectra were measured using either Jeol 400-MR or Bruker 500-
MR spectrometer at The University York Centre for Magnetic Resonance at 400/500 
MHz for 1H and 100/125 MHz for 13C with Me4Si as the internal standard. 
Multiplicities are given as singlet (s), broad singlet (br s), doublet (d), doublet of 
doublets (dd), triplet (t), quartet (q), pentet (p) or multiplet (m). Resonances were 
assigned using HH-COSY and CH-HSQC. All NMR chemical shifts (δ) were 
recorded in ppm and coupling constants (J) are reported in Hz. ACD-NMR Processor 
Academia Edition and MestReNova were used for processing spectral data. 
UV/Vis analysis 
UV/Vis analysis was performed using either a U1900 spectrometer (HITACHI) in 
line with UV solutions 2.2 software (HITACHI), or using a DS-11 FX+ 
spectrophotometer/fluoremter (DeNovix) in line with DS-11/DS-11 FX Software 
(Version 3.15). 
High performance liquid chromatography instrumentation 
Analytical HPLC was performed using either an Accucore C18 coulmn 2.6 μm 
column, 2.1 × 150 mm, or a Phenomenex Kinetex 5µ phenyl-hexyl 100 A column of 
dimension 250 ˣ 4.6 mm. Shimadzu Prominence LC-20AD pump and SDP-M20A 
Diode Array detector were used during the analysis. 
Liquid Chromatography Mass Spectrometry instrumentation 
High Performance Liquid Chromatography-Electrospray Ionisation Mass 
Spectrometry (LC-MS) was accomplished using a Dionex UltiMate® 3000 LC 
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system (ThermoScientific) equipped with an UltiMate® 3000 Diode Array Detector 
(probing 250-400 nm) in line with a Bruker HCTultra ETD II system (Bruker 
Daltonics), using Chromeleon® 6.80 SR12  software (ThermoScientific), Compass 
1.3 for esquire HCT Build 581.3, esquireControl version 6.2, Build 62.24 software 
(Bruker Daltonics), and Bruker compass HyStar 3.2-SR2, HyStar version 3.2, Build 
44 software (Bruker Daltonics) at The University York Centre of Excellence in Mass 
Spectrometry (CoEMS). All mass spectrometry was conducted in positive ion mode 
unless stated otherwise. Data analysis was performed using ESI Compass 1.3 
DataAnalysis, Version 4.1 software (Bruker Daltonics). 
LC-MS analysis of peptide and protein ligations 
Prior to analysis by LC-MS, peptide or protein ligation mixture was diluted 1:3 in 
water and then further diluted 1:1 in acetonitrile with 1 % (v/v) formic acid. Peptide 
samples were analysed using an Accucore™ C18 2.6 µm column (50 x 2.1 mm) 
(ThermoScientific).  Water with 0.1 % (v/v) formic acid (solvent A) and acetonitrile 
with 0.1 % (v/v) formic acid (solvent B) were used as the mobile phase at a flow rate 
of 0.3 mL/min at room temperature (RT). A multi-step gradient of 6.5 min was 
programmed as follows: 90% A for 0.5 min, followed by a linear gradient to 95% B 
over 3.5 min, followed by 95% B for an additional 0.5 min. A linear gradient to 95% 
A was used to re-equilibrate the column Under these conditions all peptides typically 
eluted between 2-5 min. Protein samples were analysed without the use of a column 
at RT. Water with 0.1 % (v/v) formic acid (solvent A) and acetonitrile with 0.1 % 
(v/v) formic acid (solvent B) were used as the mobile phase at a 1:1 ratio over the 
course of 3 min as follows: 0.05 mL/min to 0.25 mL/min for 1 min, 0.025 mL/min 
for 1 min, followed by 1.0 mL/min for 1 min. Under these conditions, all proteins 
typically eluted between 0.1-1.5 min. 
Green fluorescent protein and Superfolder green fluorescent protein Mass 
Spectrometry instrumentation 
Electrospray ionisation mass spectrometry (ESI-MS) of samples relating to green 
fluorescent protein (GFP) or superfolder green fluorescent protein (sfGFP) were 
obtained using a solariX XR FTMS 9.4T (Bruker) using ftms Control, ftmsControl 
2.1.0 Build: 98 software (Bruker Daltonics) at The University York Centre of 
Excellence in Mass Spectrometry (CoEMS). All mass spectrometry was conducted 
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in positive ion mode unless stated otherwise. Data analysis was performed using ESI 
Compass 1.3 DataAnalysis Version 4.1 software. 
Green fluorescent protein and Superfolder green fluorescent protein Mass 
Speectrometry analysis 
Prior to analysis, samples containing GFP or sfGFP were desalted using either a PD 
SpinTrap G25 column (GE Healthcare Life Sciences), or using PD MiniTrap G25 
column (GE Healthcare Life Sciences), eluting with water. The desalted protein 
sample (50 µL) was then diluted by addition of 50 µL of a 1:1 solution of 
water:acetonitrile 1% (v/v) formic acid for analysis. 
Analysis of trypsin digest samples 
Tryptic digestion samples were analysed using a Symmetry® C18 5µm 3.0 x 150 
mm reverse-phase column (Waters). Water with 0.1% (v/v) formic acid (solvent A), 
and acetonitrile with 0.1% (v/v) formic acid (solvent B) were used as the mobile 
phase at a flow rate of 0.08 ml/min at 40 o C. A multi-step gradient of 45 min was 
programmed as follows: 95% A for 0.1 min, followed by a linear gradient to 80% B 
over 40 min, followed by a linear gradient to 95% B for 1 min, followed by a linear 
gradient to 95% A for 4 min. 
Analysis of conjugation yields v1 
Conversion from the designated starting material to the desired material (conjugation 
yields, %) was calculated by analysing the peak intensities of starting material and 
product species, and using Equation 1:  
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Analysis of conjugation yields v2 
Conversion from the designated starting material to the desired material (conjugation 
yields, %) was calculated by analysing the peak area of the starting material and 
product species, and using Equation 2: 
 
 
 
 
Kinetic studies 
Kinetic data was obtained from reactions performed on a 20 µL scale using an 
adapted LC-MS method.42 Reactions were quenched by addition of 80 µL 1:1 
H2O:MeCN (1% formic acid) at time points 2 min, 5 min, 10 min, 20 min, and 30 
min, and then analysed by LC-MS.  Reaction yields at each time point were 
calculated and the second-order rate constants (k2) were determined by fitting the 
data to the following equation 3: 
 
 
where [A]0 and [D]0 are the initial concentrations of the acceptor (peptide aldehyde) 
and donor (small molecule aldehyde) respectively, and [A]t and [D]t are the 
concentrations of the acceptor and donor at time t. Full details on the conditions used 
for each experiment can be found in the Kinetic Data section 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis 
For expression, purification, site-selective modification experiments, and liposome 
assay experiments relating to hydrophilic surface acylated protein A (HASPA), 
green fluorescent protein (GFP) and superfolder green fluorescent protein (sfGFP), 
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all SDS-PAGE analysis was performed using 12% or 4-20% gradient 
polyacrylamide gels228. For experiments relating to dually modified proteins, all 
SDS-PAGE analysis was performed using 15% acrylamide gels. Samples were 
reduced by boiling for 5-10 min (2% SDS, 2mM 2-mercaptoethanol, 4% glycerol, 
40mM Tris-HCl pH 6.8, 0.01% bromophenol blue).  Molecular weight markers used 
were either PageRuler Plus Prestained Protein Ladder (ThermoScientific) or SDS-
PAGE Molecular Weight Standards, Low Range (Bio-Rad). Each gel was run at 200 
volts for 45-80 min. 
 
Coomassie stain 
For Coomassie stain experiments, the gel was washed with fixing solution (40% 
MeOH, 10% AcOH), stained with 0.1% Coomassie Brilliant Blue R-250 (50% 
MeOH, 10% AcOH), and finally destained with solution (50% MeOH, 10% AcOH). 
Images of the resulting gels were captured and analysed using a Syngene G:BOX 
Chemi XRQ equipped with a Synoptics 4.0 MP camera, with GeneSys software 
(Version 1.5.7.0). 
 
Fluorescent imaging 
For fluorescent imaging of fluorescently modified proteins, the SDS PAGE gel was 
washed with fixing solution (40% MeOH, 10% AcOH). Visualisation of protein 
fluorescence, and images of the resulting gels, were captured using a Syngene 
G:BOX Chemi XRQ equipped with a Synoptics 4.0 MP camera in line with 
GeneSys software (Version 1.5.7.0). 
 
Western Blot analysis 
For western blot analysis of biotinylated protein samples (12 µg) were run on 15% 
SDS–PAGE and transferred onto a nitrocellulose membrane filter (0.45 µm, 
Amersham Protran Sandwich, GE Healthcare) using an electroblot apparatus (Bio-
Rad, Hercules, CA) at 100V, 350 mA for 1 h in cooled transfer buffer (25 mM Tris–
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HCl pH 8.3, 192 mM glycine, 0.1% SDS, 20% (v/v) methanol). The membrane was 
incubated in blocking solution (Phosphate buffered saline (PBS) tablets, Sigma)) 
containing 5% non-fat dry milk powder for 16 hours at 4 °C. The membrane was 
processed through sequential incubations with primary antibody, alkaline 
phosphatase anti-biotin (goat, Vector Labs, CA) 1:1000 dilution in PBS  for 1 
hour at room temperature, followed by washing in PBS, 0.01% Tween-20, and then 
incubation with visualising substrate BCIP/NBT Alkaline Phosphatase Substrate Kit 
(Vector Labs, CA) until immunoreactive proteins on the membrane were visible. The 
reaction was stopped by washing the membrane in distilled water. The membranes 
were imaged using a Syngene G:BOX Chemi XRQ equipped with a Synoptics 4.0 
MP camera, with GeneSys software (Version 1.5.7.0). 
Procedure for trypsin digestion 
A 100 µL solution of OPAL product 60 with a total protein content of 1 mg was 
prepared. The product was analysed by MS before being subjected to the trypsin 
digest. The 100 µL solution of OPAL product 60 was dialysed into 50 mM Tris-HCl, 
pH 8.0. 36 mg of solid urea was then added to the solution, giving a final 
concentration of 6M Urea. To this solution was added DTT (5 µL of a 200 mM 
solution in 50 mM Tris-HCl, pH 8.0). The mixture was allowed to stand at room 
temperature for 1 h. The solution was then charged with iodoacetamide (20 µL of a 
200 mM solution in 50 mM Tris-HCl, pH 8.0), gently vortexted, and allowed to 
stand at room temperature in the dark for 1 h. DTT (20 µL of a 200 mM solution in 
50 mM Tris-HCl, pH 8.0) was then added to consume any unreacted iodoacetamide, 
and the solution was allowed to stand at room temperature in the dark for 1 h. 775 
µL of a 50 mM Tris-HCl, 1 mM CaCl2 (pH 7.6) was then added to reduce the urea 
concentration to >0.6 M. Trypsin solution (0.2 µg µL-1, 100 µL in resuspension 
buffer, 50 mM acetic acid) was then added. The reaction mixture was gently 
vortexted and incubated for 16 h at 37 oC. (NB: As much of this procedure as 
possible was performed in a laminar flowhood). To stop the trypsin digest 
procedure, 1 µL of formic acid was added to bring the pH of the solution to pH 3-4 
(checked by pH paper). A 50 µL aliquot of this solution was analysed directly by 
LC-MS. The remaining solution was stored in a -20 oC freezer and defrosted if more 
samples were required. 
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Sequence of proteins used 
NB: The initiatator methionine for all proteins has not been included in the protein 
sequences, as this is not present in the final full length protein. For proteins bearing 
an unnatural amino acid, the unnatural amino acid has been assigned as X. 
Horse heart myoglobin 28 
GLSDGEWQQVLNVWGKVEADIAGHGQEVLIRLFTGHPETLEKFDKFKHLKT
EAEMKASEDLKKHGTVVLTALGGILKKKGHHEAELKPLAQSHATKHKIPIK
YLEFISDAIIHVLHSKHPGDFGADAQGAMTKALELFRNDIAAKYKELGFQG 
CTB 30 
TPQNITDLCAEYHNTQIHTLNDKIFSYTESLAGKREMAIITFKNGATFQVEVP
GSQHIDSQKKAIERMKDTLRIAYLTEAKVEKLCVWNNKTPHAIAAISMAN 
Thioredoxin 31 
SDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGK
LTVAKLNIDQNPGTAPKYGIRGIPTLLLFKNGEVAATKVGALSKGQLKEFLD
ANLA 
GFP (Y39CycloOctK) 33 
SYKDDDDKVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATXGKLT
LKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQ
ERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYN
SHNVYIMADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPD
NHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYKHHHHHH 
HASPA 35 
GAYSTKDSAKEPQKRADNIDTTTRSDEKDGIHVQESAGPVQENFGDAQEKN
EDGHNVGDGANGNEDGNDDQPKEHAAGNLEHHHHHH 
HASPA(G1S) 37 
SAYSTKDSAKEPQKRADNIDTTTRSDEKDGIHVQESAGPVQENFGDAQEKN
EDGHNVGDGANGNEDGNDDQPKEHAAGNLEHHHHHH 
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GFP(Y39ThzK) 40 
SYKDDDDKVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATXGKLT
LKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQ
ERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYN
SHNVYIMADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPD
NHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYKHHHHHH 
sfGFP(N150K) 39 
VSKGEELFTGVVPILVELDGDVNGHKFSVRGEGEGDATNGKLTLKFICTTGK
LPVPWPTLVTTLTYGVQCFSRYPDHMKRHDFFKSAMPEGYVQERTISFKDD
GTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHXVYITAD
KQKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSV
LSKDPNEKRDHMVLLEFVTAAGITHGMDELYKGSHHHHHH 
 
 
CTB 30 preparation 
The protocol for obtaining this protein is adapted from a published protocol. 77 A 
stab from a stock of Escherichia coli BL21 DE23 containing a pSAB2.2 plasmid 
(kindly provided by Dr Thomas Branson). encoding CTB 29 was used to inoculate 
LB growth media (5 mL) containing ampicillin (100 μg mL-1) and this starter 
culture was incubated at 37 °C for 20 h. Starter culture (1 mL) was added to LB 
growth media (4 x 1 L) which was then incubated at 37 °C and monitored until the 
OD600 reached ca. 0.5 before IPTG (1 M final concentration) was added to each 
flask in induce protein over-expression. The incubation was continued for 24 h at 30 
°C before isolating the cells by centrifugation at 10000 x g for 10 min. The bacterial 
cell pellet was discarded and the supernatant was retained. Solid ammonium sulfate 
was added to the supernatant (final concentration 60% w/v) and stirred for 1 h. The 
solution was then centrifuged at 17000 x g for 25 min and the supernatant discarded. 
The protein pellet was resuspended in 0.1 M phosphate buffer and centrifuged at 
15000 x g for 8 mins to remove any insoluble material. The supernatant was filtered 
through a 0.45 μm filter (Sartorius Minisart) and loaded onto 2 x 5 mL HisTrap FF 
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Ni columns. Protein purification was then performed by first washing the Ni column 
with 0.1 M phosphate buffer containing 20 mM imidazole (pH 7, dubbed Buffer A) 
and then eluting bound protein with 0.1 M phosphate buffer containing 500 mM 
imidazole (pH 7, dubbed Buffer B) over a gradient of 0-100% Buffer B over 30 min 
using an AKTA Start (GE Healthcare Life Technologies). Protein presence in 
collected fractions was monitored by UV spectroscopy at 280 nm. Fractions thought 
to contain the desired protein were first subjected to SDS-PAGE analysis. 
 
 
 
 
 
 
 
 
 
 
 
NB: CTB exists as a stable pentamer (ca. 58 kDa) which breaks down into 
monomers (ca. 12 kDa) if boiled or subjected to conditions used in the LC MS 
Fractions containing the desired, sufficiently pure protein were then pooled and 
buffer exchanged into 0.1 M phosphate buffer via dialysis (using SnakeSkin Dialysis 
Tubing, Life Technologies). Concentration of CTB 29 was measured by UV 
spectroscopy at 280 nm (ε = 11585 mol-1 dm3 cm-1, taken from reference 229). 
 
 
97.4 
66.2 
45.0 
31.0 
21.5 
14.4 
kDa Not boiled 
Boiled 
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Synthesis of small molecules 
Benzamidoxime 105: 
 
 
 
 
Synthesis of benzamidoxime 105 was performed as previously reported132. To the 
ethanolic solution (40 mL) of 2-amino benzonitrile (2 g, 17 mmol) and 
hydroxylamine hydrochloride (1.3 g, 18.7 mmol), aqueous NaHCO3 (1.71 g, 20.4 
mmol) solution (12 mL) was added. The mixture was refluxed overnight, allowed to 
cool to room temperature, and diluted with 40 mL ethanol. The solid was filtered off 
and washed with cold ethanol (2 x 10 mL). All ethanol fractions were pooled and 
concentrated in vacuo. The crude solution was then purified by flash 
chromatography (DCM:MeOH 95:5) to give the pure benzamidoxime 105 as a light 
orange, flaky solid (1.7 g, 65%). 1H NMR (400 MHz, DMSO-d6): δ 9.57 (s, 1H), 
7.37-7.34 (d, J = 7.79, 1H), 7.04-6.99 (t, J = 9.62 1H), 6.67-6.4 (d, J = 8.24 1H), 
6.54-6.50 (t, J = 6.87 1H), 6.21 (br, 2H), 5.72 (br, 2H). 13C NMR (100 MHz, 
DMSO-d6): 152.88, 146.79, 129.00, 127.29, 115.46, 114.85, 114.19. ESI-HRMS: 
Found [M+H]+ 152.0817, C7H10N3O, requires 152.0818. 
 
 
Palmitoyl phthalimide 149 
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Synthesis of this compound was adapted from a protocol previously described for 
the synthesis of alkyl phthalimides230. To a stirred solution of cetyl alcohol (1.19 g, 
4.90 mmol), N-hydroxyphthalimide (0.96 g, 5.88 mmol), and PPh3 (1.70 g, 6.47 
mmol) in THF (17 mL) was added DIAD (1.27 mL, 5.88 mmol). The solution was 
stirred under a nitrogen atmosphere at room temperature overnight. The solvent was 
removed in vacuo and the resultant white powder was dissolved in hexane and 
filtered. The solvent was removed in vacuo to give compound 131 as a white powder 
(0.61 g, 32%). 1H NMR (400 MHz, CDCl3): δ 7.83 , 7.76 (2d, 4H, J = 3.1 Hz, ArH), 
4.20 (t, 2H, J = 6.8 Hz, OCH2), 1.79 (p, 2H, J = 6.9 Hz, CH2), 1.48 (p, 2H, J = 6.9 
Hz, CH2), 1.26 (bs, 24H, CH2), 0.88 (t, 1H, J = 6.9 Hz, CH3). 13C NMR (125 MHz, 
CDCl3): δ 163.67 (2) (C=O), 134.39 (2), 128.95 (2), 123.44 (2) (ArC), 78.63 
(OCH2), 31.90, 29.65, 29.63, 29.61, 29.54, 29.47, 29.34, 29.30, 28.12, 25.50, 22.67 
(all CH2), 14.1 (CH3). ESI-HRMS: Found [M+Na]
+ 410.2662, C24H37NNaO3, 
requires 410.2666. 
 
Palmitoyl aminooxy 128 
 
 
 
 
To a solution of 149 (0.039 g, 0.151 mmol) in DCM (1 mL) was added hydrazine 
monohydrate (76 μl, 2.47 mmol). The solution was stirred vigorously for 45 minutes, 
during which time a white solid appeared. The solution was filtered through cotton 
wool, and the filtrate was collected. The resulting filtrate then concentrated under a 
stream of nitrogen to give 128 as a white solid in quantitative yield that was used 
without further purification. 1H NMR (500 MHz, CDCl3): δ 3.64 (t, 2H, J = 6.7 Hz, 
OCH2), 1.56 (p, 2H, J = 6.8 Hz, CH2), 1.25 (bs, 26H, CH2), 0.87 (t, 1H, J = 6.9 Hz, 
CH3). 13C NMR (125 MHz, CDCl3): δ 76.39 (OCH2), 32.07, 29.83 (2), 29.80 (2), 
29.73 (2), 29.66, 28.55, 26.15, 22.83 (all CH2), 14.25 (CH3). ESI-HRMS: Found 
[M+H]+ 258.2793, C16H36NO, requires 258.2791 
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PEG2K phthalimide 150 
 
 
 
 
 
Synthesis of this compound was performed as previously reported204. Under an 
atmosphere of nitrogen, a solution of poly(ethylene glycol) monomethyl ether, 
average molecular weight 2000 g mol-1 (2.00 g, 0.994 mmol), N-hydroxyphthlimide 
(194 mg, 1.19 mmol), and PPh3 (312 mg, 1.19 mmol) in DCM (10 mL) was charged 
with diisopropyl azodicarboxylate (212 µL, 1.09 mmol) via dropwise addition. The 
reaction mixture was then allowed to stir under nitrogen for 18 h at room 
temperature. The solution was then directly added to 400 mL of diethyl ether, and 
the suspension was stirred vigorously for 20 min. The suspension was filtered, and 
the resulting solid was washed with diethyl ether (3 x 70 mL), and residual solvent 
was removed in vacuo. The dry solid was then subjected to the same procedure a 
second time to give the product as a white powder that was used without further 
purification (1.5 g, 75%). 1H NMR (400 MHz, CDCl3): δ 7.82, 7.75 (2d, 4H, J = 3.1 
Hz, ArH), 3.70-3.50 (poly(ethylene glycol) signals), 3.37 (s, 3H, OCH3). 13C NMR 
(125 MHz, CDCl3): δ 163.4 (2) (C=O), 134.4 (2), 128.9 (2), 123.4 (2) (ArC), 71.8, 
70.5 (OCH2), 58.9 (OCH3). 
PEG2K aminooxy 121 
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Synthesis of this compound was performed as previously reported204. To a solution 
of 132 (1.00 g, 0.494 mmol) in DCM (10 ml) was added hydrazine hydrate (76 µL, 
2.47 mmol). The solution was stirred vigorously for 30 min, during which time a 
white solid appeared. The solution was filtered through cotton wool, and the filtrate 
was collected. The resulting filtrate was then concentrated under a stream of nitrogen 
to give 121 as a white solid in quantitative yield that was used without further 
purification. 1H NMR (500 MHz, CDCl3): δ 3.44 (poly(ethylene glycol) signals), 
3.16 (s, 3H, OCH3). 13C NMR (125 MHz, CDCl3): δ 70.08 (OCH2, poly(ethylene 
glycol) signals), 58.51 (OCH3). 
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Solid Phase Peptide Synthesis (SPPS) and donor synthesis 
Peptides were synthesised via manual solid phase peptide synthesis (SPPS) using an 
in situ neutralisation/HCTU activation procedure for Fmoc chemistry on an H-Gly-2-
ClTrt resin (Sigma) using Fmoc protected amino acids as described below: 
Preloaded resin preparation. The preloaded 2-chlorotrityl resin was weighed out 
into a 2 mL SPPS cartridge fitted with a PTFE stopcock, swollen in DMF for 30 min 
and then filtered. 
Amino acid coupling. DIPEA (11.0 eq.) was added to a solution of amino acid (5.0 
eq.) and HCTU (5.0 eq.) dissolved in the minimum volume of DMF and the solution 
added to the resin. The reaction mixture was gently agitated by rotation for 1 h, and 
the resin filtered off and washed with DMF (3 × 2 min with rotation).  
Fmoc deprotection. A solution of 20% piperidine in DMF was added to the resin 
and gently agitated by rotation for 2 minutes. The resin was filtered off and repeated 
four more times, followed by washes with DMF (5 × 2 min with rotation). 
Cleavage and Isolation. Resins containing full synthesised peptides were washed 
with DCM (3 × 2 min with rotation) and MeOH (3 × 2 min with rotation). The resin 
was dried on a vacuum manifold and further dried on a high vacuum line overnight. 
A solution of cleavage cocktail 95:2.5:2.5 (v/v) TFA:H2O:triisopropylsilane was 
then added to the resin, and the resulting mixture was gently agitated by rotation for 
60 min. The reaction mixture was drained into ice-cold Et2O and centrifuged at 6000 
rpm at 4 °C until pelleted (ca. 5-10 min). The supernatant was carefully decanted 
and subsequently resuspended, centrifuged and supernatant decanted three more 
times. The precipitated peptide pellet was then either dissolved 10% MeCN or in 
10% aq. AcOH and lyophilised. Lyophilised peptides were then stored at -20 oC until 
required. 
Notes on folate containing peptides 
For designing peptides containing lysine modified at the Nε position with folic acid, 
Fmoc-Lys (Dde)-OH was incorporated into the peptide chain as described above. 
Upon synthesising the desired peptide chain, and prior to Cleavage and Isolation, 
the resin bound peptide was treated with NH2NH2.H2O (2% in DMF) and gently 
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agitated by rotation for 5 min. This process was repeated, and the resin bound 
peptide was washed with DMF (3 × 2 min with rotation). A solution of folic acid 
(2.5 eq), HCTU (2.5 eq.), and DIPEA (5.0 eq.) in 1:1 DMSO:DMF was then added 
to the resin, and the resulting mixture was gently agitated by rotation for 8 h. The 
resin was then filtered off, washed with DMF (9 x 2 min with rotation), and the 
desired peptide was then obtained following the Cleavage and Isolation step 
mentioned prior. The desired peptide was then further purified via size-exclusion 
chromatography (Sephadex LH-20 in water), and fractions containing pure, desired 
peptide were lyophilised and stored at -20 oC until required. 
 
NB: Precursor 135 and 136, along with HPLC data for the peptides, was kindly 
provided by Robin Brabham. HPLC data for SVARLG 150 was kindly provided by 
Amanda Dixon. 
 
 
 
 
Synthesis of SLYRAG 26 
 
 
 
 
 
 
 
SLYRAG 26 was synthesised as previously described121. 
 
 
 
Synthesised using 400 mg 
resin (1.1 mmol g-1 loading) 
Yield = 280 mg (95 %) 
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Synthesis of SVARLG 150 
 
 
 
 
 
 
 
 
 
 
 
 
Synthesis of fluorescent label precursor 151 
 
 
 
 
 
 
 
 
 
 
 
HRMS: Found [M+H]+ 789.3511, C37H53N6O11S, requires 789.3488. HPLC:tR 
11.28 min. 
Synthesised 
using 85 mg 
resin (0.54 
mmol g-1 
loading) 
Yield = 33 
mg (92 %) 
Synthesised 
using 400 
mg resin 
(0.63 mmol 
g-1 loading) 
Yield = 130 
mg (86 %) 
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Synthesis of fluorescent probe 85 
 
 
 
 
 
To a solution of 133 (10 mg in 500 µL, 10 mM, 0.1 M PB, 0.1 M NaCl pH 7.0) was 
added methionine (250 µL, 200 mM, 0.1 M PB, 0.1M NaCl pH 7.0) and NaIO4 (210 
µL, 112 mM, 0.1 M PB, 0.1 M NaCl pH 7.0). The reaction was mixed thoroughly, 
and allowed to sit for 2 min on ice in the dark. The solution was then loaded onto a 
solid phase extraction cartridge (Grace Davison Extract Clean, 8 ml reservoir, Fisher 
Scientific) equilibrated with water/acetonitrile. After initial washing with water, the 
product was eluted over a gradient of acetonitrile. The product was then diluted with 
water, and subsequently lyophilised to give 11 as a pale yellow, fluffy powder (4 mg, 
40%). LRMS: Found [M+H]+ 758.34, C36H48N5O11S, requires 758.34. 
Synthesis biotin affinity tag precursor 152 
 
 
 
 
 
 
 
 
 
HRMS: Found [M+H]+ 782.3781, C35H56N7O11S, requires 782.3753. HPLC:tR 9.99 
min. 
Synthesised 
using 100 
mg resin 
(0.54 mmol 
g-1 loading) 
Yield = 41 
mg (98 %) 
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Synthesis of biotin affinity tag 86 
 
 
 
 
To a solution of 134 (10 mg in 500 µL, 10 mM, 0.1 M PB, 0.1 M NaCl pH 7.0) was 
added methionine (250 µL, 200 mM, 0.1 M PB, 0.1M NaCl pH 7.0) and NaIO4 (210 
µL, 112 mM, 0.1 M PB, 0.1 M NaCl pH 7.0). The reaction was mixed thoroughly, 
and allowed to sit for 2 min on ice in the dark. The solution was then The solution 
was then loaded onto a solid phase extraction cartridge (Grace Davison Extract 
Clean, 8 ml reservoir, Fisher Scientific) equilibrated with water/acetonitrile. After 
initial washing with water, the product was eluted over a gradient of acetonitrile. The 
product was then diluted with water, and subsequently lyophilised to give 86 as a 
white, fluffy powder (9 mg, 84%). LRMS: Found [M+H]+ 751.39, C34H51N6O11S, 
requires 751.40. 
Synthesis of bioorthogonal azide handle precursor 153 
 
 
 
 
 
 
 
 
 
 
HRMS: Found [M+H]+ 699.3322, C29H47N8O12, requires 699.3308. HPLC:tR = 9.83 
min. 
Synthesised 
using 100 mg 
resin (0.54 
mmol g-1 
loading) 
Yield = 32 mg 
(84 %) 
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Synthesis of bioorthogonal azide handle 87 
 
 
 
To a solution of 135 (10 mg in 500 µL, 10 mM, 0.1 M PB, 0.1 M NaCl pH 7.0) was 
added methionine (250 µL, 200 mM, 0.1 M PB, 0.1M NaCl pH 7.0) and NaIO4 (210 
µL, 112 mM, 0.1 M PB, 0.1 M NaCl pH 7.0). The reaction was mixed thoroughly, 
and allowed to sit for 2 min on ice in the dark. The solution was then loaded onto a 
solid phase extraction cartridge (Grace Davison Extract Clean, 8 ml reservoir, Fisher 
Scientific) equilibrated with water/acetonitrile. After initial washing with water, the 
product was eluted over a gradient of acetonitrile. The product was then diluted with 
water, and subsequently lyophilised to give 14 as a pale green, fluffy powder (8 mg, 
80%). LRMS: Found [M+Na]+ 690.29, C28H41N7NaO12, requires 690.27. 
Synthesis of folate targeting moiety precursor 154 
 
 
 
 
 
 
 
 
 
 
HRMS: Found [M+H]+ 1124.5037, C50H70N13O17, requires 1124.5007. HPLC:tR 1.9 
min. 
Note: HPLC analysis 
of 136 was instead 
performed using the 
‘LC-MS analysis of 
peptide and protein 
ligations’ method 
as described 
previously for 
peptide analysis. 
 
Synthesised 
using 100 mg 
resin (0.54 
mmol g-1 
loading) 
Yield = 11 mg 
(18 %) 
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Synthesis of folate targeting moiety 88 
 
 
 
 
 
 
To a solution of 135 (10 mg in 500 µL, 9 mM, 0.1 M PB, 0.1 M NaCl pH 7.0) was 
added methionine (250 µL, 200 mM, 0.1 M PB, 0.1M NaCl pH 7.0) and NaIO4 (210 
µL, 112 mM, 0.1 M PB, 0.1 M NaCl pH 7.0). The reaction was mixed thoroughly, 
and allowed to sit for 2 min on ice in the dark. The solution was then loaded onto a 
solid phase extraction cartridge (Grace Davison Extract Clean, 8 ml reservoir, Fisher 
Scientific) equilibrated with water/acetonitrile. After initial washing with water, the 
product was eluted over a gradient of acetonitrile. The product was then diluted with 
water, and subsequently lyophilised to give 13 as a yellow, fluffy powder (3 mg, 
31%). LRMS: Found [M+2H]2+ 547.33, C49H66N12O17, requires 547.72.  
Aldol product 83 
 
 
       
 
To a solution of compound 81 (0.05 g, 0.27 mmol) in 0.1 M PB pH 7.0 (700 µL) was 
added  NaIO4 (0.06 g, 0.28 mmol). The reaction was mixed until complete 
dissolution was achieved, and then allowed to sit at rt in the dark for 45 min. 
Complete oxidation of 81 to 82 was observed by LC-MS analysis. To this solution, 
L-proline 61 (0.006 g, 0.05 mmol) and phenylacetaldehyde 54 (0.031 mL, 0.032 g, 
0.027 mmol) were added. The reaction mixture was mixed thoroughly, and then 
allowed to sit at 37 oC for 1 hour. Conversion to the desired aldol product 83 was 
monitored by LC-MS. The solvent was removed in vacuo, and the residue 
resuspended in ethyl acetate, resulting in the precipitation of L-proline 61 which was 
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filtered off. The filtrate was evaporated in vacuo and the crude reaction mixture was 
subjected to HPLC, ESI-MS and NMR analysis. ESI-MS confirmed full conversion 
of the starting material to the aldol product (see below for ESI-MS trace). 
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Peptide and protein chemical modifications 
Oxidation of SLYRAG 26 to glyoxyl-LYRAG 27 
 
 
 
 
Oxidation of SLYRAG 26 to glyoxyl-LYRAG 27 was carried out by dissolving a 
desired amount of peptide in 1 mL of 25 mM phosphate buffer (PB) pH 7.0, 
followed by addition of 2 equivs. of NaIO4. The solution was vortexed, then allowed 
to sit at room temperature in the dark for 1 h. The solution was then loaded onto a 
solid phase extraction cartridge (Grace Davison Extract Clean, 8 mL reservoir, 
Fisher Scientific) equilibrated with water/acetonitrile. After initial washing with 
water, the product was eluted over a gradient of acetonitrile. Fractions containing 
pure, oxidised peptide (as judged by LC-MS analysis) were pooled and subsequently 
lyophilised to give glyoxyl-LYRAG 27 as an orange solid, which was stored at -20 
oC until required. 
Oxidation of SVARLG 155 to glyoxyl-VARLG 132 
 
 
 
Oxidation of SVARLG 155 to give glyoxyl-VARLG 132 as a white powder was 
performed in the same manner as described for the preparation of glyoxyl-LYRAG 
27. 
 
 
 
 
26 27 
27-hyd 
214 
 
 
 
Transamination of horse heart myoglobin 28 to glyoxyl myoglobin 13 
 
 
 
 
 
 
 
A 480 µL aliquot of a 250 µM of myoglobin S1 stock solution in 25 mM PB pH 6.5 
was charged with 1.2 mL of a 25 mM pyridoxal-5-phosphate 8 solution in 25 mM 
PB pH 6.5 (pH adjusted to pH 6.5 using 2M NaOH), and then charged with 720 µL 
of 25 mM PB pH 6.5. Final pH of solution was checked either by pH probe or pH 
paper. The mixture was briefly agitated, and incubated at 37 oC without further 
agitation for 24 h. The solution was then purified via spin concentration using 10,000 
MWCO, and the resulting glyoxyl-myoglobin solution was concentrated to 200 µM, 
eluting with water. Oxidation to glyoxyl-myoglobin 13 was confirmed by LC-MS. 
Oxidation of CTB 29 to glyoxyl-CTB 30 
 
 
 
 
 
A 100 µL aliquot of an 453 µM CTB 29 stock in 0.1 M PB, 0.1 M NaCl, pH 7.0 was 
charged with 7 µL of a 66 mM L-methionine stock solution in 0.1 M PB, 0.1 M 
NaCl, pH 7.0, and 7 µL of a 33 mM NaIO4 stock solution in 0.1 M PB, 0.1 M NaCl, 
pH 7.0. The solution was mixed by gentle pipetting, and allowed to sit on ice in the 
dark for 4 min. The reaction was immediately purified using a PD SpinTrap G25 
desalting column (GE Healthcare Life Sciences), eluting into 25 mM PB pH 7.5. 
Quantitative oxidation to glyoxyl-CTB 30 was confirmed by LC-MS analysis. 
28 
8 
13 
29 30 
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Oxidation of thioredoxin 31 to glyoxyl-thioredoxin 32 
 
 
 
 
 
A 100 µL aliquot of an 85 µM thioredoxin 31 stock in 25 mM PB pH 7.5 was 
charged with 1 µL of a 66 mM L-methionine stock solution in 0.1 M PB, 0.1 M 
NaCl, pH 7.0, and 1 µL of a 33 mM NaIO4 stock solution in 0.1 M PB, 0.1 M NaCl, 
pH 7.0. The solution was mixed by gentle pipetting, and allowed to sit on ice in the 
dark for 4 min. The reaction was immediately purified using a PD SpinTrap G25 
desalting column (GE Healthcare Life Sciences), eluting into 25 mM PB pH 7.5. 
Quantitative oxidation to glyoxyl-thioredoxin 32 was confirmed by LC-MS analysis. 
Oxidation of GFP (Y39CycloOctK) 33 to glyoxyl-GFP 34 
 
 
 
 
 
 
A 100 µL aliquot of a 100 µM GFP 33 (Y39CycloOctK) stock in 1 x PBS, pH 7.4, 
was charged with 3 µL of a 66 mM L-methionine stock solution in 0.1 M PB, 0.1 M 
NaCl, pH 7.0, and 2 µL of a 33 mM NaIO4 stock solution in 0.1 M PB, 0.1 M NaCl, 
pH 7.0. The solution was mixed by gentle pipetting, and allowed to sit on ice in the 
dark for 4 min. The reaction was immediately purified using a PD SpinTrap G25 
desalting column (GE Healthcare Life Sciences), eluting into 25 mM PB pH 7.5. 
Quantitative oxidation to glyoxyl-GFP (Y39CycloOctK) 34 was confirmed by LC-
MS analysis. 
 
31 32 
33 34 
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Transamination of HASPA 35 to glyoxyl-HASPA 36 
 
 
 
 
 
 
 
 
Transamination of HASPA 35 was performed in an identical fashion to that 
described for Transamination of horse heart myoglobin 28 to glyoxyl myoglobin 
13. 
 
Oxidation of HASPA(G1S) 37 to glyoxyl-HASPA 36 
 
 
 
 
 
 
 
A 100 µL aliquot of an 600 µM HASPA(G1S) 37 stock in 0.1 M PB, 0.1 M NaCl, 
pH 7.0 was charged with 10 µL of a 66 mM L-methionine stock solution in 0.1 M 
PB, 0.1 M NaCl, pH 7.0, and 10 µL of a 33 mM NaIO4 stock solution in 0.1 M PB, 
0.1 M NaCl, pH 7.0. The solution was mixed by gentle pipetting, and allowed to sit 
on ice in the dark for 4 min. The reaction was immediately purified using a PD 
SpinTrap G25 desalting column (GE Healthcare Life Sciences), eluting into 25 mM 
PB pH 7.5. Quantitative oxidation to glyoxyl-HASPA 36 was confirmed by LC-MS 
analysis. 
37 36 
35 36 8 
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Oxidation of [15N]HASPA(G1S) 37-15N to glyoxyl-[15N]HASPA 36-15N 
 
 
 
 
 
 
A 50 µL aliquot of an 822 µM [15N]HASPA(G1S) 37-15N stock in 0.1 M PB, 0.1 
M NaCl, pH 7.0 was charged with 36 µL of 0.1 M PB, 0.1 M NaCl, pH 7.0 buffer, 7 
µL of a 66 mM L-methionine stock solution in 0.1 M PB, 0.1 M NaCl, pH 7.0, and 7 
µL of a 33 mM NaIO4 stock solution in 0.1 M PB, 0.1 M NaCl, pH 7.0. The solution 
was mixed by gentle pipetting, and allowed to sit on ice in the dark for 4 min. The 
reaction was immediately purified using a PD SpinTrap G25 desalting column (GE 
Healthcare Life Sciences), eluting into 25 mM PB pH 7.5. Quantitative oxidation to 
glyoxyl-HASPA 36-15N was confirmed by LC-MS analysis. 
 
Palladium decaging of sfGFP(N150ThzK) 39116 
 
 
 
 
 
A 99 μl aliquot of a 300 μM sfGFP(N150ThzK) 39 stock in 1 x PBS, pH 7.4, was 
charged with 1 μl of a 30 mM allylpalladium(II) chloride dimer. The solution was 
mixed by gentle pipetting, and allowed to sit at room temperature for 60 min without 
further agitation. The reaction was then quenched by addition of 10 µL of a 3-
mercaptopropanoic acid solution, 1% v/v solution, 10 x PBS (final concn = 0.1% v/v) 
to each aliquot, and allowed to sit at 25 oC for 15 min without further agitation. The 
reaction was then desalted using a PD MiniTrap G-25 (GE Healthcare Life 
39 41 
37-15N 36-15N 
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Sciences), eluting with 25 mM PB pH 7.5. Conversion to the decaged protein 
aldehyde 41 was confirmed by ESI-MS analysis. 
Palladium decaging of GFP(Y39ThzK) 40 116 
 
 
 
 
 
 
A 99 μl aliquot of a 300 μM GFP(Y39ThzK) 40 stock in 1 x PBS, pH 7.4, was 
charged with 1 μl of a 30 mM allylpalladium(II) chloride dimer stock solution in 
DMSO. The solution was mixed by gentle pipetting, and allowed to sit at room 
temperature for 60 min without further agitation. The reaction was then quenched by 
addition of 10 µL of a 3-mercaptopropanoic acid solution, 1% v/v solution, 10 x PBS 
(final concn = 0.1% v/v) to each aliquot, and allowed to sit at 25 oC for 15 min 
without further agitation. The reaction was then desalted using a PD MiniTrap G-25 
(GE Healthcare Life Sciences), eluting with 25 mM PB pH 7.5. Conversion to the 
decaged protein aldehyde 42 was confirmed by ESI-MS analysis. 
Modification of glyoxyl-LYRAG 27 with acetaldehyde 43 
 
 
 
 
 
A 1 mL aliquot of a 1 mM glyoxyl-LYRAG 27 stock in 0.1 M TEAB pH 8.5 was 
charged with a drop of acetaldehyde 43. The reaction was vortexed, and allowed to 
sit at 37 oC overnight without further agitation. The anticipated aldol product 45 was 
confirmed by LC-MS. 
 
40 
42 
27 45 
43 
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Synthesis of anticipated dually modified peptide 48 
 
 
 
 
 
 
 
 
A 200 µL aliquot of aldol-modified-LYRAG 45 (prepared as described earlier) in 0.1 
M TEAB, pH 8.5, was acidified to pH 4 with glacial acetic acid (checked by pH 
paper). The solution was then charged with 799 µL of Milli-Q (MQ) H2O, and 1 µL 
of aniline 46 A 1 mg sample of aminooxy acetic acid was then added to the solution, 
vortexted, and allowed to sit at 37 oC overnight without further agitation. The 
anticipated dually-modified product 48 was confirmed by LC-MS. 
Synthesis of anticipated aldol products 55-59 
 
 
 
 
A 200 µL aliquot of a 5 mM glyoxyl-LYRAG 27 stock in MQ H2O was charged 
with 10 µL of a 1M donor 50, 51, 52 or 53 stock solution in MQ H2O (or 100 µL of 
a 10 mM donor 54 stock solution in MQ H2O). The reaction was then charged with 
690 µL (or 600 µL) of MQ H2O, followed by addition of 100 µL of 1M TEAB pH 
8.5. The solution was vortexed, and allowed to sit at 37 oC overnight without further 
agitation. The anticipated aldol products 55-59 were confirmed by LC-MS. 
 
 
 
27 
46 
48 47 
100 mM 
50 mM 
27 
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Synthesis of anticipated aldol products 56 and 59 at neutral pH 
 
 
 
 
 
A 200 µL aliquot of a 5 mM glyoxyl-LYRAG 27 stock in 25 mM PB, pH 7.5, was 
charged with 10 µL of a 1M donor 50, 51, 52 or 53 stock solution in 25 mM PB pH 
7.5 (or 100 µL of a 10 mM donor 54 stock solution in 25 mM PB pH 7.5). The 
reaction was then charged with 790 µL (or 700 µL) of 25 mM PB pH 7.5. The 
solution was vortexed, and allowed to sit at 37 oC overnight without further 
agitation. Conversion to the anticipated aldol products 56 or 59 were confirmed by 
LC-MS. 
 
Screening of conditions for the uncatalysed synthesis of aldol-product 60 
 
 
 
 
 
A 100 µL aliquot of a 200 µM glyoxyl myoglobin 13 stock (prepared as described 
earlier) in MQ H2O was charged with 75 µL of 50 mM PB, and then charged with 25 
µL of a 80 mM, 200 mM, 400 mM, or 800 mM donor 51 stock solution in 50 mM 
PB. Following mixing by pipetting, the reaction was allowed to sit at 37 oC for 24 h 
without further agitation. Conversion to the anticipated aldol product 60 was judged 
by LC-MS. 
 
27 51 or 54 56 or 59 
13 51 60 
100 µM 
10, 25, 50 or 100 mM 
1 mM 1 mM or 
10 mM 
200 µL 
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Screening of L-proline 61 concentration in the synthesis of 56 
 
 
 
 
A 200 µL aliquot of a 5 mM glyoxyl-LYRAG 27 stock in 25 mM PB, pH 7.5, was 
charged with 10 µL of a 1M donor 50, 51, 52 or 53 stock solution in 25 mM PB pH 
7.5 (or 1.12 µL of 54). The reaction was then charged with 690 µL (or 698.88 µL) of 
25 mM PB pH 7.5, followed by addition of 100 µL of a 20 mM or 200 mM L-proline 
61 stock solution. The solution was vortexed, and allowed to sit at 37 oC overnight 
without further agitation. Conversion to the anticipated aldol products 56 or 59 were 
confirmed by LC-MS. 
Screening of L-proline 61 concentration in the synthesis of 60 
 
 
 
 
 
 
A 100 µL aliquot of a 200 µM glyoxyl myoglobin 13 stock (prepared as described 
earlier) in MQ H2O was charged with 65 µL or 50 µL 50 mM PB pH 7.5. The 
solution was then charged with 10 µL or 25 µL of a 200 mM L-proline 61 stock 
solution in 50 mM PB pH 7.5. The solution was then charged with 25 µL of a 200 
mM donor 51 stock solution in 50 mM PB pH 7.5 Following mixing by pipetting, 
the reaction was allowed to sit at 37 oC for 1 h, 2h, 4h, or 6h, without further 
agitation. Conversion to the anticipated aldol product 60 was judged by LC-MS. 
 
27 51 or 54 56 or 59 
1 mM 1 mM or 
10 mM 
61 
0.2 mM or 2 mM 
13 
51 
60 
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61 
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Screening catalysts and donors for the synthesis of aldol product 72 and 73 
 
 
 
 
 
A 12.5 µL aliquot of a 80 µM glyoxyl-thioredoxin 32 stock (prepared as described 
earlier) in 25 mM PB pH 7.5 was charged with 2.5 µL of a 200 mM L-proline 61 or 
proline tetrazole 70 stock solution in 25 mM PB pH 7.5. The solution was then 
charged with 1 µL of a 200 mM donor 51 or 10 mM donor 54 stock solution in 25 
mM PB pH 7.5, followed by addition of 5 µL of 25 mM PB pH 7.5. Following 
mixing by pipetting, the reaction was allowed to sit at 37 oC for 1 h without further 
agitation. Conversion to the anticipated aldol product 72 or 73 was judged by LC-
MS. 
Synthesis of fluorescently labelled thioredoxin 89 
 
  
 
 
 
 
 
A 25 µL aliquot of 80 µM glyoxyl-thioredoxin 32 stock prepared as described earlier 
in 25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline tetrazole 70 stock 
solution in 25 mM PB pH 7.5. The solution was then charged with 10 µL of a 4 mM 
fluorescent label 85 stock solution in 25 mM PB pH 7.5. Following mixing by 
32 
70 
85 89 
32 
61 or 70 
25 mM 
72 or 73 51 or 54 
50 µM 10 mM or 
500 µM 
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pipetting, the reaction was allowed to sit at 37 oC for 60 min without further 
agitation. Quantitative labelling to fluorescently labelled thioredoxin 89 was 
confirmed by LC-MS analysis. 
Synthesis of biotinylated thioredoxin 94 
  
 
 
 
 
 
A 25 µL aliquot of 80 µM glyoxyl-thioredoxin 32 stock (prepared as described 
earlier) in 25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline tetrazole 
70 stock solution in 25 mM PB pH 7.5. The solution was then charged with 10 µL of 
a 4 mM biotin affinity tag 86 stock solution in 25 mM PB pH 7.5. Following mixing 
by pipetting, the reaction was allowed to sit at 37 oC for 60 min without further 
agitation. Quantitative labelling to biotinylated thioredoxin 94 was confirmed by LC-
MS analysis. 
Synthesis of azide labelled thioredoxin 90 
 
 
 
 
 
 
A 25 µL aliquot of 80 µM glyoxyl-thioredoxin 32 stock (prepared as described 
earlier) in 25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline tetrazole 
32 
70 
86 
94 
32 
70 
87 
90 
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70 stock solution in 25 mM PB pH 7.5. The solution was then charged with 10 µL of 
a 4 mM bioorthogonal azide handle 87 stock solution in 25 mM PB pH 7.5. 
Following mixing by pipetting, the reaction was allowed to sit at 37 oC for 60 min 
without further agitation. Quantitative labelling to azide labelled thioredoxin 90 was 
confirmed by LC-MS analysis. 
 Synthesis of fluorescently labelled myoglobin 93 
 
 
 
 
 
A 25 µL aliquot of 200 µM glyoxyl-myoglobin 13 stock (prepared as described 
earlier) in 25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline tetrazole 
70 stock solution in 25 mM PB pH 7.5. The solution was then charged with 10 µL of 
a 4 mM fluorescent label 85 stock solution in 25 mM PB pH 7.5. Following mixing 
by pipetting, the reaction was allowed to sit at 37 oC for 60 min without further 
agitation. Quantitative labelling to fluorescently labelled myoglobin 93 was 
confirmed by LC-MS analysis. 
Synthesis of folate labelled GFP (Y39CycloOctK) 96 
 
 
 
 
 
A 25 µL aliquot of 100 µM glyoxyl-GFP 34 stock (prepared as described earlier) in 
25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline tetrazole 70 stock 
solution in 25 mM PB pH 7.5. The solution was then charged with 10 µL of a 5 mM 
13 
70 
85 
93 
34 
70 
88 
96 
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folate targeting moiety 88 stock solution in 25 mM PB pH 7.5. Following mixing by 
pipetting, the reaction was allowed to sit at 37 oC for 60 min without further 
agitation. Quantitative labelling to folate labelled GFP 96 confirmed by ESI-MS 
analysis. 
Synthesis of biotinylated GFP 92  
 
 
 
 
 
 
 
A 25 µL aliquot of 100 µM glyoxyl-GFP (Y39CycloOctK) 34 stock (prepared as 
described earlier) in 25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline 
tetrazole 70 stock solution in 25 mM PB pH 7.5. The solution was then charged with 
10 µL of a 2 mM biotin affinity tag 86 stock solution in 25 mM PB pH 7.5. 
Following mixing by pipetting, the reaction was allowed to sit at 37 oC for 60 min 
without further agitation. Quantitative labelling to biotinylated GFP 92 was 
confirmed by ESI-MS analysis. 
Synthesis of internally azide labelled sfGFP 99 
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A 25 µL aliquot of 160 µM sfGFP(ThzK150Oxo) 41 (prepared as described earlier) 
in 25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline tetrazole 70 stock 
solution in 25 mM PB pH 7.5. The solution was then charged with 10 µL of a 5 mM 
bioorthogonal azide handle 87 stock solution in 25 mM PB pH 7.5. Following 
mixing by pipetting, the reaction was allowed to sit at 37 oC for 60 min without 
further agitation. Quantitative labelling to internally azide labelled sfGFP 99 was 
confirmed by ESI-MS analysis 
Synthesis of internally azide labelled GFP 100 
 
 
 
 
 
 
A 25 µL aliquot of 240 µM GFP(ThzK39Oxo) 42 (prepared as described earlier) in 
25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline tetrazole 70 stock 
solution in 25 mM PB pH 7.5. The solution was then charged with 10 µL of a 5 mM 
bioorthogonal azide handle 87 stock solution in 25 mM PB pH 7.5. Following 
mixing by pipetting, the reaction was allowed to sit at 37 oC for 60 min without 
further agitation. Quantitative labelling to internally azide labelled GFP 100 was 
confirmed by ESI-MS analysis 
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Synthesis of azide labelled HASPA 95 
 
 
 
 
 
 
 
A 25 µL aliquot of 400 µM glyoxyl-HASPAG1S 36 (prepared as described earlier) 
in 25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline tetrazole 70 stock 
solution in 25 mM PB pH 7.5. The solution was then charged with 10 µL of a 5 mM 
bioorthogonal azide handle 87 stock solution in 25 mM PB pH 7.5. Following 
mixing by pipetting, the reaction was allowed to sit at 37 oC for 60 min without 
further agitation. Quantitative labelling to azide labelled HASPA S57 was confirmed 
by LC-MS analysis. 
Fluorescent labelling of glyoxyl-CTB 30 
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A 25 µL aliquot of 400 µM [15N]HASPA(G1S) 36-15N (prepared as described 
earlier) in 25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline tetrazole 
70 stock solution in 25 mM PB pH 7.5. The solution was then charged with 10 µL of 
a 2 mM fluorescent label 85 stock solution in 25 mM PB pH 7.5. Following mixing 
by pipetting, the reaction was allowed to sit at 37 oC for 60 min without further 
agitation. Quantitative labelling to fluorescently labelled [15N]HASPA 91-15N was 
confirmed by LC-MS analysis. 
 
 
Synthesis of biotinylated myoglobin 97 
 
 
 
 
 
 
 
 
A 25 µL aliquot of 200 µM glyoxyl-myoglobin 5 stock (prepared as described 
earlier) in 25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline tetrazole 9 
stock solution in 25 mM PB pH 7.5. The solution was then charged with 10 µL of a 
4 mM biotin affinity tag 12 stock solution in 25 mM PB pH 7.5. Following mixing 
by pipetting, the reaction was allowed to sit at 37 oC for 60 min without further 
agitation. Quantitative labelling to biotinylated myoglobin S58 was confirmed by 
LC-MS analysis. Structural integrity of the myoglobin protein was determined by 
UV/Vis analysis. 
 
13 
70 
86 
97 
229 
 
 
 
Synthesis of azide labelled myoglobin 116 
 
 
 
 
 
 
 
A 25 µL aliquot of 200 µM glyoxyl-myoglobin 13 stock (prepared as described 
earlier) in 25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline tetrazole 
70 stock solution in 25 mM PB pH 7.5. The solution was then charged with 10 µL of 
a 4 mM bioorthogonal azide handle 87 stock solution in 25 mM PB pH 7.5. 
Following mixing by pipetting, the reaction was allowed to sit at 37 oC for 60 min 
without further agitation. Quantitative labelling to azide labelled myoglobin 116 was 
confirmed by LC-MS analysis. 
Synthesis of fluorescently labelled [15N] HASPA 91 
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A 25 µL aliquot of 400 µM [15N]HASPA(G1S) 36-15N (prepared as described 
earlier) in 25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline tetrazole 
70 stock solution in 25 mM PB pH 7.5. The solution was then charged with 10 µL of 
a 2 mM fluorescent label 85 stock solution in 25 mM PB pH 7.5. Following mixing 
by pipetting, the reaction was allowed to sit at 37 oC for 60 min without further 
agitation. Quantitative labelling to fluorescently labelled [15N]HASPA 91-15N was 
confirmed by LC-MS analysis. 
Synthesis of internally biotinylated sfGFP 101 
 
 
 
 
 
 
 
A 25 µL aliquot of 160 µM sfGFP(150GlyoxylK) 41 (prepared as described earlier) 
in 25 mM PB pH 7.5 was charged with 5 µL of a 200 mM proline tetrazole 70 stock 
solution in 25 mM PB pH 7.5. The solution was then charged with 10 µL of a 5 mM 
biotin affinity tag 86 stock solution in 25 mM PB pH 7.5. Following mixing by 
pipetting, the reaction was allowed to sit at 37 oC for 60 min without further 
agitation. Quantitative labelling to internally biotinylated sfGFP 101 was confirmed 
by ESI-MS analysis 
Site-selective biotinylation of GFP in cell lysate and subsequent protein 
pulldown 
A 10 mL culture of cells expressing GFP(Y39ThzK) 40 (prepared as described 
previously 116) was harvested by centrifugation. The resulting cell pellets were 
resuspended in 1.25 mL of 4 x PBS and lysed by sonication on ice for 9 x 30s with 
30 s intervals. The cell lysate was clarified by centrifugation (17000 x g, 4 oC, 15 
41 
70 
86 
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min), and the pelleted, insoluble matter was discarded. The supernatant was retained, 
and both the concentration and content of GFP 40 was determined by UV/Vis 
absorbance measured at 488 nm assuming a molar extinction coefficient of ε = 
55,000 M-1 cm-1 for GFP (GFP concn = 0.643 mg mL-1, GFP content = 803 µg). A 1 
mL sample of the supernatant was then carried forward for palladium-mediated 
decaging (GFP concn = 0.643 mg mL-1, GFP content = 0.643 µg). Ten 100 µL 
aliquots of cell lysate were charged with 1 µL of a 30 mM allylpalladium(II) 
chloride dimer stock solution in DMSO (final concn = 300 µM). Following mixing 
by pipetting, the reactions were allowed to sit at 25 oC for 1 h without further 
agitation. The reactions were then quenched by addition of 10 µL of a 3-
mercaptopropanoic acid solution, 1% v/v solution, 10 x PBS (final concn = 0.1% v/v) 
to each aliquot, and allowed to sit at 25 oC for 15 min without further agitation. The 
reactions were pooled, desalted using PD MiniTrap G-25 columns (GE Healthcare 
Life Sciences), eluting with 25 mM PB pH 7.5, and concentrated to 180 µL using 
10,000 MWCOs (Amicon Ultra-0.5 mL Centrifugal Filters) to give the ‘post-
decaged’ lysate containing GFP(ThzK39Oxo) S14 (GFP concn = 2.5 mg mL-1, GFP 
content = 451 µg, protein recovery from initial supernatant sample used= 70%). A 
125 µL aliquot of ‘post-decaged’ lysate (GFP concn = 2.5 mg mL-1, GFP content = 
313 µg) was then carried forward for site-selective biotinylation. Five 25 µL aliquots 
of ‘post-decaged’ lysate in 25 mM PB pH 7.5 were charged with 5 µL of a 200 mM 
proline tetrazole 9 stock solution in 25 mM PB pH 7.5. The five solutions were then 
charged with 10 µL of a 5 mM biotin affinity tag 12 stock solution in 25 mM PB pH 
7.5. Following mixing by pipetting, the reactions were allowed to sit at 37 oC for 60 
min without further agitation. Excess affinity tag 12 was removed via spin 
concentration using 10,000 MWCOs (Amicon Ultra-0.5 mL Centrifugal Filters) to 
give 100 µL of the ‘post-OPAL’ lysate containing internally biotinylated GFP S16 
(GFP concn =1.73 mL-1, GFP content = 173 µg, protein recovery from ‘post-
decaged’ lysate sample used = 55%). A ‘post-OPAL’ lysate sample containing a 5 
µg GFP content was retained for SDS-PAGE analysis. The remaining ‘post-OPAL’ 
lysate (GFP content = 168 µg) was loaded onto a 2 mL monomeric avidin agarose 
column (prepared in house using Pierce™ Monomeric Avidin Agarose according to 
the user guide provided, ThermoFisher Scientific), washed with 1 x PBS pH 7.4, and 
eluted using 2 mM biotin in 1 x PBS pH 7.4, collecting 1 mL fractions, according to 
the user guide provided. In total, one 2 mL fraction of flowthrough was collected 
232 
 
 
 
(Fraction FT), six fractions of 2 mL washes with 1 x PBS were collected (Fractions 
1-6), and 14 fractions of 1 mL washes with 2 mM biotin in 1 x PBS pH 7.4 were 
collected (Fractions 7-20). Fractions were first visualised for protein fluorescence 
using a Syngene G:BOX Chemi XRQ equipped with a Synoptics 4.0 MP camera in 
line with GeneSys software (Version 1.5.7.0), and fractions of interest were 
subsequently analysed via SDS-PAGE. Fractions 1, 7, 8, 9, 10, 11, 12, 13, and 14, 
were also analysed by UV/Vis absorbance measured at 488 nm for GFP content. 
Fraction 1 was determined to contain 40 µg total GFP content, whereas fractions 7, 
8, 9, 10, 11, 12, 13, and 14, were determined to contain 123 µg total GFP content, 
leaving 5 µg of 168 µg ‘post-OPAL’ GFP material unaccounted for. Overall, the 
pooled fractions 7-14 resulted in a 73% recovery of internally biotinylated GFP 102 
that was originally loaded onto the monomeric avidin agarose column. 
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Synthesis of aldol-oxime-LYRAG 106 
 
 
 
 
 
 
A 20 µL aliquot of a 5 mM aldol-modified-LYRAG 59 stock in MQ H2O was 
charged with 879 µL of 0.1 M NaOAc, pH 4.5. The solution was then charged with 1 
µL of O-benzylhydroxylamine 103. The reaction was vortexed, and incubated 37 oC 
overnight without further agitation. Successful conversion to dually modified peptide 
106 was confirmed by LC-MS analysis. 
Synthesis of aldol-iso-Pictet-Spengler-LYRAG 107 
 
 
 
 
 
 
 
 
A 20 µL aliquot of an aldol-modified-LYRAG 59 stock in MQ H2O was charged 
with 780 µL of 0.1 M NaOAc. The solution was then charged with 200 µL of a 50 
mM indole 104 stock solution in DMSO. The reaction was vortexed, and incubated 
59 
106 
59 
104 
107 
103 
0.1 mM 
10 mM 
0.1 mM 
10 mM 
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37 oC overnight without further agitation. Successful conversion to dually modified 
peptide 107 was confirmed by LC-MS analysis.  
Synthesis of aldol-ABAO-LYRAG 108 
 
 
 
 
 
 
A 20 µL aliquot of a 5 mM aldol-modified-LYRAG 59 stock in MQ H2O was 
charged with 780 µL of 0.1 M NaOAc, pH 4.5. The solution was then charged with 
100 µL of ABAO 105 stock solution in DMSO. The reaction was vortexed, and 
incubated 37 oC overnight without further agitation. Successful conversion to dually 
modified peptide 108 was confirmed by LC-MS analysis. 
Screening of aniline catalysts for oxime ligation 
 
 
 
 
 
 
 
A 10 µL aliquot of a 5 mM 56 or 59 stock in MQ H2O was charged with 879 µL of 
0.2 M NaOAc, pH 4.5, or with 879 µL of 0.2 M PB pH 7.5. The solution was then 
charged with 1 µL of O-benzylhydroxylamine 103, and then charged with 100 µL of 
59 
105 
108 
56 or 59 
106 or 109 103 
18, 46, 110, 111 
0.1 mM 
10 mM 
0.1 mM 
10 mM 
100 mM 
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1M aniline catalyst in DMSO. The reaction was vortexed, and incubated 37 oC 
overnight without further agitation. Successful conversion to dually modified peptide 
106 or 109 was confirmed by LC-MS analysis. 
Screening effects of pH on aniline catalysed oxime ligation of 60 
 
 
 
 
 
 
 
A 100 µL aliquot of aldol-modified myoglobin 60 (prepared as described earlier) in 
0.2 NaOAc pH 4.5, or in 0.2 M PB pH 7.5, containing 100 mM aniline 46, was 
charged with 100 µL a 20 mM aminooxy 101 stock solution in 0.2 M NaOAc pH 
4.5, or in 0.2 M PB pH 7.5. Following mixing by pipetting, the reaction was allowed 
to sit at 37 oC for 18 h without further agitation. Conversion to the dually modified 
product 101 was assessed by LC-MS analysis. 
Synthesis of fluorescently labelled, biotinylated thioredoxin 119 
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A 120 µL aliquot of fluorescently labelled thioredoxin 89 (prepared as described 
previously) was desalted using a PD SpinTrap G-25 column (GE Healthcare Life 
Sciences), eluting with 5 mM PB pH 7.5. A 10 µL aliquot of desalted protein was 
then charged with 3.8 µL of 0.2 M PB pH 7.5, and 4.8 µL of MQ H2O. The solution 
was then charged with 1.2 µL of a 250 mM aminooxy biotin 117 stock solution in 50 
mM PB pH 7.5 (pH adjusted to pH 7.5 using 2M NaOH), and then charged with 0.2 
µL of a 1M p-anisidine 18 stock solution in DMSO. Following mixing by pipetting, 
the reaction was allowed to sit at 37 oC for 42 h without further agitation. Successful 
conversion to dually modified protein 119 was confirmed by LC-MS.  
Synthesis of azide labelled, biotinylated thioredoxin 120 
 
 
 
 
 
 
A 120 µL aliquot of 50 µM azide labelled thioredoxin 90 (prepared as described 
previously) was desalted using a PD SpinTrap G-25 column (GE Healthcare Life 
Sciences), eluting with 5 mM PB pH 7.5. A 10 µL aliquot of desalted protein was 
then charged with 3.8 µL of 0.2 M PB pH 7.5, and 4.8 µL of MQ H2O. The solution 
was then charged with 1.2 µL of a 250 mM aminooxy biotin stock 117 solution in 50 
mM PB pH 7.5 (pH adjusted to pH 7.5 using 2M NaOH), and then charged with 0.2 
µL of a 1M p-anisidine 18 stock solution in DMSO. Following mixing by pipetting, 
the reaction was allowed to sit at 37 oC for 18 h without further agitation. Successful 
conversion to dually modified protein 120 was confirmed by Western Blot. 
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Synthesis of fluorescently labelled, PEGylated myoglobin 26 
 
 
 
 
 
 
A 120 µL aliquot of 100 µM fluorescently labelled myoglobin 93 (prepared as 
described previously) was desalted using a PD SpinTrap G-25 column (GE 
Healthcare Life Sciences), eluting with 5 mM PB pH 7.5. A 10 µL aliquot of 
desalted protein was then charged with 3.8 µL of 0.2 M PB pH 7.5, and 4.8 µL of 
MQ H2O. The solution was then charged with 1.2 µL of a 250 mM aminooxy PEG 
2K 121 stock solution in 50 mM PB pH 7.5 (pH adjusted to pH 7.5 using 2M HCl), 
and then charged with 0.2 µL of a 1 M p-anisidine 18 stock solution in DMSO. 
Following mixing by pipetting, the reaction was allowed to sit at 37 oC for 18 h 
without further agitation. Successful labelling to give dually modified protein 122 
was confirmed SDS PAGE analysis. 
Synthesis of azide labelled, biotinylated myoglobin 118 
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A 120 µL aliquot of 100 µM azide labelled myoglobin 116 (prepared as described 
previously) was desalted using a PD SpinTrap G-25 column (GE Healthcare Life 
Sciences), eluting with 5 mM PB pH 7.5. A 10 µL aliquot of desalted protein was 
then charged with 3.8 µL of 0.2 M PB pH 7.5, and 4.8 µL of MQ H2O. The solution 
was then charged with 1.2 µL of a 250 mM aminooxy biotin stock 117 solution in 50 
mM PB pH 7.5 (pH adjusted to pH 7.5 using 2M HCl), and then charged with 0.2 µL 
of a 1 M p-anisidine 21 stock solution in DMSO. Following mixing by pipetting, the 
reaction was allowed to sit at 37 oC for 18 h without further agitation. Successful 
coversion to give dually modified protein 118 was confirmed by LC-MS analysis. 
 
Chemical myristoylation of HASPA 
 
 
 
 
 
 
 
 
A 17 µL aliquot of 500 µM glyoxyl-HASPA 36 stock (prepared as described earlier) 
in 25 mM PB pH 7.5 was charged with 1 µL of a 1.5 M L-proline 61 stock solution 
in 25 mM PB pH 7.5. The solution was then charged with 6 µL of DMSO, and then 
charged with 36 µL of a 25 mM tetradecanal 126 stock solution in DMSO. 
Following mixing by pipetting, the reaction was incubated at 37 oC overnight 
without further agitation. Quantitative labelling to chemically myristoylated HASPA 
127 was confirmed by LC-MS analysis (note elimination of β-hydroxyl to afford 
enone of 127 is also observed). Samples were then diluted to >20% DMSO content, 
36 
61 
126 127 
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purified via PD MiniTrap G-25 columns (GE Healthcare Life Sciences), eluting MQ 
H2O, and subsequently lyophilised to give a white powder (stored at -80 
oC). 
Chemical myristoylation of 15N labelled HASPA 
Chemical myristoylation of glyoxyl-[15N]HASPA(G1S) 36-15N was identical to 
that of chemical myristoylation of unlabelled  glyoxyl-HASPA 36. 
Synthesis of dually acylated HASPA 33 
 
 
 
 
 
 
Prior to dual modification, samples of chemically myristoylated HASPA 127 
(prepared as described earlier) were pooled to give an estimated maximum protein 
content of 160 µg (based on initial HASPA protein concentration). The pooled 
samples were diluted to >20% DMSO content, purified via PD MiniTrap G-25 
columns (eluting into water), and subsequently lyophilised to give a white powder 
that was stored at -80 oC until required. For the dual acylation of HASPA, the 
lyophilised aliquot of chemically myristoylated HASPA 127 was resuspended in 1 x 
PBS buffer (120 µL, pH 7.4), and then buffered exchanged using a PD SpinTrap G-
25 column (GE Healthcare Life Sciences, eluting into 25 mM PB pH 6.5). The 
solution was then charged with 280 µL of 25 mM palmitoyl aminooxy 128 in EtOH, 
and then charged with 3.6 µL of aniline 46. The solution was briefly vortexed, and 
the reaction was allowed to sit at 37 oC for 96 h without further agitation. After 96h 
successful conversion to 129 was achieved as judged by LC-MS. 
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Screening of aniline catalysts for retro-aldol activity on peptides 
 
 
 
 
 
A 10 µL aliquot of a 5 mM stock of aldol-modified-LYRAG 59 in 0.2 M NaOAc pH 
4.5 or in 0.2 M PB pH 7.5 was charged with 440 µL of 0.2 M NaOAc pH 4.5 or 440 
µL of 0.2 M PB pH 7.5. The solution was then charged with 50 µL of a 1M stock 
solution of aniline catalyst 18, 46, 110, or 111 in DMSO. The reaction was vortexed, 
and incubated at 37 oC overnight without further agitation. Successful conversion to 
glyoxyl-LYRAG 27 was judged by LC-MS analysis. 
 
Screening of buffer concentration and the retro aldol activity on peptides 
 
 
 
 
 
 
A 1 µL aliquot of a 5 mM stock of aldol-modified-LYRAG 59 in H2O was charged 
with a volume 0.2 M PB pH 7.5 and a volume of H2O, followed by addition of 5 µL 
of a 1 M stock solution of p-anisidine 18, in such a manner that the final 
concentration of PB was 10 mM, 50 mM, or 100 mM. The reactions were vortexed, 
and incubated at 37 oC overnight without further agitation. Successful conversion to 
glyoxyl-LYRAG 27 was judged by LC-MS analysis. 
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Screening of aniline catalyst for retro-aldol activity on proteins 
 
 
 
 
 
A 12.5 µL aliquot of fluorescently labelled thioredoxin 93 in 0.2 M PB pH 7.5 was 
charged with 10 µL 0.2 M PB pH 7.5, followed by addition of 5 µL of a 1M stock 
solution of aniline catalyst 18, 46, 110, or 111 in DMSO. Following mixing by 
pipetting, the reaction was incubated at 37 oC for 18 h (or 42 h) without further 
agitation. Successful conversion to glyoxyl-thioredoxin 32 was judged by LC-MS 
analysis. 
Synthesis of modified mannich product 136 
 
 
 
 
 
 
A 200 µL aliquot of a 5 mM stock of glyoxyl-VARLG 132 was charged with 500 µL 
of 0.2 M PB pH 6.5, followed by addition of 250 µL of H2O. The solution was then 
charged with 10 µL of DMSO, followed by addition of 20 µL of a 1 M solution of 
aniline 133 in DMSO and 20 µL of a 1 M solution of phenol 134 in DMSO. The 
reaction was vortexed, and incubated at 37 oC for 24 h without further agitation. 
Modification of glyoxyl-VARLG 132 was assessed by LC-MS analysis. 
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Synthesis of modified mannich product 137 
 
 
 
 
 
 
A 200 µL aliquot of a 5 mM stock of glyoxyl-VARLG 132 in MQ H2O was charged 
with 500 µL of 0.2 M PB pH 6.5, followed by addition of 250 µL of H2O. The 
solution was then charged with 10 µL of DMSO, followed by addition of 20 µL of a 
1 M solution of aniline 133 in DMSO and 20 µL of a 1 M solution of phenol 135 in 
DMSO. The reaction was vortexed, and incubated at 37 oC for 24 h without further 
agitation. Modification of glyoxyl-VARLG 132 was assessed by LC-MS analysis 
Initial experiments towards a catalyst free aldol ligation 
 
 
 
 
 
A 200 µL aliquot of a 5 mM stock of glyoxyl-VARLG 132 in MQ H2Owas charged 
with 500 µL of 0.2 M PB pH 6.5, followed by addition of 250 µL of H2O. The 
solution was then charged with a volume of DMSO followed by addition of a 
volume of of a 1 M solution of phenol 135 in DMSO, in such a manner that the final 
concentration of 135 was 1 mM, 5 mM, or 10 mM. The reaction was vortexed, and 
incubated at 37 oC for 24 h without further agitation. Modification of glyoxyl-
VARLG 132 was assessed by LC-MS analysis. 
132 
133 
135 137 
132 
1 mM 
20 mM 
20 mM 
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Screening of pH in the modified Mannich bioconjugation protocol 
 
 
 
 
 
 
A 200 µL aliquot of a 5 mM stock of glyoxyl-VARLG 132 in MQ H2O was charged 
with 500 µL of 0. 2 M NaOAc pH 4.5, or with 250 µL of 0.2M PB pH 7.5, followed 
by addition of 250 µL of H2O. The solution was then charged with 25 µL of DMSO, 
followed by addition of 20 µL of a 1 M solution of aniline 133 in DMSO and 5 µL 
of a 1 M solution of phenol 135 in DMSO. The reaction was vortexed, and incubated 
at 37 oC for 24 h without further agitation. Modification of glyoxyl-VARLG 132 was 
assessed by LC-MS analysis.  
Screening of pH in the phenol-mediated ligation 
 
 
 
 
 
A 200 µL aliquot of a 5 mM stock of glyoxyl-VARLG 132 in MQ H2O was charged 
with 500 µL of 0.2 M NaOAc pH 4.5, or with 500 µL of 0.2M PB pH 7.5, followed 
by addition of 250 µL of H2O. The solution was then charged with 45 µL of DMSO, 
followed by addition of 5 µL of a 1 M solution of phenol 135 in DMSO. The 
reaction was vortexed, and incubated at 37 oC for 24 h without further agitation. 
Modification of glyoxyl-VARLG 132 was assessed by LC-MS analysis 
132 
135 
133 
132 
135 
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Screening aromatic compounds for modification of α-oxo aldehydes 
 
 
 
A 200 µL aliquot of a 5 mM stock of glyoxyl-VARLG 132 in MQ H2O was charged 
with 500 µL of 0.2 M NaOAc pH 4.5, or with 500 µL of 0.2M PB pH 7.5, followed 
by addition of 250 µL of H2O. The solution was then charged with 45 µL of DMSO, 
followed by addition of 5 µL of a 1 M solution of phenol in DMSO. The reaction 
was vortexed, and incubated at 37 oC for 24 h without further agitation. Modification 
of glyoxyl-VARLG 132 was assessed by LC-MS analysis. 
Synthesis of anticipated PHILIPA product 148 
 
 
 
 
 
 
A 5 µL aliquot of 600 µM glyoxyl-myoglobin 13 stock (prepared as described 
earlier) in H2O was charged with 20 µL of 0.2 M PB pH 7.5. The solution was then 
charged with 3.8 µL of DMSO, followed by addition of 200 mM phenol 135 stock 
solution in 25 DMSO. Following mixing by pipetting, the reaction was allowed to sit 
at 37 oC for 60 min without further agitation. Conversion to the hypothesised phenol 
product 148 was assessed by LC-MS analysis. 
 
  
139/140/141/142/143/144 
132 
13 148 
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Mass spectrometry data of modified peptides 
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Calculated [M+H]+ = 666.36 
Found [M+ H]+ = 666.32 
Glyoxyl-LYRAG 27 
Calculated [M+H]+ = 635.31 (ald), 653.32 (hyd) 
Found [M+ H]+ = 635.41 (ald), 653.44 (hyd) 
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Aldol-LYRAG 45 
Calculated [M+H]+ = 679.33 
Found [M+ H]+ = 679.32 
Aldol-Oxime-LYRAG 48 
Calculated [M+H]+ = 752.36 
Found [M+ H]+ = 752.34 
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Aldol-LYRAG 56 
Calculated [M+H]+ = 707.36 
Found [M+ H]+ = 707.26 
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Aldol-LYRAG 55 
Calculated [M+H]+ = 693.35 
Found [M+ H]+ = 693.38 
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Aldol-LYRAG 57 
Calculated [M+H]+ = 707.36 
Found [M+ H]+ = 707.39 
Aldol-LYRAG 58 
Calculated [M+H]+ = 735.340 
Found [M+ H]+ = 735.45 
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Aldol-LYRAG 59 
Calculated [M+H]+ = 755.36 
Found [M+ H]+ = 755.39 
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Aldol-Oxime-LYRAG 106 
Calculated [M+H]+ = 860.42 
Found [M+ H]+ = 860.57 
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Aldol-IPS 107 
Calculated [M+H]+ = 985.47 
Found [M+ H]+ = 985.45 
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Aldol-ABAO 108 
Calculated [M+H]+ = 888.43 
Found [M+ H]+ = 888.44 
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Aldol-Oxime-LYRAG 109 
Calculated [M+H]+ = 812.42 
Found [M+ H]+ = 812.40 
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Myristoylated-LYRAG 130 
Calculated [M+H]+ = 847.52 
Found [M+ H]+ = 847.72 
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SVARLG 151 
Calculated [M+H]+ = 602.35 
Found [M+ H]+ = 602.26 
Glyoxyl-VARLG 132 
Calculated [M+H]+ = 571.31 (ald), 589.32 (hyd) 
Found [M+ H]+ = 571.32 (ald), 589.33 (hyd) 
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Mannich product 136 
Calculated [M+H]+ = 814.44 
Found [M+ H]+ = 814.52 
Mannich product 137 
Calculated [M+H]+ = 844.45 
Found [M+ H]+ = 844.49 
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Phenol product 138 
Calculated [M+H]+ =725.38 
Found [M+ H]+ = 725.49 
Phenol product 145 
Calculated [M+H]+ =681.35 
Found [M+ H]+ = 681.52 
Possible 
products 
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Phenol product 146 
Calculated [M+H]+ =693.39 
Found [M+ H]+ = 693.56 
Phenol product 147 
Calculated [M+H]+ =725.34 
Found [M+ H]+ = 725.46 
Possible 
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Mass spectrometry data of proteins and modified proteins 
Horse Heart Myoglobin 28 
 
 
 
 
 
 
 
 
 
 
 
 
 Glyoxyl-myoglobin 13 
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Calculated: 16968 Da (Hydrate)
Found: 16968 Da (Hydrate)
Peak at 16951 Da can refer to either 
myoglobin or glyoxyl-myoglobin (aldehyde)
Peak at 17170 Da is an unknown, PLP related 
byproduct
m/z
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Glyoxyl-CTB 30 
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Thioredoxin 31 
 
 
 
 
 
 
 
 
 
 
 
 
Glyoxyl-thioredoxin 32 
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Calculated: 11675 Da
Found: 11677 Da
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Calculated: 11661 Da (Hydrate)
Found: 11662 Da (Hydrate)
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Peak at 11644 refers to glyoxyl-
thioredoxin (aldehyde) 
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Calculated: 28669 Da
Found: 28677 Da
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Glyoxyl-GFP 34 
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Calculated: 28656 Da (Hydrate)
Found: 28655 Da (Hydrate)
m/z
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Hydrophilic acylated surface protein A (HASPA) 35 
 
 
 
 
 
 
 
 
 
 
 
HASPA(G1S) 37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
592
16+
631
15+
676
14+
728
13+
788
12+
860
11+
946
10+
1051
9+
1182
8+
+MS
0
20
40
60
80
100
Intens.
[%]
400 600 800 1000 1200 1400 m/z
9449
1+
+MS, Deconvoluted
0
200
400
600
800
Intens.
[%]
8000 9000 10000 11000 12000 13000 m/z
100
0
In
te
n
s
it
y
 (
%
)
m/z
m/z
9449
1+
9491
1+
+MS, Deconvoluted
0
2
4
6
7x10
Intens.
9100 9200 9300 9400 9500 9600 9700 9800 9900 m/z
Calculated: 9445 Da
Found: 9449 Da
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Calculated: 9475 Da
Found: 9477 Da
m/z
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Glyoxyl-HASPA 36 (generated from NaIO4 oxidation of 37) 
 
 
 
 
 
 
 
 
 
 
 
 
[15N]HASPA(G1S) 37-15N 
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Calculated: 9462 Da (Hydrate)
Found: 9464 Da (Hydrate)
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Calculated: 9606 Da
Found: 9607 Da
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Calculated: 27957 Da
Found: 27957 Da
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Glyoxyl-[15N]HASPA S36-15N (generated from NaIO4 oxidation of 37-15N) 
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Calculated: 9593 Da (Hydrate)
Found: 9593 Da (Hydrate)
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sfGFP(N150GlyoxylK) 41 
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Calculated: 27916 Da (Hydrate)
Found: 27916 Da (Hydrate)
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Calculated: 28631 Da
Found: 28633 Da
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GFP(Y39GlyoxylK) 42 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aldol-myolglobin 60 
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Calculated: 17022 Da
Found: 17023 Da
Peak at 17170 Da is an 
unknown, PLP related byproduct
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Calculated: 28572 Da (Ald)
Found: 28574 Da (Ald)
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Calculated: 12393Da
Found: 12395 Da
Fluroescently tagged thioredoxin 89 
 
 
 
 
 
 
 
 
 
 
 
 
Biotin tagged thioredoxin 94 
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Calculated: 12401 Da
Found: 12401 Da
m/z
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Calculated: 17708 Da
Found: 17711 Da
m/z
Azide tagged thioredoxin 90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fluorescently labelled myoglobin 93 
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Calculated: 12311 Da
Found: 12314 Da
m/z
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Calculated: 12357 Da
Found: 12358 Da
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Azide tagged myoglobin 116 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fluorescently labelled CTB 98 
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Calculated: 17617 Da
Found: 17617 Da
Peak at 17169 Da is an unknown, 
PLP related byproduct
m/z
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Biotin tagged GFP 92 
 
 
 
 
 
 
 
 
 
 
 
 
 Folate tagged GFP (Y39CycloOctK) 96  
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Found: 29731 Da
Peak at 1093 Da corresponds to 
unreacted probe that is present after 
SpinTrap purification. Consider further 
methods of purification if purer 
protein samples are required for 
downstream use.
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Calculated: 29388 Da
Found: 29388 Da
m/z
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Calculated: 29240 Da 
Found: 29242 Da 
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Internal (position 150) azide labelled sfGFP 99 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal (position 39) azide labelled GFP 100 
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Calculated: 28566 Da
Found: 28563 Da
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Chemically myristoylated HASPA(G1S) 127  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemically myristoylated [15N]HASPA(G1S) 127-15N 
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Calculated: 9656 Da
Found: 9657 Da
m/z
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Calculated: 9787 Da
Found: 9786 Da
m/z
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Azide tagged HASPA(G1S) 95 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fluorescently tagged [15N]HASPA(G1S) 91-15N 
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Calculated: 10111 Da
Found: 10113 Da
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Calculated: 10333 Da
Found: 10333 Da
m/z
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Internal (position 150) biotinylated sfGFP 102 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fluorescently labelled, biotinylated thioredoxin 119 
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Calculated: 12817 Da
Found: 12818 Da
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Calculated: 28649 Da
Found: 28650 Da
m/z
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Azide labelled, biotinylated myoglobin 118 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dually acylated HASPA 129 
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Calculated: 9895 Da
Found: 9898 Da
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Calculated: 18035 Da
Found: 18038 Da
Peak at 17174 Da is an 
unknown, PLP related byproduct
N3
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PHILIPA myoglobin product 148 
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Calculated: 17014 Da
Found: 17018 Da
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Kinetic data for OPAL 
Donor 
Organo 
catalyst 
Organocatalyst 
loading (mM) 
Rate Constant 
(M-1 s-1) 
Error of Rate Constant 
(M-1s-1) 
51 
61 
1 0.0009 0.00006 
10 0.0033 0.0001 
25 0.0100 0.0006 
63 
1 0.0005 0.00003 
10 0.0037 0.0002 
25 0.0058 0.0005 
64 
1 >0.00001 - 
10 0.0009 0.00006 
25 0.0016 0.00016 
65 
1 0.0010 0.00008 
10 0.0062 0.0006 
25 0.0108 0.00115 
66 
1 0.0097 0.000788 
10 0.0581 0.00512 
25 0.0942 0.0108 
67 
1 0.0004 0.00003 
10 0.0024 0.00008 
25 0.0052 0.00008 
68 
1 0.0006 0.000063 
10 0.0030 0.0003 
25 0.0057 0.0006 
69 
1 0.0022 0.00015 
10 0.0166 0.0012 
25 0.0252 0.0035 
70 
1 0.0092 0.001 
10 0.0551 0.004 
25 0.0977 0.009 
71 
1 0.0009 0.0002 
10 0.0049 0.00066 
25 0.0103 0.00121 
54 
61 
1 1.6840 0.106 
10 4.6620 0.219 
25 7.8990 0.579 
70 
1 3.7920 0.294 
10 11.8200 1.18 
25 23.9470 1.98 
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k2 = 0.0009 M-1 s-1 
R2 = 0.98 
 
k2 = 0.0033 M-1 s-1 
R2 = 0.98 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 1 mM 
of catalyst 61. 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 10 mM 
of catalyst 61. 
51 
27 
61 
56 
51 
27 
61 
56 
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k2 = 0.0100 M-1 s-1 
R2 = 0.95 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 25 
mM of catalyst 61. 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 1 
mM of catalyst 63. 
k2 = 0.0005 M-1 s-1 
R2 = 0.98 
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Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 10 
mM of catalyst 63. 
k2 = 0.0037 M-1 s-1 
R2 = 0.98 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 25 
mM of catalyst 63. 
k2 = 0.0058 M-1 s-1 
R2 = 0.97 
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Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 1 mM 
of catalyst 64 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 10 mM 
of catalyst 64. 
 
k2 = 0.0009 M-1 s-1 
R2 = 0.98 
 
Experimentally determined k2 is extremely low ( >0.0001 M-1 s-1) 
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Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 25 
mM of catalyst 64. 
 
k2 = 0.0016 M-1 s-1 
R2 = 0.96 
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Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (50 mM) using 1 mM 
of catalyst 65. 
 
k2 = 0.0010 M-1 s-1 
R2 = 0.98 
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k2 = 0.0062 M-1 s-1 
R2 = 0.96 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (50 mM) using 10 mM 
of catalyst 65. 
 
k2 = 0.0108 M-1 s-1 
R2 = 0.96 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (50 mM) using 25 mM 
of catalyst 65. 
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Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (10 mM) using 1 mM 
of catalyst 66. 
 
k2 = 0.0097 M-1 s-1 
R2 = 0.97 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (10 mM) using 10 mM 
of catalyst 66. 
 
k2 = 0.0581 M-1 s-1 
R2 = 0.97 
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Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 1 
mM of catalyst 67. 
 
k2 = 0.0004 M-1 s-1 
R2 = 0.97 
 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (10 mM) using 25 mM 
of catalyst 66. 
 
k2 = 0.0942 M-1 s-1 
R2 = 0.95 
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Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 10 
mM of catalyst 67. 
 
k2 = 0.0024 M-1 s-1 
R2 = 0.99 
 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 25 
mM of catalyst 67. 
 
k2 = 0.0052 M-1 s-1 
R2 = 0.99 
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k2 = 0.0006 M-1 s-1 
R2 = 0.96 
 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 1 
mM of catalyst 68. 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 10 
mM of catalyst 68. 
 
k2 = 0.0030 M-1 s-1 
R2 = 0.96 
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 Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 1 mM 
of catalyst 69. 
 
k2 = 0.0022 M-1 s-1 
R2 = 0.98 
 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 25 
mM of catalyst 68. 
 
k2 = 0.0057 M-1 s-1 
R2 = 0.96 
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Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 10 
mM of catalyst 69. 
 
k2 = 0.0166 M-1 s-1 
R2 = 0.98 
 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 25 
mM of catalyst 69. 
 
k2 = 0.0252 M-1 s-1 
R2 = 0.95 
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k2 = 0.0092 M-1 s-1 
R2 = 0.97 
 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (10 mM) using 1 
mM of catalyst 70. 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (10 mM) using 10 mM of 
catalyst 70. 
 
 
k2 = 0.0551 M-1 s-1 
R2 = 0.99 
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Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (10 mM) using 25 
mM of catalyst 70. 
 
k2 = 0.0977 M-1 s-1 
R2 = 0.97 
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Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 1 
mM of catalyst 71. 
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k2 = 0.0009 M-1 s-1 
R2 = 0.83 
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56 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 10 
mM of catalyst 71. 
 
k2 = 0.0049 M-1 s-1 
R2 = 0.93 
 
 
27 
71 
51 
56 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (0.5 mM) with donor 51 (100 mM) using 25 
mM of catalyst 71. 
 
k2 = 0.0103 M-1 s-1 
R2 = 0.95 
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 Kinetic data for OPAL of glyoxyl-LYRAG 27 (50 µM) with donor 54 (150 µM) 
using 10 mM of catalyst 61. 
 
k2 = 4.366 M-1 s-1 
R2 = 0.99 
 
 
k2 = 1.684 M-1 s-1 
R2 = 0.98 
 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (50 µM) with donor 54 (150 µM) using 1 
mM of catalyst 61. 
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k2 = 3.792 M-1 s-1 
R2 = 0.97 
 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (50 µM) with donor 54 (150 µM) using 1 
mM of catalyst 70. 
 
k2 = 7.899 M-1 s-1 
R2 = 0.98 
 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (50 µM) with donor 54 (150 µM) using 25 
mM of catalyst 61. 
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k2 = 11.820 M-1 s-1 
R2 = 0.96 
 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (50 µM) with donor 54 (150 µM) using 10 mM 
of catalyst 70. 
 
Kinetic data for OPAL of glyoxyl-LYRAG 27 (50 µM) with donor 54 (150 µM) using 25 mM of 
catalyst 70. 
 
k2 = 23.947 M-1 s-1 
R2 = 0.98 
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NB: This spectra was kindly recorded by Darshita Budhadev 
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NB: This spectra was kindly recorded and processed by Darshita Budhadev. 
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ABAO   2-amino benzamidoxime 
ADC   Antibody Drug Conjugate 
C-C   Carbon-Carbon 
CD   Circular dichroism 
CNTF   Ciliary neurotrophic factor protein 
CTA   Cholera toxin subunit A 
CTB   Cholera toxin subunit B 
CuAAC  Copper-mediated azide-alkyne cycloaddition 
DAR   Drug-antibody ratio 
DMF   Dimethylforamide 
DMSO   Dimethylsulfoxide 
E. Coli   Escherichia Coli 
FDA   Food and Drug Administration 
FGE   Formylglycine Generating Enzyme 
fGly   Formylglycine 
FAPP   Farnseyl aldehyde pyrophosphate 
FPP   Farnseyl pyrophosphate 
GFP   Green fluorescent protein 
HASP   Hydrophilic acylated surface protein 
HIPS   Hydrazino-iso-Pictet Spengler 
HCTU   2-(6-Chloro-1-H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium hexafluorophosphate 
HPLC   High performance liquid chromatography 
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HRMS   High resolution mass spectrometry 
HRP   Horseradish peroxidase 
IL-8   Interleukin-8 
IPTG   Isopropyl β-D-1-thiogalactopyranoside 
KAHA   α-keto acid hydroxylamine  
LAP   Lipoic acid ligase acceptor peptide 
LB   Lysogeny broth 
LC-MS  Liquid chromatography-mass spectrometry 
LplA   Lipoic acid ligase 
LRMS   Low resolution mass spectrometry 
MBP   Maltose binding protein 
MNP   Multivalent nanoparticle 
M. tuberculosis Mycobacterium tuberculosis 
MS/MS  Tandem mass spectrometry 
MWCO  Molecular weight cutoff 
NaIO4   Sodium periodate 
NaOAc  Sodium acetate 
NHS   National Health Service 
NMR   Nuclear magnetic resonance 
NMT   N-myristoyltransferase 
OPAL   Organocatalyst-mediated protein aldol ligation 
PB   Phosphate buffer 
PBS   Phosphate buffer saline 
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PEG   Polyethylene glycol 
PFTase  Protein farnesyl-transferase 
PLP   Pyridoxal-5-phosphate 
PTM   Post-translational modification 
ReACT  Redox-activated chemical tagging 
RS   Rapoport’s Salt 
scFv   Single chain Fragment variable 
sfGFP   Superfolder green fluorescent protein 
SMCC   Succinimidyl trans-4-(maleimidylmethyl) cyclohexane-1-
carboxylate 
SPAAC  Strain-promoted azide-alkyne cycloaddition 
SPANC  Strain-promoted alkyne nitrone cycloaddition 
SPPS   Solid phase peptide synthesis 
TCEP   Tris(2-carboxyethyl)phosphine 
TEAB   Triethanolamine bicarbonate 
TFA   Trifluoroacetic acid 
tK   Trapped Knoevenagel 
TKM   Tandem Knoevenagel Condensation Michael Addition 
TTL   Tubulin tyrosine ligase 
UV-Vis   Ultraviolet-visible 
YEB   Ylide ester biotin phosphonium salt precursor 
2PCA   2-pyridinecarboxaldehyde 
3ForTyr  3-formyl-L-tyrosine 
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